The role of the WASP family proteins in cellular migration and invasion in prostate cancer by Moazzam, Muhammad
i 
 
 
 
 
 
 
“The role of the WASP family proteins in cellular 
migration and invasion in prostate cancer” 
 
MD Thesis 
by 
Candidate: Muhammad Moazzam 
Supervisors: Professor Wen G Jiang and 
Professor Howard Kynaston 
 
 
 
 
 
 
 
 
 
ii 
 
Declaration  
This work has not previously been accepted in substance for any degree and is not 
concurrently submitted in candidature for any degree.  
Signed …………………………………………. (candidate) Date…………………  
Statement 1  
This thesis is being submitted in partial fulfilment of the requirements for the degree of 
MD.  
Signed …………………………………………. (candidate) Date…………………  
Statement 2  
This thesis is the result of my own independent work/investigation. Other sources are 
acknowledged by explicit references.  
Signed …………………………………………. (candidate) Date…………………  
Statement 3  
I hereby give consent for my thesis, if accepted, to be available for photocopying and for 
inter-library loan, and for the title and summary to be made available to outside 
organisations.  
Signed …………………………………………. (candidate) Date…………………  
Statement 4 - bar on access approved  
I hereby give consent for my thesis, if accepted, to be available for photocopying and for 
inter-library loans after expiry of a bar on access approved by the Graduate 
Development. 
 Committee.  
Signed …………………………………………. (candidate) Date…………………  
iii 
 
Acknowledgements 
 
I would like to express my deep gratitude to Professor Kynaston and Professor Jiang, 
my research supervisors, for their excellent support, guidance and mentoring 
throughout my project. They gave me open and generous access to their guidance and 
compassionate help. I was granted with all the time and help needed to complete this 
thesis. It has been an honour to study under two world-renowned experts in their 
appropriate fields. They gave me the opportunity to complete this MD in a interesting 
and fascinating topic, namely the role of WASP proteins in prostate cancer which will 
add to understanding the mechanism of cellular movement and prostate cancer 
metastasis.  
I would also like to express my great appreciation for Dr Lin Ye, who has been a keen 
laboratory mentor for me and helped me in every fashion to complete the laboratory 
work, preparation of presentations and completion of this thesis. I am also very thankful 
to Andy Sanders who has also provided exceptional support in the laboratory.  
And finally, the biggest thanks go to my wife Dr Farah Afgan Chouhdry, whose love, 
support and encouragement throughout this project, has given me the opportunity to 
complete this thesis.   
 
 
 
 
 
iv 
 
Summary: 
 
Prostate cancer metastasis is a complex process, involving multiple pathways in its 
orchestration. Malignant cells are influenced by different growth factors from the 
extracellular environment which promote or inhibit cell movement and metastasis. HGF 
has been implicated in progression and metastasis of prostate cancer. A cell interacts 
with the environment through surface molecules like integrins. These interactions are 
further translated in to different responses through various intracellular machineries. 
Furthermore organization of the actin cytoskeleton is vital for many cellular functions. 
WAVEs are member of WASP family of proteins, which have important role in regulation 
of actin dynamics through regulation of actin related protein (ARP 2/3). The role of 
individual members of WASP family has been investigated in development and 
progression of different cancers. We documented the expression of different WAVE 
family members in various prostate cancer cell lines. Expression of WAVE-3 was 
effectively knocked down with the use of hammer head ribozymes. Loss of WAVE-3 
expression resulted in reduced cell movement and invasion in the PC-3 cell line. These 
cells failed to show any significant increase in cellular movement and invasive potential 
following treatment with HGF. Further experiments to investigate the underlying 
mechanism of this phenotypic change revealed that optimum levels of phosphorylated 
paxillin play an important role in this change. Our study also indicates that reduced 
potential of invasive capability following WAVE-3 knock down, may be related to 
reduced availability of MMP-2 in the cellular environment. 
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Chapter 1 
Prostate cancer 
2 
 
1.1: Incidence and mortality: 
 
Prostate cancer is the fourth most common male malignant neoplasm worldwide. The 
incidence is highly variable among different countries and ethnic populations. The 
highest incidence is noted in North America, especially in African Americans and the 
lowest in Asia. Prostate cancer is responsible for 15% of all cancers in developed 
countries compared with under developed countries where it accounts for only 4% of all 
diagnosed cancers (Parkin et al. 2001). The mortality of prostate cancer also varies 
widely among countries, being highest in Sweden and lowest in Asia. In Europe, 
prostate cancer is the most common solid neoplasm in males, with an incidence rate of 
214 cases per 1000 men (Boyle et al. 2005).  
1.2: Epidemiology: 
1.2.1: Racial differences: 
 
Environmental factors seem to play important role in prostate cancer risk around the 
world. Japanese and Chinese men in the United States have a higher risk of dying from 
the disease compared to their relatives living in Japan and China. However, Asian-
Americans have the lowest prostate cancer incidence indicating the role of genetics as 
well (Muir et al. 1991; Landis et al. 1999). 
1.2.2: Age at diagnosis: 
 
Prostate cancer is rare in men below 50 years of age and accounts for less than 0.1% 
of all diagnosed prostate cancers. The cumulative risk of clinically diagnosed prostate 
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cancer at 85 years of age ranges from 0.5% to 20% worldwide. However, there is 
evidence from autopsy series that 30% of men in their fourth decade, 50% in their sixth 
decade and more than 75% of men older than 85 years can have microscopic evidence 
of prostate cancer (Sakr et al. 1993). This effect is clearly shown by PSA-based 
screening and its role in age migration effect (Bartsch et al. 2001). 
1.2.3: Stage at diagnosis: 
 
The introduction of PSA testing has increased the incidence of localised disease along 
with the decrease in metastatic disease, at presentation. There is also a downward 
migration of the pathological stage with an increasing incidence of organ confined 
disease in radical prostatectomy specimens (Jhaveri et al. 1999). This improvement has 
been noted in clinical stages T1 to T3. Due to earlier diagnosis, 5 and 10 year survival 
rates have also improved. This may be due to lead time bias but there is ongoing 
debate over this effect which may be answered from ongoing trials in United States and 
Europe (Pinsky et al. 2012; Schroder et al.  2012). 
 
1.3: Risk factors 
1.3.1: Familial and genetic influences: 
 
Prostate cancer can be divided into three phenotypes: sporadic, familial and hereditary. 
Familial prostate cancer is defined as, occuring in men with one or more affected 
relatives. While hereditary prostate cancer is a subset of familial cancer with three or 
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more affected members, with prostate cancer in three successive generations or two 
affected individuals before the age of 55 years. Fortunately hereditary prostate cancers 
are responsible for only 15% of all prostate cancers. Cancers usually arise from 
individual cells that have acquired one or more mutations resulting in malignant 
transformation followed by clonal expansion. Most of these mutations affect genes 
involved in signaling for cell proliferation, cell cycle control, cell death, and DNA repair. 
There have been at least eight well established prostate cancer susceptibility genes 
reported in the literature, including RNase, Hereditary prostate cancer-1 (HPC1) (Goode 
et al. 2001), Hereditary prostate cancer-2 (HPC2) (Smith et al. 2004), the macrophage 
scavenger receptor 1 gene (SR-A/MSR1) (Platt et al.2001), Check point homolog-2 
(CHEK2) (Dong et al. 2003), Breast cancer type-2 (BRCA2) (Edwards et al. 2003), 
Serum paraoxonase/arylesterase 1 (PON1) (Marchesani et al. 2003) and 8-Oxoguanine 
glycosylase (OGG1) (Boiteux  et al. 2000). Despite of the fact that there is a long list of 
susceptibility genes, prostate cancer appears to be polygenic in origin. However, out of 
the most common cancers, prostate cancer is the only malignancy for which a highly 
penetrant allele has not yet been identified. Importantly, we might be able to exploit 
these findings to develop more sensitive tools for early diagnosis of prostate cancer and 
for better treatment of this dreadful disease. 
 
1.3.2: Role of prostatic inflamation: 
 
Chronic inflammation associated with cellular proliferation is a well known factor in the 
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development of infection associated cancers appearing in the oesophagus, stomach, 
bladder and liver (Coussens and Werb, 2002; Platz and De Marzo, 2004). Two previous 
meta-analyses comprising 34 case-control studies have reported a statistically 
significant association of prostate cancer with a previous history of sexually transmitted 
infection or prostatitis (Dennis et al. 2002). Proliferative inflammation in atrophy is a 
well-documented lesion and is characterized by epithelial atrophy, low apoptotic index 
and increased proliferative index (Putzi and De Marzo, 2000). Inflammation produces 
oxidative stress which can lead to DNA damage and mutations. If the cellular defence is 
compromised it can contribute to the development of prostate cancer. There is enough 
evidence to support the above-mentioned theory (Coussens and Werb, 2002): 
(1):  Defects in genes like HPC1 / RNase L are known to predispose knockout mice to 
infections 
(2): Chronic inflammation is known to produce oxidative stress 
(3): Inflammatory lesions associated with proliferative inflammatory atrophy are found in 
abundance in histopathological specimens from prostate 
(4):  Defects in antioxidant enzymes permit oxidative damage to DNA 
(5):  Defects in genes like SR-A/MSR1 can allow uncontrolled inflammatory response. 
(6):  Defects in RNase L allow mutated cells to escape apoptosis which can result in 
colonal expansion of malignant cells. 
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1.4: Molecular epidemiology 
1.4.1: Androgens: 
Androgens are responsible for development, maturation and maintenance of the 
prostate gland and there is little doubt about the role of androgens in prostate cancer 
development. Long-term absence of androgen exposure appears protective against 
prostate cancer, however whether the normal range of androgen concentration can 
increase the risk remains unclear. Androgen receptor abnormalities resulting in a longer 
response have also been implicated in development of hormone refractory disease. 
Genes involved in biosynthesis of androgens like cytochrome P450c17 have been 
found mutated. Polymorphism of CYP3A4, an enzyme responsible for oxidative 
degradation of testosterone has been found in locally advanced and poorly 
differentiated tumors (Rebbeck et al. 2000). 
1.4.2: Oestrogens: 
Oestrogens are known to be protective against prostate cancer by inhibiting epithelial 
cell growth and alternatively increasing the risk by producing inflammation in 
combination with androgens (Naslund et al. 1988). Studies on mice lacking estrogen 
receptor-β have demonstrated prostatic epithelial cell hyperplasia characterized by 
arrested cellular differentiation, which provide an ideal environment for the development 
of epithelial cancer (Imamov et al. 2004). There have been mixed conclusions regarding 
serum oestrogen level and prostate cancer risk due to interpretation of serum levels and 
the fact that estradiol can be produced from testosterone by intraprostatic aromatase 
(Risbridger et al. 2003). 
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1.5: Diagnosis: 
 
1.5.1: DRE, PSA and TRUS: 
The most commonly used primary diagnostic tools for prostate cancer are digital rectal 
examination (DRE), prostate specific antigen (PSA) and transrectal ultrasonography 
(TRUS). Due to peripheral localization, DRE can be positive when tumour volume is 
around 0.2ml or more, in the form of palpable nodule. However it can be variable 
depending opon the location and experience of the examiner. Digital rectal examination 
is only positive in 18% of patients diagnosed with prostate cancer (Richie J et al. 1993). 
Prostate-specific antigen (PSA) is a kallikrein-like serine protease produced by the 
epithelial cells of the prostate, but it is organ-specific not cancer-specific. Serum levels 
may be elevated in the presence of benign prostatic hypertrophy (BPH), prostatitis and 
other non-malignant conditions. However PSA as an independent variable is a better 
predictor of cancer than suspicious findings on DRE or TRUS (Catalona et al. 1994). 
There is no specific cut off normal value for prostate cancer but higher values indicate 
more likely presence of cancer. Several modifications of serum PSA value have been 
described, which may improve the specificity of PSA in the early detection of prostate 
cancer. They include: PSA density, PSA density of the transition zone, age-specific 
reference ranges and PSA molecular forms. However, these derivatives and certain 
PSA isoforms (cPSA, proPSA, BPSA, iPSA) have limited usefulness in the routine 
clinical setting (Djavan et al. 2000; Mikolajczyk et al. 2001; Nurmikko et al. 2000; Partin 
et al. 2003). 
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1.5.2: Transrectal ultrasonography (TRUS) and biopsy: 
TRUS may be able to demonstrate the classical picture of a prostatic nodule in the 
peripheral zone but this may not be the case in every patient. However, it provides an 
invaluable way to sample prostatic tissue by site directed biopsy from the peripheral 
zone of the prostate gland. It is usual practice to take 8 cores (4 from each lobe) and 
additional biopsies can be taken from suspicious areas like nodules. More than 12 cores 
are not significantly more conclusive (Eichler et al. 2006). The British Prostate Testing 
for Cancer and Treatment Study has recommended 10-core biopsies (Donovan et al. 
2003). 
1.6: Staging classification of prostate cancer: 
 
Two main classification systems for clinical staging exist today: the Whitmore-Jewett 
(Jewett 1956; Whitmore 1956) and the tumor, node, metastases (TNM) classification 
systems. TNM classification has been widely used and accepted internationally and 
recognized. It was first adapted by the American Joint Committee for Cancer Staging 
and End Results Reporting (AJCC) in 1975. It was modified in 1992 and adopted by 
International Union against Cancer (UICC) as well. 
1.7: Grading of prostate cancer 
 
Multiple systems exist for grading of prostatic adenocarcinoma but the Gleason grading 
system (Gleason and Mellinger, 1974) is widely accepted. The Gleason score can be 
assessed using biopsy material from core biopsy and operative specimens. Cytological 
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features have no role but it is based on the differentiation of a glandular pattern and a 
score between 1-5 is assigned to most prevalent and second most prevalent pattern. 
The prognostic importance of Gleason grading is well established. The 15-year risk of 
dying from prostate cancer, in relation to Gleason score of 2-4 is 8% as compared to 
93% for Gleason score of 8-10 (Albertsen et al. 1998). 
 
1.8: Staging investigations for prostate cancer 
 
1.8.1: T-Stage:  
Distinction between intracapsular (T1-T2) and extracapsular (T3-T4) disease has the 
most profound impact on treatment decisions. Extensive examinations for adequate T-
staging are only recommended when curative treatment is an option. Both CT and MRI 
are used for local T staging but they may not be sufficiently reliable for local tumor 
extension. However endorectal MRI can elicit more precise zonal anatomy of the 
prostate as compared to external MRI (Heijmink et al. 2007). 
1.8.1: N-Stage:  
N-staging is performed in patients for whom potentially curative treatments are planned. 
Higher PSA value, T2-T3 stage, high Gleason score and perineural invasion are 
associated with higher risk of nodal metastasis (Pisansky et al. 1996; Stone et al. 1998; 
Partin et al. 2001). As compared to MRI, CT appears to be a slightly better tool for 
investigation of lymph node enlargement (Hoivels et al. 2008). Commonly used criteria 
for enlarged lymph nodes are 1cm for rounded nodes and 2cm for oval nodes. 
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1.8.2: M-Stage: 
Bone metastases are present in 85% of patients dying from prostate cancer (Whitmore 
et al. 1984). Elevated skeletal alkaline phosphatase levels are found in 70% of affected 
patients (Lorente et al. 1996). Early detection of bone metastases is important to 
prevent any complications related to skeletal destruction. Bone scintigraphy is highly 
valuable for assessing bone metastases which is found superior to clinical evaluation, 
bone radiographs and serum markers like alkaline phosphatase (McGregor et al. 1978). 
Technetium diphosphates are most commonly used compounds with high bone to soft 
tissue ratio (Buell et al. 1982). 
In addition to bone, prostate cancer can metastasize to any organ but most commonly 
affected organs include distant lymph nodes, lung, liver, brain and skin. Further 
investigations to rule out metastases to these sites are performed only if clinically 
indicated. Serum PSA levels prior to the treatment can reliably indicate the possibility of 
bone metastases and the requirement for a bone scan. A bone scan is not usually 
indicated if the serum PSA level is less than 20 ng/ml in asymptomatic patients with well 
or moderately differentiated tumours. However, in patients with poorly differentiated 
tumours and clinically locally advanced disease, a staging bone scan is indicated 
irrespective of the serum PSA value (Rana et al. 1992). 
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TNM staging for prostate cancer (Sobin et al. 2002): 
T - Primary tumor 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 
Clinically inapparent 
tumor not palpable 
or visible by imaging 
T1a: Tumor incidental histological finding 
in 5% or less of tissue resected 
T1b: Tumor incidental histological finding 
in more than 5% of tissue resected 
T1c: Tumor identified by needle biopsy 
(e.g. because of elevated prostate-specific 
antigen (PSA) level 
T2 
Tumor confined 
within the prostate1 
T2a: Tumor involves one half of one lobe 
or less 
T2b: Tumor involves more than half of one 
lobe, but not both lobes 
T2c: Tumor involves both lobes 
T3 
Tumor extends 
through the 
prostatic capsule2 
T3a: Extracapsular extension (unilateral or 
bilateral) 
T3b: Tumor invades seminal vesicle(s) 
T4 
Tumor is fixed or invades adjacent structures other than seminal 
vesicles: bladder neck, external sphincter, rectum, levator 
muscles, or pelvic wall 
 
Table 1.1: TNM staging of prostate cancer 
1: Tumor found in one or both lobes by needle biopsy, but not palpable or visible by 
imaging, is classified as T1c. 
2:  Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is not 
classified as T3, but as T2. 
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N - Regional lymph nodes3 
Nx Regional lymph nodes cannot be 
assessed 
N0 
No regional lymph node metastasis 
N1 
Regional lymph node metastasis 
 
 
M - Distant metastasis4 
Mx 
Distant metastasis cannot be assessed 
M0 
No distant metastasis 
M1 
Distant metastasis 
M1a: Non-regional lymph 
node(s) 
M1b: Bone(s) 
M1c: Other site(s) 
 
Table 1.1(continued): TNM staging of prostate cancer 
3:  Metastasis no larger than 0.2 cm can be designated pN1mi. 
4:  When more than one site of metastasis is present, the most advanced category 
should be used. 
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1.9: Treatment:  
 
Prostate cancer is diagnosed in 15 to 20% of all men during their lifetime but the risk of 
death is only 3%, as the primary cause. Several autopsy studies of people dying from 
different causes have shown the presence of prostate cancer ranging from 60 to 70%, 
depending upon the age group (Haas et al. 2008). 
 
1.9.1: Conservative management 
 
Due to their low risk of death in low-grade well differentiated tumours and reducing the 
risk of treatment, there are two conservative management strategies proposed in the 
literature: 
Watchful waiting: This is also known as deferred treatment or symptom guided 
treatment and refers to conservative treatment of prostate cancer until the element of 
local or distant symptoms appear. Broadly it means that a patient could be offered 
palliative treatment in the form of transurethral resection of the prostate and hormonal 
treatment or radiotherapy for palliation of symptoms. However, deferred treatment for 
locally advanced or metastatic disease is not indicated. Watchful waiting can be 
considered as a viable option in patients with well differentiated localized prostate 
cancer with limited life expectancy or asymptomatic older patients with medical co-
morbidities. 
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Active surveillance: This is also known as active monitoring which includes a decision 
not to treat the patient immediately but to follow him with active monitoring. Active 
monitoring is performed at predefined intervals and includes clinical evaluation, 
measurement of serum markers like PSA and if indicated prostate biopsy along with 
repeat staging of disease. If the cancer shows any progression according to predefined 
parameters, treatment is undertaken provided the patient agrees to the potential 
benefits and risks of complications. In contrast to watchful waiting, active surveillance 
aims to reduce the ratio of overtreatment in patients with a low-risk prostate cancer 
without giving up option of radical treatment. Patients with clinically confined prostate 
cancer (T1-T2), Gleason score less than or equal to 7 and PSA <10 ng/ml are suitable 
candidates for this strategy. 
 
1.9.2: Radical prostatectomy (RP):  
Radical prostatectomy aims at complete eradication of disease and involves surgical 
removal of the prostate gland along with seminal vesicles and terminal parts of the vas 
deferens. Radical prostatectomy is indicated in patients with low and intermediate risk 
localized prostate cancer (cT1b-T2 and Gleason score 2-7 and PSA < 20) and a life 
expectancy > 10 years. Pelvic lymph node dissection is usually performed to rule out 
any pelvic lymph node metastasis. Most clinicians rely on nomograms (Partin tables), 
based upon the preoperative biochemical markers and biopsy results, to decide about 
the pelvic lymph node dissection (Makarov et al. 2007).  Patients with low PSA (less 
than 10) and low Gleason score (7 or less) have a very low potential for the lymph node 
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metastases and may be spared from lymph node dissection (Makarov et al. 2007).  
There are multiple surgical approaches for radical prostatectomy including open, 
laparoscopic and perineal approaches. Laparoscopic and robotic prostatectomy are 
gaining popularity due to shorter convalescence and the results are comparable in short 
term follow-up (Chan et al. 2008). A perineal approach lacks the feasibility of direct 
access to pelvic lymph nodes and a slightly higher risk of rectal injury (Bishoff et al. 
1998). RP is the only treatment which has demonstrated the improved overall survival 
and cancer specific survival, in one prospective randomised trial. When compared with 
conservative management, RP demonstrated a relative reduction of all cause mortality 
and prostate cancer-specific mortality (Bill-Axelson et al. 2011). 
 
1.9.3: Radiotherapy: 
There are no randomized studies comparing radical prostatectomy with either external 
beam therapy or brachytherapy for localized prostate cancer. Three-dimensional 
conformal radiotherapy (3D-CRT) is the gold standard, however intensity modulated 
radiotherapy (IMRT) which is an optimized form of 3D-CRT, is gradually gaining 
popularity in centres of excellence. 
A recent systematic review from multiple studies was able to demonstrate that 
radiotherapy continues to be an important and valid alternative to surgery (Grimm et al. 
2012). In localized prostate cancer T1c-T2c N0 M0, 3D-CRT with or without IMRT is 
recommended even for young patients who refuse surgical intervention. There is fairly 
strong evidence that intermediate and high-risk patients benefit from dose escalation 
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(Zietman et al. 2010; Kuban et al. 2011). For patients in the high-risk group, short-term 
ADT prior to and during radiotherapy results in increased overall survival (Bolla et al. 
2010). Transperineal interstitial brachytherapy with permanent implants is an option for 
patients with cT1-T2a, Gleason score < 7 (or 3 + 4), PSA ≤ 10 ng/mL, prostate volume 
below 50 mL, without a previous TURP and significant lower urinary tract symptoms 
(Salembier et al. 2007). 
 
1.9.4: Hormonal therapy: 
Androgen-suppressing strategies have become the mainstay of the management of 
advanced prostate cancer. It may be effective in relieving symptoms of metastatic 
disease but has not proven to be of any significant survival benefit (McLeod, 2003). In 
advanced prostate cancer, all forms of castration as monotherapy (e.g. orchiectomy, 
LHRH agonist and diethyl stilbisterol DES) have equivalent therapeutic efficacy. 
Intermittent androgen-deprivation therapy is a viable option (Irani et al. 2008), even 
though long-term data from prospective randomized clinical trials are still awaited. In 
advanced prostate cancer, immediate androgen-deprivation therapy (given at diagnosis) 
significantly reduces disease progression as well as the complication rate due to 
progression itself compared with deferred androgen-deprivation therapy, delivered at 
symptomatic progression (Nair et al. 2002). 
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Chapter 2 
Cancer metastasis and role of cell movement 
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Although surgery, chemotherapy and radiation therapy effectively control many cancers 
at the primary site, the development of metastatic disease always leads to a poor 
prognosis. In an ideal world, elimination of metastases would make almost all of the 
cancers curable. Most metastatic lesions are not treated by surgery, as the presence of 
one lesion often indicates wider systemic dissemination. Chemotherapy, hormonal 
therapy and radiation serve palliative purposes in the metastatic setting, and may offer a 
modest but statistically significant extension of survival. In spite of these facts, most 
deaths from cancer are due to metastases that are resistant to conventional therapies 
(Chambers et al. 2002). Morbidity and mortality arising from metastatic disease can 
result from direct organ damage by the growing lesions, paraneoplastic syndromes, or 
from the complications of treatment. The major problem during the treatment of 
metastasis is the biological heterogeneity of cancer cells in the primary and metastatic 
sites. This heterogeneity is exhibited in the form of specific biological characteristics 
such as expression of cell receptors, enzymes and growth properties. Expression or 
suppression of these biological characteristics can make these tumours susceptible or 
resistant to certain treatments (Ramaswamy et al. 2003). 
Tumour metastasis is not a random process but consists of a series of discrete 
biological processes, when the tumour cells disseminate from the primary neoplasm to 
a distant location. It involves not only possession of certain characteristics by the 
tumour cells but also depends on host response and favourable properties of the 
secondary site. Tumour cells must invade the tissue surrounding the primary tumour, 
enter either the lymphatics or the bloodstream, survive and eventually arrest in the 
circulation, extravasate into a tissue and grow at the new site (Ramaswamy et al. 2003). 
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This seemingly simple process involves expression of certain essential genes at critical 
timing, enabling the cancer cell to complete the whole process (Wang et al. 2005).  
2.1: Metastatic cascade:  
Cancer cells must use their cytoskeletons to adapt and survive in a variety of hostile 
environments to successfully metastasise. Firstly, they must leave the site of the 
primary tumour and enter the blood or lymphatic system. They are often aided by 
angiogenesis in and around the tumour and also by stromal cells such as fibroblasts 
and macrophages that both remodel the extracellular matrix and provide signals to the 
tumour cells for migration. One of the key cellular processes that triggers the beginning 
of an invasive or metastatic programme in many cancers is the de-differentiation of 
epithelial cells toward a primitive mesenchymal state. This process is referred to as 
epithelial to mesenchymal transition (EMT). Having undergone EMT, cells become more 
fibroblast like (Lee et al. 2006). This fibroblastic morphology allows polarised assembly 
of the actin cytoskeleton into protrusive and invasive structures that help the cell to 
travel through the extracellular matrix (ECM). EMT was origionally identified in 
embryonic development studies (Nieto, 2001). This transition is marked by reduced 
expression of E-cadherins, cytokeratins and occludins along with upregulation of MMPs 
(Lee et al. 2006). These cells also alter their gene expression to acquire an amoeboid 
phenotype. This phenotype is characterized by lack of polarity and crawling type of 
cellular movement (Friedl, 2004). EMT also helps invasive cells to break away from the 
rest of tumour population and thus change from collective to individual metastatic 
activity (Gupta and Massague 2006). The cancer cell, having entered the blood or 
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lymph system, then has to survive in the circulation and is transported to distant sites in 
the body (Schmidt-Kittler et al. 2003; Pantel et al. 2006). 
 
2.2: Physiological and pathological role of cellular motility: 
A variety of cellular motility processes are essential throughout the life cycle of cells. 
From the early stages of development, cell movement is essential for the generation of 
the entire organism. Primary muscle cells migrate to places where limbs are formed, 
endothelial cells form the blood vessel walls, neurons migrate to their proper positions 
and send out axons and dendrites to find their target cells (Dormann, 2003). Also in 
adult organisms cell motility is crucial as a response to a pathological situation. 
Vertebrate immune cells invade into infected tissue to eliminate infectious agents. 
Fibroblasts, surrounding a wound, migrate towards each other during wound healing. 
Not surprisingly, many pathologic events arise from aberrant motility such as 
inappropriate immune responses and migration leading to chronic inflammatory 
diseases or malignancy.  
Basic concepts in cellular motility were introduced by Abercrombie. He identified the thin 
layers of cytoplasm which protrude beyond the migrating cell surface. This structure 
was described as “leading lamella” or “lamellipodium”, when parallel to substrate and 
reffered as “ruffle”; when it curled upwards (Abercrombie, 1980). Subsequent studies 
revealed the presence of concentrated layers of actin filaments in lamellipodia and 
demonstrated that protrusion was based on actin polymerization (Heath and Holifield, 
1993). Filopodia are plasma membrane protrusions which have been described as 
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“finger-like”. They are formed by tightly packed parallel actin filaments (Mattila and 
Lappalainen, 2008). Cells are thought to use these structures as probes to detect the 
cues in extracellular environment (Gupton and Gertler, 2007). 
Cells move in response to signals from their environment. These are sensed by 
transmembrane receptors by which signaling cascades are initiated and ultimately affect 
cytoskeletal and adhesive structures of the cell. Several actin rich cellular structures 
have been defined (Small, 1994; Kaverina et al. 2002). There is a close interplay 
between the different intracellular cytoskeletal systems (especially actin and microtubule 
containing structures) and these systems also interact with the cell–substratum and 
cell–cell adhesive machinery. Nevertheless, the actin microfilament system is still 
considered to be the engine of cellular migration. The temporally and spatially controlled 
turnover of specific actin structures drives protrusion. In recent years, many regulatory 
actin binding proteins have been characterised. In addition, some of the molecular 
components and relevant signaling cascades from the plasma membrane to the actin 
cytoskeleton have been identified yielding key roles to phosphoinositides (and enzymes 
involved in their metabolism), small GTPases, kinases and a variety of focal adhesion 
components. 
There is sufficient evidence to suggest that invasive cancer cells acquire a migratory 
phenotype which is associated with an increased expression of several genes involved 
in cell motility (Wang et al. 2005). Migration of metastatic cells through tissues and 
endothelial barriers is complex and comprises a highly regulated cycle of cell shape 
changes including protrusion, retraction, adhesion and detachment. Cancer cells 
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respond to mitogenic stumuli through formation of numerous cell surface projections 
(Chambers et al. 2003).  
  
 
2.3: Role of integrins and focal adhesion complexes in cell 
motility: 
For a cell to translocate (i.e. to move from one place to another), the cell needs to 
attach at a new site and retract its rear end (Small et al. 1999). The new attachment 
sites or focal contacts, that constitute a physical link between the substrate and the 
actin cytoskeleton, are formed behind the leading edge (Lauffenburger et al. 1996). The 
cell attaches to the ECM through surface proteins like integrins. Integrins are attached 
to the actin cytoskeleton through multiple adaptor proteins (Figure: 2.1). Integrins are 
heterodimers containing two chains, the α (alpha) and β (beta) subunits. There are 19 
alpha and 8 beta subunits which have been described. Various combinations have been 
found during characterization of different integrins (Eble et al. 2002; Berrier, 2007). 
Integrin mediated focal contacts are used by cells for firm attachment to substrate. 
Smaller adhesion sites known as focal complexes are utilized by motile cells for 
advancing movement. Integrins like αvβ3 are found to be upregulated in 
neovascularisation and invasive tumors (Mattern et al. 2005). Many integrin related 
accessory proteins interact with small guanosine tri-phosphatases (GTPase) like Rho, 
which causes suppression of myosin light chain phosphatase through its effect on 
ROCK (Jaffe, 2005). The Rho-ROCK mediated inhibition of myosin light chain 
phosphatase allows myosin light chain kinase (MLCK) to phosphorylate myosin light 
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chain, leading to activation of myosin-II (non muscle myosin) (Riento, 2003). The active 
myosin-II binds with actin filaments to generate the traction force which retracts the tail 
end of cell. 
With the advancement in knowledge of integrins it was revealed that they are not merely 
serving as attachment sites for cells to extracellular matrix. They also act as two way 
transmitter of signals between intracellular machinery and the external environment. 
Cytoplasmic extensions of integrins do not possess any enzymatic activity so they need 
to recruit a variety of proteins before focal adhesion complexes can act as a conduit for 
transmission of signals (Berrier, 2007).   
Paxillin was first identified as a 68 KDa protien which showed increased tyrosine 
phosphorylation following the transformation of chick embryonic fibroblasts by the Src-
expressing Rous sarcoma virus (Glenney et al. 1989). The subsequent analysis of 
fibroblasts derived from paxillin deficient embryos has indicated defects in cell 
migration, responsible for severe developmental phenotype (Hagel et al. 2002). From 
prior studies it became evident that paxillin act as nexus for the function of Rho family of 
GTPases thus controlling essential regulators responsible for actin and adhesion 
dynamics (Turner et al. 1990). 
Studies on molecular structure and peptide sequence analysis have revealed multiple 
protein binding modules leading to the belief that paxillin is a molecular adapter or 
scaffold protein (Turner et al. 1990). The C terminal of paxillin contains four LIM 
domains, which are double zinc finger motifs that mediate protein to protein interaction 
(Perez-Alvarado et al. 1994). It has been established that phosphorylation of these 
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domains contributes to the regulation of focal adhesion targeting by paxillin. The LIM 
domain of paxillin also serves as a binding site for several structural and regulatory 
proteins including tubulin and tyrosine phosphatase (Brown, 1998). The N terminal of 
paxillin controls most of its signaling activity. It consists of five leucine and aspartate rich 
LD motifs which are capable of interaction with multiple proteins (Tumbarello et al. 
2002). The N-terminal also contains a proline rich region which interacts with vinculin 
binding protein, ponsin and this combination is important for formation of costameres 
(sites of actin-membrane interactions) in cardiac muscle cells (Zhang et al. 2006). 
Multiple tyrosine, serine and threonine phosphorylation sites are present in the paxillin 
molecule, which are targeted by different kinds of kinases in response to adhesion 
stimuli and growth factors. The polarised cell migration require regulation of RHO family 
of small GTPases which includes Cdc42, Rac1 and Rho A. Cdc42 is required for cell 
polarisation and formation of filopodia, whereas Rac1 induces the formation of broad 
sheet like extensions or lamellipodia. Cdc42 and Rac1 are also involved in the 
assembly of early adhesion complexes at the leading edge and disassembly at the rear 
end (Ridley, 2001).  These GTPases are essential for controlling the actin cytoskeleton 
and actin associated adhesions during cellular movement. 
All the members of this family functions as molecular switches by cycling between an 
inactive (GDP- bound) and active state (GTP- bound). This cycling is controlled by a 
large group of guanine-nucleotide exchange factors (GEFs), which catalyse the 
exchange of GDP for GTP and by GTPase activating proteins (GAPs), which promote 
the hydrolysis of GTP to GDP. Paxillin contributes to the coordination of their 
downstream signals by indirectly recruiting various GEFs, GAPs and effector proteins. 
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For example, upon the ligation of an integrin to either a fibronectin or collagen substrate, 
paxillin becomes tyrosine phosphorylated, primarily on tyrosine residues 31 and 118 
(Y31 and Y118, respectively) (Burridge et al. 1992; Bellis et al. 1997; Petit et al. 2000) in 
a FAK and Src-dependent manner (Schaller and Parsons, 1995). The CrkII-DOCK180-
ELMO complex, which regulates Rac1 signaling (Grimsley et al. 2004), can interact with 
the phosphorylated Y31 and Y118 residues of paxillin via the SH2 domain of CrkII 
(Birge et al. 1993; Valles et al. 2004) and, by means of the unconventional Rac1- and 
Cdc42-GEF activity of DOCK180 (Brugnera et al. 2002), activates Rac1 to promote cell 
migration. Interestingly, the phosphorylation of Y31 and Y118 has also been shown to 
regulate RhoA activity. Phosphorylated paxillin binds directly to p120RasGAP (RASA1), 
which diminishes the interaction of p120RasGAP with p190RhoGAP (ARHGAP5) at the 
plasma membrane; this culminates in the suppression of localised RhoA activity by 
p190RhoGAP (Tsubouchi et al. 2002). Therefore, paxillin that is phosphorylated at Y31 
and Y118 can indirectly activate Rac1 and inhibit RhoA, and both of these activities are 
necessary for efficient leading-edge protrusion during cell migration. 
The LD4 motif of paxillin plays a particularly important role in its activity to control Rho 
GTPases activity and focal adhesion turnover. This motif is responsible for recruiting a 
molecular complex comprising of G-protien-coupled receptor kinase interacting protein 
(GIT1 or GIT2, p21-activated serine/threonine kinase (PAK), PAK-interacting exchange 
factor (PIX) and NCK. Fibroblasts expressing a mutant form of paxillin lacking the LD 
motif cannot recruit GIT1/2–PIX-PAK-NCK complex to focal adhesion sites and 
therefore exhibit abnormal membrane protrusion dynamics (West et al. 2001). These 
cells are also deficient in polarised cell movement (Brown et al. 2002). 
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Figure 2.1: Schematic presentation of integrin-linked focal adhesion complex, which 
provide the main sites of cell adhesion to extracellular matrix and associated with the 
actin cytoskeleton to control cell movement. 
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2.4: Role of actin in cell motility:  
To migrate, cells use dynamic rearrangements of the actin cytoskeleton for the 
formation of protrusive structures and for generation of intracellular forces that lead to 
net cell translocation. This is initiated by a transition from a non-polarized to a polarized 
state, dictated by the extracellular signals and their concentration gradient cues. These 
activated motile cells extend distinct protrusive regions in the direction of translocation 
with advancing front and retracting rear end (Moissoglu et al. 2006). Whereas several 
actin-rich structures have been described in motile cells, two cellular features are 
typically associated with cell migration (lamellipodia and filopodia) (Small, 1994). 
Another important aspect for directed movement is coordinated assembly and 
disassembly of these adhesion sites. When new focal adhesions are being established 
in the advancing end, they are also being disassembled at the rear end for retraction 
and transported to sites of active adhesion formation (Moissoglu et al. 2006). 
During progressive movement, a motile cell forms protrusive structures which appear in 
the form of broad sheets (lamellipodium) and narrow finger like projections (filopodium). 
Lamellipodia and filopodia are composed of actin filaments. These are formed by 
polymerization of globular actin (G-actin), an ATP binding protein which exists as 
monomers bound to profiling and sequestering proteins such as thymosin-β4, into 
double stranded helical filaments (F-actin). These are structurally and kinetically 
polarized, possessing a faster growing (+)-end and a slower growing (−)-end. Once 
incorporated at the (+)-end, ATP-G-actin hydrolyses its bound ATP. After release of 
inorganic phosphate, ADP-actin molecules are left in the filament and finally dissociate 
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at the (−)-end (Figure: 2.2). ADP-actin monomers are subsequently reloaded with ATP 
and shuttle back to the barbed ends for a new round of polymerization. Addition of ATP-
actin occurs preferentially at the positive (+)-ends and dissociation of ADP-containing 
molecules at the negative (−)-ends. Each end is in equilibrium with a monomer 
concentration called the critical monomer concentration. Under steady state conditions, 
when the monomer concentration lies between the critical concentrations of both ends, 
the number of actin molecules added at the fast growing ends balances the number of 
molecules dissociating from the pointed ends, resulting in a dynamic equilibrium called 
treadmilling (Wang et al. 1985). Migrating cells reach speeds of 1–20 μm/min depending 
on the cell type, implicating actin polymerization rates of 10–200 subunits/second. In 
contrast, the observed in vitro elongation rate is approximately 0.2–0.5 subunits/second 
(Zigmond et al. 1993). This discrepancy is due to the regulatory action of many actin 
binding proteins that accelerate several steps of the polymerization cycle, resulting in an 
efficient system that is optimised for progressive cell movement.  
 
2.5: Control of actin polymerization: 
In a resting cell, there is little or no need of an active turnover of actin filaments. 
Therefore, the fast growing ends are blocked (see below) and the large pool of actin 
monomers is in complex with polymerization-inhibiting or sequestering proteins. Upon 
cell activation by external stimuli (growth factors, chemoattractants etc) dramatic, often 
local, increases in actin polymerization are observed. This burst of actin polymerization  
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is initiated by uncapping (+)-ends, by severing existing filaments thereby creating free 
polymerizable ends, and by de novo polymerization (Pollard, 2003). Although neglected 
for a long time, in vivo nucleation is now considered as a major determinant in cell 
motility.  
Three important nucleation mechanisms are now being suggested. Most of the time 
each of these relies on the proteins which form regulatory complexes. These proteins 
include WASP family proteins, Diaphanous related formins (DRFs) and Ena/VASP 
proteins. Current views indicate that the branched actin filament network in the 
lamellipodia are formed by WASP/Arp2/3, the contractile ring in dividing cells is 
organized by DRFs and F-actin bundles in filopodia and stress fibers by Ena/VASP 
proteins and DRFs, respectively (Nürnberg et al. 2011). 
 
2.6: Role of ARP 2/3: 
The Arp2/3-complex, in conjunction with WASP-family members, has emerged as the 
major factor responsible for de novo nucleation at the leading edge of a lamellipodium 
(Svitkina et al. 1999). The Arp2/3 complex is a multiprotein complex containing seven 
different subunits of which two are actin related (Arp2 and Arp3) (Svitkina et al. 1999). 
The Arp2/3-complex creates Y-shaped junctions on existing filaments resulting in the 
branched actin networks that are stabilized by cortactin (Machesky et al. 1994). The 
intrinsically inactive Arp2/3-complex is synergistically activated by pre-existing actin 
filaments (Mullins et al. 1998), by ATP (Weaver et al. 2002) and by proteins of the 
WASP/WAVE family. 
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2.7: Regulation of actin dynamics by WASP family proteins: 
Rapid reorganisation of the actin cytoskeleton underlies morphological changes and 
motility of cells. WASP family proteins have received a great deal of attention as the 
signal-regulated molecular switches that initiate actin polymerization (Miki and 
Takenawa, 2003). The first member, WASP, was identified as the product of a gene of 
which dysfunction causes the human hereditary disease Wiskott-Aldrich syndrome. 
There are now five members in this protein family, namely WASP, N-WASP, 
WAVE/Scar-1, 2, and 3 (Parolini et al. 1997; Fukuoka et al. 1997; Hiroaki et al. 1998; 
Suetsugu et al. 1999). 
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Figure 2.2: Dynamics of actin polymerisation and depolymerisation. (1) Extracellular 
signals activate receptors. (2) The associated signal transduction pathways produce 
active Rho-family GTPases and PIP2 which (3) activate WASP/WAVE proteins. (4) 
WASP/WAVE bring together Arp2/3 complex and an actin monomer on the side of a 
preexisting filament to form a branch. (5) Growth at the barbed end of the new branch 
pushes the membrane forward. (6) Capping protein terminates growth. Actin filaments 
age by hydrolysis of ATP bound to each actin subunit (white subunits turn yellow) 
followed by dissociation of the phosphate (subunits turn red). (7) Cofilin promotes 
phosphate dissociation, severs ADP-actin filaments and promotes dissociation of ADP-
actin from filament ends. Profilin catalyzes the exchange of ADP for ATP (turning the 
subunits white), returning subunits to the pool of ATP-actin.  
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2.7.1: Wiskott-Aldrich syndrome: 
The Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder with variable clinical 
phenotypes that correlate with the type of mutations in the WAS protein (WASP). This 
immunodeficiency disease presents with characteristic clinical phenotypes that include 
thrombocytopenia with small platelets, eczema, recurrent infections caused by 
immunodeficiency, and an increased incidence of autoimmune manifestations and 
malignancies (Sullivan et al. 1994). Clinical manifestations suggesting WAS are often 
present at birth and consist of petechiae, bruising, and bloody diarrhoea. Excessive 
hemorrhage after circumcision is an early diagnostic sign. Eczema is a frequent 
manifestation of classic WAS during infancy and childhood. The most consistent finding 
at diagnosis is thrombocytopenia and small platelets. Infections, including otitis media 
with drainage of mucoid purulent material, pneumonia most often caused by bacteria 
and rarely by Pneumocystis carinii, and skin infections, are frequent complaints during 
the first 6 months of life. Patients with variable presentation may have less problems 
with eczema and infections and often receive misdiagnoses of idiopathic 
thrombocytopenia (ITP), considerably increasing the actual age of diagnosis. 
 
2.7.2: WASP and N-WASP: 
In 1994, Derry et al., identified the gene that is mutated in WAS patients and named it 
Wiskott - Aldrich syndrome Protein (WASP) (Derry et al. 1994). Northern blotting 
analysis indicated that WASP is expressed exclusively in hematopoietic cells (Parolini et 
al. 1997). Two years later, a novel protein with ~50% amino acid identity to the WASP  
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gene product (WASP) was reported as a binding partner for the Grb2/Ash adapter 
protein. As compared to WASP, this protein was expressed ubiquitously, but its 
strongest expression was observed in nerve cells, and thus it was named Neural-WASP 
(N-WASP) (Fukuoka et al. 1997). These proteins share many structural and functional 
properties. Both proteins possess an EVH1 (or WH1) domain, a highly basic region, a 
GBD/CRIB motif, a proline-rich region, and a VCA region. The EVH1 domain binds the 
evolutionarily conserved WASP-interacting protein (WIP) family of proteins. The WIP 
family proteins are essential functional partners for WASP and N-WASP, probably 
responsible for regulation of their specific localization (Martinez-Quiles et al. 2001). 
 
2.7.3: Structure of WASP-WAVE proteins: 
In the mammalian world, WASP and WASP family verpolin homology (WAVE) proteins 
share a similar domain structure and each consist of approximately 500 amino acids. 
These proteins share two main regions of homology: a central segment rich in proline 
residues and a carboxy-terminal module comprising three characteristic domains called 
the VCA domain.The V domain is a monomeric actin binding site which binds to 
monomeric F-actin, the CA domain binds the Arp2/3 complex (Miki et al. 1998). The 
Arp2/3 complex is activated through binding with the VCA domain and this complex 
then catalyses actin polymerization (Machesky et al. 1999). Comparative analysis of the 
catalytic properties of the VCA module of WASP, N-WASP and WAVE revealed that the 
isolated domains display the unique kinetics of actin assembly. The VCA domain of N-
WASP has a distinctly higher rate of nucleation than the VCA of both WASP and WAVE 
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domains which are distinctly shorter and have less activity (Machesky et al. 1999). The 
amino-terminal half of the molecule is defined by two functional groups on the basis of 
the presence of either WASP homology 1/Ena (Ena-vasodilator stimulated 
phosphoprotein) VASP homology 1 (WH1/EVH1) domain (found in WASP and N-
WASP) or WAVE homology domain/suppressor of cAMP receptor (SCAR) homology 
domain (WHD/SHD), specific to WAVE isoforms (Takenawa et al. 2001). The N-terminal 
consists of more than 85% of the entire amino acid sequence (Takenawa and 
Suetsugu, 2007). 
The molecular design of WASP family is organised in the form of a conserved C-
terminal domain, responsible for output function of the molecule and divergent N-
terminal region which is used for targeting by stimulants and also regulates the activity 
of the C-terminal or output domain (Takenawa and Suetsugu, 2007). 
 
2.7.4: Role of WAVE-1: 
WAVE-1 was identified as the third member of the WASP protein family with verprolin 
homology, functioning as a regulator of actin reorganization downstream of Rac and an 
essential step in the formation of membrane ruffles (Hiroaki et al. 1998). In the same 
time period, this protein was identified as SCAR, which is involved in tip formation and 
chemotaxis in Dictyostelium (Bear et al. 1998). In spite of its general function as a 
regulator of actin reorganization, its distribution and expression appeared to be limited 
to the brain (Nagase et al. 1998). 
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Mitochondrial fission and trafficking to dendritic protrusions have been implicated in 
dendritic spine development. There is indirect evidence that WAVE-1 is supposed to be 
responsible for depolarisation-induced mitochondrial movement into dendritic spines 
and filopodia and regulates spine morphogenesis (Sung et al. 2008). Depolarization-
induced degradation of the p35 regulatory subunit of cyclin-dependent kinase 5 (Cdk5), 
with the resultant decreased inhibitory phosphorylation on WAVE-1, depends on NMDA 
receptor activation. Thus, WAVE-1 dephosphorylation and activation are probably 
associated with mitochondrial redistribution and spine morphogenesis (Sung et al. 
2008). 
The WAVE-1 expression was increased in children with acute lymphoblastic leukemia 
(ALL). Expression was more marked in children with more aggressive form of disease 
as compared to patients in complete remission. WAVE-1 might be implicated in the 
development of ALL and may serve as a marker for the evaluation of the severity of ALL 
in children (Wang et al. 2008). 
The myelin sheath can be compared to the neuronal growth cone in that the unfurled 
sheath looks like a giant lamellum. WAVE-1 is critical for formation of oligodendrocyte 
lamellae and myelin sheaths. However some, but not all myelination seems to be 
impaired by knockout of WAVE-1 function and it appears that other regulators of actin 
nucleation help oligodendrocytes to produce myelin in parallel with WAVE-1 function. 
Oligodendrocyte maturation is also disturbed with WAVE-1 knockout and it has been 
proposed that proper localization and transport of signaling molecules relevant to the 
integrin signaling cascade were disrupted by loss of WAVE-1 function (Sloane, 2007). 
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WAVE-1 and WAVE-2 are overexpressed in mouse melanoma cell lines when these 
cell lines become metastatic (Kurisu et al. 2005). WAVE-1 is not essential for protrusion 
of the leading edge of lamellipodia but it is involved in the formation of dorsal ruffles, 
circular assemblies of actin filaments formed upwardly in the dorsal surface of cell. In 
WAVE-1-knockout cells, extension of the leading edge occurs faster than in wild-type 
cells (Kurisu et al. 2005). However, the leading edges in WAVE-1-knockout cells are 
unstable and have shorter half-lives than those of wild-type cells. Consistent with this 
finding, WAVE-1 is localised slightly behind the leading edge, and therefore, WAVE-1 
might be important for the accumulation of actin filaments behind the leading edge to 
increase the mechanical force necessary for protrusion (Yamazaki et al. 2005).  
 
2.7.5: Role of WAVE-2 
WAVE-2 has been found to be located at front end of membrane protrusive structures, 
formed in the direction of cellular movement. Recruitment to these sites is facilitated by 
binding of WAVE-2 with compounds like PIP3 (Oikawa et al. 2004). It has been 
observed that WAVE-2 mediates the downstream effects of Rac, by activating ARP 2/3 
complex mediated actin polymerization and formation of lamellipodium (Yan et al. 
2003). WAVE-2 appears to be particularly important for directional mesenchymal cell 
migration in fibroblasts (Yamazaki et al. 2003). WAVE-2 plays an important role in 
migration of B16F10 melanoma cells in 3-D matrix. Knock down studies of WAVE-2 in 
B16F10 melanoma cells using siRNA (small interfering RNA ) method showed, reduced 
cell migration and metastases in to the lungs via regulation of membrane protrusions 
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(Kurisu et al. 2005). Polarized cell movement is triggered by the development of a PIP3 
(phosphatidylinositol tri-phosphates) gradient at the leading edge of membrane. WAVE-
2 binds to PIP3 through its basic domain. The binding of PIP3 to WAVE-2 seems 
essential for WAVE-2 mediated rearrangement of the actin cytoskeleton (Oikawa et al. 
2004).  WAVE-2 has been observed to be significantly over expressed and associated 
with poor prognosis in breast (Fernando et al. 2007), colorectal (Iwaya et al. 2007) and 
hepatocellular cancers (Yang et al. 2006). 
 
2.7.6: Role of WAVE-3  
WAVE-3 was originally found to be truncated and inactivated in a patient with 
ganglioneuroblastoma (Sossey-Alaoui et al. 2002). Inactivation of Scar/WAVE-3 was 
hypothesised to lead to an accumulation of neural crest cells that are defective in 
migration yet retain some potential for proliferation. The resulting enlarged ganglia 
would contain accumulated undifferentiated proliferating cells that could potentially be 
differentiated if given the right signals at a later time. This is a typical manifestation of 
ganglioneuroblastoma (Sossey-Alaoui et al. 2002). In recent studies, Scar/WAVE-3 was 
shown to accumulate at puncta, which appeared to be precursors to new filopodia and 
protrusions that latter became dendritic spines (Pilpel et al. 2005). These puncta were 
shown to be places of accumulation of F-actin and actually overexpression of 
Scar/WAVE-3 in hippocampal neurons, induced accumulation of F-actin in these 
regions (Pilpel et al. 2005).  
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From neuroblastoma work, Sossey-Alaoui and colleagues found that in general, 
Scar/WAVE-3 has a positive rather than a negative role in promoting the metastasis and 
invasion of cancer cells. Condeelis and colleagues found an upregulation of 
Scar/WAVE-3 in their microarray analysis of motile tumour cells (Condeelis et al. 2005). 
Scar/WAVE-3 expression appears to be increased in various cancer cell lines and in 
human breast cancer samples (Sossey-Alaoui et al. 2002, 2005, 2007). In one study, 
Scar/WAVE-3 was linked to expression of metalloproteases MMP-1, MMP-3 and MMP-
9 which associated with cancer cell invasion (Sossey-Alaoui et al. 2005). Silencing of 
Scar/WAVE-3 using siRNA showed a reduced motility and invasiveness of cancer cells, 
using matrigel assays. These results were similar to what has been previously shown 
for WAVE-1 and WAVE-2. The loss of Scar/WAVE-3 led to an increase formation of 
actin stress fibres and focal adhesion complexes, indicating the possibility that the 
Scar/WAVE-3 or the balance of Scar/WAVE proteins in the cell can influence the 
mobility or contractility of the actin cytoskeleton (Sossey-Alaoui et al. 2005). In vivo 
studies showed reduction of Scar/WAVE-3 expression levels also led to a decrease in 
the number of lung metastases of breast cancer cells in SCID mice and also inhibited 
primary tumor establishment in the SCID mice (Sossey-Alaoui et al. 2007). Recent work 
from Fernando et al. has confirmed similar findings in prostate cancer cell lines, where 
WAVE-3 does not appear to change the growth rate but drastically reduces the motility 
and invasion of PC-3 and DU-145 prostate cancer cells (Fernando et al. 2009).   
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2.8: Role of matrix metalloproteinases (MMPs) in cancer 
invasion and metastasis: 
 
Extracellular and intracellular proteases are integral parts of many developmental and 
embryological processes. Without these essential molecules cells cannot interact 
properly with the surrounding environment. Their role in development was first 
described in the process of involuting tadpole tail. It was observed that diffusible 
enzymes from the fragments of tail were able to degrade the native fibrillar collagen gels 
(Gross and Lapiere, 1962). Since the initial discovery multiple families of these proteins 
have been identified in uni and multi-cellular organisms, including humans. One 
particular closely related family of proteins, Matrix Metaloprotienases (MMPs), has been 
identified which depend heavily upon metal ions for their catalytic activity (Nelson et al. 
2000). In addition to degradation of extracellular matrix, they also cleave the cell surface 
molecules and influence the cell behaviour in several ways. Through this role MMPs 
can influence processes like tissue development, wound repair, inflammatory diseases 
and neoplastic development (Nelson et al. 2000). 
Matrix metalloproteinases are zinc containing endopeptidases which help to dissolute 
extracellular matrix proteins. At present, 25 vertebrate MMPs and 22 human 
homologues have been identified. All MMP family members share specific 
characteristics consisting of a pro-domain, a catalytic domain and a highly conserved 
active site domain. The active site domain contains HEXGHXXGXXH motif where the 
three histidine residues constitute three zinc ligands and the glutamic acid residue 
(Giannelli et al. 1997). With the exception of MMP-7 all MMPs exhibit a hemopexin-
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homology domain which associates with substrate specificity. In addition MMP-2 and 
MMP-9 also contain a fibronectin type gelatin binding domain. MMPs are either 
secreted (MMPs 1–13 and 18–20) or anchored to the cell membrane through a 
transmembrane domain (MMPs 14–17). Functionally, MMPs are subdivided into 
collagenases, stromelysins and gelatinases, depending upon substrate preference. 
Gelatinases have earned their name for their preferential degradation of denatured 
collagen. They include MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B). Due to their 
ability to degrade collagen IV MMP-2 and MMP-9 are also known as 72kD collagenase 
IV and 92kD collagenase IV. Like other MMPs substrate specificity extends beyond 
collagen IV and also includes collagen I, V, and X for MMP-9 and laminin for MMP-2 
(Birkedal-Hansen et al. 1993; Giannelli et al. 1997). 
 
2.8.1: Regulation of MMP activity: 
The physiological and pathological role of MMPs depends upon their presence in a 
specific environment, location and time interval. To achieve this, the activity of MMPs is 
usually regulated at four levels including transcription, post transcriptional modification, 
proteolytic activation of the zymogen form and inhibition of the active enzyme. It has 
been observed that MMPs are not expressed continuously but a variety of stimuli like 
growth factors, cytokines and cell to cell or cell to extracellular matrix (ECM) interactions 
can induce expression of MMPs (Vu, 2000).  
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2.8.2: Expression of MMPs 
MMPs overlap with each other for their substrate specificities so biological function is 
largely controlled through their expression. Primary regulation is at the transcription 
level. MMP genes expression is influenced by numerous stimulatory and suppressive 
factors through multiple pathways (Vu, 2000). Expression of MMPs can be up or down-
regulated by phorbol esters, integrin derived signals, ECM proteins, cell stress and 
changes in cell shape (Kheradmand et al. 1998). Type I collagen stimulates discoidin 
domain-containing receptor-like tyrosine kinases that induces MMP-1 expression and 
become inactive when it binds to MMP-1-cleaved collagen (Vogel et al. 1997). 
Expression of MMP-2 is controlled sparingly with modest up or down regulation under 
various circumstances (Birkedal-Hansen et al. 1993). MMP-1, MMP-2, MMP-3 and 
MT1-MMP expression can also be stimulated by the extracellular matrix 
metalloproteinase inducer (EMMPRIN). It is a cell surface glycoprotein from an 
immunoglobulin superfamily and also acts as surface receptor for MMP-1 (Guo et al. 
2000). 
In contrast to other gelatinases, MMP-9 expression is highly inducible by several 
cytokines and growth factors including interleukins, interferons, EGF, VEGF, PDGF and 
the extracellular matrix metalloproteinase inducer (EMMPRIN) (Hipps et al. 1991). This 
differential expression can be traced back to the promoter regions in the gene. The 
promoter region of MMP-2 lacks any binding sites for AP-1 and ETS transcription 
factors (Westermarck et al. 1999). Cytokines and growth factors activate expression of 
MMP-9 through mitogen activated protein kinase (MAPK) pathway which incorporates 
ERK 1/2, JNK/MAPK 1/2 and p38 proteins (Westermarck et al. 1999). The highly 
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inducible nature of MMP-9 by growth factors can be detected in invasive tumors in mice 
carrying a β-galactosidase gene under the control of MMP-9 promotor (Kupferman et al. 
2000).  The 5'-flanking regulatory regions of inducible MMPs contain an AP-1 cis-
regulatory element in the proximal promoter, approximately 70 nucleotides upstream of 
the transcription initiation site (Fini et al. 1998). The promoter regions of AP-1 contains 
the PEA3 site, another important cis-element which binds members of the ETS family of 
transcription factors and cooperates with the AP-1 motif for optimal activation of the 
MMP-1, MMP-3 and MMP-9 promoters (Gum et al. 1996; Westermarck et al. 1997; Vu 
et al. 2000). Expression of ETS-1 has been observed in stromal fibroblasts near 
invading tumour cells and angiogenic vascular endothelial cells (Westermarck et al. 
1997). 
It is very important to emphasize that integrins and extracellular matrix mediated signals 
also control the expression of MMPs. It was initially observed that antibodies blocking 
the α5β1 integrin mediated adhesion, also reduced MMP expression in fibroblasts 
(Werb et al., 1989). Later studies showed that α2β1 integrin regulates MMP-1 
expression (Riikonen et al. 1995; Dumin et al. 2001). Antibodies to α3β1 integrin-
tetraspanin induced MMP-2 expression and αMβ2 integrin stimulated MMP-9 expression 
(Larjava et al. 1993; Wize et al. 1998). Integrins also appear to play important role in the 
delivery of MMPs to the cell surface as part of transport vesicles (Ginestra et al. 1997; 
Dolo et al. 1999; Taraboletti et al. 2002). 
 
2.8.3: Activation of MMPs: 
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Most MMPs are produced in an inactive and latent form, known as zymogens and are 
activated once transported out from the cells. This inactive form is maintained by 
interaction between the sulphhydryl group of highly conserved cystine within the peptide 
and catalytic zinc ion. This interection essentially blocks the zinc dependent activation of 
the water molecules, required for attack on the peptide bonds (Van Wart and Birkedal-
Hansen, 1990). 
Treatment of latent MMPs by chaotropic agents, such as organomercurials, or partial 
proteolytic cleavage dissociates the covalent bond between zinc and the sulfhydryl 
group which leads to activation of the catalytic site (Nagase, 1997). Although many 
proteases can cleave the MMPs in vitro, the activation mechanism for the majority of 
MMPs in vivo remains unclear. Evidence from different experimental studies has 
demonstrated the close association of plasminogen activator and plasmin system with 
MMP activation (Mignatti et al. 1996). However studies from mice deficient in 
plasminogen have demonstrated adequate levels of MMPs, along with adequate 
invasive potential (Rosenthal et al. 1998). MMPs are capable of mutual and in some 
cases auto-activation (usually under in vitro condition). MMP-1 can activate latent MMP-
2. MMP-13 can be activated by MT1-MMP, MMP-3 and MMP-10 (Knäuper et al. 1996). 
 
2.8.4: Inhibition of MMPs 
The proteolytic activity of MMPs is primarily controlled by tissue inhibitors of 
metalloproteinases (TIMPs), once released and activated in the tissues. These are 
small proteins of 21–28 kDa that specifically block MMP activity by binding to the highly 
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conserved zinc-binding site of active MMPs. There are currently four known TIMP family 
members. All four TIMPs possess 12 conserved cysteine residues, required for the 
formation of six disulfide bonds (Gomez et al. 1997). The amino-terminal domain is 
specifically required to inhibit activated MMP (Gomez et al. 1997). Data from several 
experiments based on synthetic peptides have demonstrated that many regions are 
involved in complex formation with interstitial collagenase (Bodden et al. 1994). Most 
importantly a specific sequence surrounding two of the disulfide bonds of TIMP-1 is 
highly effective in inhibiting collagenase activity (Bodden et al. 1994).  
TIMP-1 and TIMP-2 inhibit the activity of most MMPs, and similar to TIMP-2 and pro-
MMP-2, TIMP-1 can form a complex with pro-MMP-9 (Goldberg et al. 1992). The TIMP-
1/proMMP-9 complex recruits MMP-3 resulting in formation of more stable tertiary 
complex composed of proMMP-9/TIMP- 1/MMP-3. The resulting complex inhibits active 
MMP-3 (Kolkenbrock et al. 1995). TIMP-3 inhibits the proteolytic activity of MMPs 1, 2, 
3, 7, 9 and 13 (Knäuper et al. 1996). TIMP-4 inhibits the activity of MMP-2 and MMP-7. 
It also inhibits MMP-1, MMP-3 and MMP-9 to lesser extent (Liu et al. 1997).  
 
2.8.5: Role of MMP in cell migration: 
Cell migration is a complex process and a critical event in cancer progression and 
establishment of metastasis. In the initial phase of migration, the cell extends 
membrane processes such as lamellipodia and filopodia at the cell front. Lamellipodia 
are sheet like processes and filopodia are needle like projections (Lauffenburger et al. 
1996). Invadopodia are a specialized form of needle like projections which are located 
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in basal part of cells and can be observed in two dimensional cell culture models (Chen 
et al. 1999). Invadopodia have been studied previously and are characterized by 
proteolytic degradation (Chen and Wang, 1999). Along the leading edge of invasive cell, 
new adhesion contacts by integrins and other molecules are also being established. 
This complex process requires integrins for adhesion/de-adhesion, as well as matrix 
metalloproteinases (MMPs) for localized proteolysis at the adhesion site.  
Formation of adhesive contacts is regulated by the Rho family of GTPases and includes 
Cdc42, Rac and Rho. These adhesive sites further progress to make mature focal 
contacts which comprise a highly dynamic network of proteins (Zamir and Geiger, 
2001). Formation of adhesive structures is accompanied by tyrosine phosphorylation of 
cystoskeleton associated proteins such as focal adhesion kinase (FAK), paxillin and 
tensin which are mediators of intracellular signaling (Weisberg et al. 1997). FAK is a 
125-kDa tyrosine kinase which mediates multiple functions such as cell motility, survival 
and proliferation (Parsons et al. 2000). Increased expression of FAK in human tumours 
is associated with invasiveness (Owens et al. 1995) and inhibition of FAK through 
dominant negative mutant can reduce aggressiveness (Aguirre Ghiso et al. 1999). 
FAK negative fibroblasts cannot exhibit migration; however viral Src-protien restores the 
migration through reactivation of Src pathway. Src is associated with integrins and 
uPAR and acts by linking FAK to integrins, such as αVβ5 in VEGF mediated stimulation. 
However it is quite interesting to note that although motility of FAK naive fibroblasts is 
recovered, invasion and expression of gelatinases is not restored. The authors 
suggested that FAK activity is required for synchronisation of motility and invasion (Hsia 
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et al. 2003). In a recent study, MT1-MMP and MT3-MMP activity was linked to 
proteolytic cleavage of FAK in vascular smooth muscle cells (Shofuda et al. 2004). 
Generation of new adhesion is necessary at the advancing edge but also needs a 
mechanism to release them on the tail end. Release mechanism on the tail end involves 
multiple mechanisms including mechanical stretch from cytoskeleton, changes in 
integrin pathways (Lauffenburger et al. 1996) and proteases along with their inhibitors 
(Czekay et al. 2003). Only a few other proteins are involved in cell detachment at the tail 
end. These include tenascin-C, thrombospondin-1 and 2 and SPARC (secreted protein, 
acidic and rich in cysteine) (Murphy-Ullrich, 2001). Focusing on these concepts it is 
easy to understand that integrins and their ligand interactions are key regulators of cell 
migration. Relatively small changes in levels of integrins and their affinity to ligands can 
substantially change the speed of cell migration. In addition, inhibition of cell movement 
can be achieved not only by integrin blocking antibodies but also with antibodies that 
activate them and proteases which change matrix components (Schenk et al. 2003).  
Kryczka et al demonstrated that MMP-2 is up-regulated in resected colorectal tumours 
and degrades β1 integrins with release of fragments containing the β1 I-domain. The 
β1 cleavage pattern is similar to that produced by digestion of α5β1 and α2β1 with 
MMP-2. This study suggested that MMP-2 amplifies the motility of colon cancer cells, 
not only by digesting the extracellular matrix components in the vicinity of cancer cells 
but also by inactivating their major β1 integrin receptors (Kryczka et al. 2012). 
MMPs generate pro-migratory signals by cleavage of growth factors. MMP-9 can 
activate VEGF and TGF-β, promoting tumour growth and angiogenesis (Bergers et al. 
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2000; Yu et al. 2000). Gelatinases are also linked to cell spreading during cell migration. 
Activated Rho-A is necessary but not sufficient for cell invasion (Stam et al. 1998). 
MMP-9 co-localizes with activated Rho-A and constitutively active Rho-A increases the 
secretion of MMP-9 (Abécassis et al. 2003). Other evidence for MMPs involvement in 
cell spreading comes from studies involving inhibitors of MMPs. MMP-2 inhibition by 
over expression of TIMP-2 causes extensive cell spreading (Ray and Stetler-Stevenson, 
1995). Inhibitors of MMPs augment cell adhesion by reducing cadherin cleavage and 
stabilize   cell to cell contact by inhibiting ECM degradation (Ho et al. 2001). 
 
2.8.6: MMPs in tumour progression: 
It is important to emphasize that several MMPs were first cloned and have been 
repeatedly re-cloned as cancer-associated genes (Sternlicht and Werb, 1999). 
Increased expression of MMPs has been demonstrated in cancers of breast, colon, 
skin, lung, ovary and prostate. This phenomenon is often accompanied by increased 
aggressiveness of tumours and decreased survival among patients (Egeblad and Werb, 
2002). Expression of MMPs may be variable at different stages of cancer, especially 
during different steps of metastasis. In melanoma, expression of MMP-9 is increased 
during the early stage of disease and the opposite is true in the later stages of the 
disease (van den Oord et al. 1997). Studies involving breast and colonic cancer have 
demonstrated that MMP-9 expression was associated with equivocal effect on survival 
and development of metastatic disease (Zeng et al. 1996; Takeha et al. 1997; Pacheco 
et al. 1998; Scorilas et al. 2001). 
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2.8.7: MMP in angiogenesis: 
Every tumour needs the development of new blood vessels in order to meet the 
demands of oxygen and nutrients supply. MMPs, especially gelatinases, are involved in 
this critical step. This phenomenon has been well established in vitro (Schnaper et al. 
1993; Seftor et al. 2001) and in vivo studies (Itoh et al. 1998; Vu et al. 1998). The exact 
underlying mechanism involved is still obscure and MMPs are thought to use multiple 
pathways. Bergers et al. demonstrated in a model of pancreatic islet carcinogenesis that 
MMP-2 and MMP-9 were up-regulated in angiogenic tumors (Bergers et al. 2000). In 
this study the up-regulation of MMPs resulted in release of VEGF which is a potent 
growth factor for angiogenesis. It was also observed that the phenomenon of 
angiogenesis was mainly dependent upon intact MMP-9 activity rather than MMP-2, in 
MMP knockout mice models (Bergers et al. 2000).  
MMP-9 activity was required to expose a cryptic pro-migratory control site in collagen 
during retinal neo-vascularization (Hangai et al. 2002). A monoclonal antibody 
recognizes an epitope in denaturised collagen type IV (HUIV26). Exposure of this 
epitope is required for angiogenesis in vivo and is associated with αVβ3 binding to 
collagen type IV. Exposure of this epitope is crucial in angiogenesis and it involves αVβ3 
binding to collagen type IV (Hangai et al. 2002). It is interesting to note that the 
appearance of HUIV26 epitope in melanoma tumour vasculature, takes place with the 
appearance of MMP-2 (Xu et al. 2001). 
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2.8.8: MMPs in cancer mediated inflammation: 
Chronic inflammation associated with some tumours is thought to be associated with 
progression through release of MMPs by inflammatory cells (Coussens et al. 1999 and 
2000). These cells include neutrophils, dendritic cells, macrophages, eosinophils and 
lymphocytes which can significantly alter the tumour micro-environment through 
provision of additional agents like cytokines, interferons and MMPs. Chemokines are 
important mediators of leucocyte recruitment in to tumors. They also modify endothelial 
and tumour cell chemotaxis and affect the migratory and invasive behaviour of tumour 
cells. These chemokines need to be proteolytically processed in order to get activated 
by different proteases, including MMPs. A prime example of this activity comes from 
platelet factor (PF)-4, a monokine induced by interferon IFN-γ, interferon inducible 
protein-10 (IP-10/CXCL-10) and stromal-cell derived factor-1 (SDF-1) representing 
angiogenic chemokines, which can be cleaved and activated by MMPs like gelatinases 
(Moore et al. 1998). MMP-9 has been implicated in the down regulation of the immune 
response to cancer by cleaving interleukin-2α receptor, activation of TGF-β and by 
shedding of ICAM-1 (Yu et al. 2000; Fiore et al. 2002; McQuibban et al. 2002). MMP-2 
is able to influence the process of inflammation through proteolytically processing the 
chemoattractants for monocytes and suppression of inflammation in vivo (McQuibban et 
al. 2002). Due to the active role of inflammation in the dynamics of neoplastic process, 
different anti-inflammatory agents like cyclo-oxygenase inhibitors are added to 
anticancer treatment (Williams et al. 1999; Liu et al. 2002). 
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2.9: Aims of the study: 
 
Cancer metastasis is a complex process and cellular motility plays an important and 
vital role. Growth factors provide important signals in the development of metastasis. 
Binding of growth factors leads to morphological changes in the actin cytoskeleton 
through a variety of pathways. There is some evidence in the literature that WAVEs play 
an important role in the regulation of actin cytoskeleton through regulation of the ARP 
2/3 complex. The basic aim of this research project was to examine the role of WAVEs 
in prostate cancer, in response to growth factors and to dissect the underlying 
mechanism which can be potentially used as a common step to stop the process of 
metastasis. 
The specific aims of the study were, 
1: To study and determine the expression levels of different members of the WAVEs 
family of proteins in various epithelial cell lines. 
2: To create prostate cancer cell lines through a process of cellular cloning, which are 
deficient in specific gene, for subsequent use in functional studies. 
3: To determine the role of WAVE-3 in growth factor induced cellular changes including 
growth, cell matrix interaction, invasion and cellular motility. 
4: To determine the role and interaction of different pathways which could potentially be 
responsible for morphological changes in prostate cancer cells.  
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Chapter 3  
Materials and Methods 
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3.1: General materials: 
 
3.1.1: Cell lines 
 
Seven prostate cancer or prostatic epithelial cell lines were used in the study. PC-3 cells 
were acquired from the ECACC (European Collection of Animal Cell Culture, Salisbury, 
UK). PC3 cell line has high metastatic potential and was established in 1979 from bone 
metastasis of prostate cancer, in a 62-year-old Caucasian male (Kaighn et al. 1979). 
DU-145, LNCaP-FGC, CA-HPV10 and PZ-HPV-7 were supplied by the ATCC 
(American Type Culture Collection). DU-145 cell line was derived from brain metastases 
and has moderate metastatic potential (Stone et al. 1978). LNCaP cells are androgen-
sensitive human prostate adenocarcinoma cells, derived from the left supraclavicular 
lymph node metastasis, from a 50-year-old Caucasian male (Horoszewicz et al. 1980). 
CA-HPV10 cells were derived from adenocarcinoma of prostate, followed by 
transfection with viral DNA from HPV (Weijerman et al. 1994). PZ-HPV-7 cell line was 
derived from peripheral zone epithelium of normal prostate and immortalized by 
transfection with viral DNA from HPV (Weijerman et al. 1994). PNT-1A and PNT-2C2 
were generous gifts provided by Professor Norman Maitland (University of York, 
England, UK). PNT cell lines were derived from normal prostate epithelium, 
immortalized by transfection with a plasmid containing SV40 genome. All cells were 
routinely maintained in DMEM-F12 medium supplemented with 10% foetal calf serum 
and antibiotics. 
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3.1.2: Primers 
 
Two different categories of primers were designed for this study. The first set was able 
to detect the mRNA level of a particular gene through conventional RT-PCR (Table: 3.1 
& 3.2). The second set of primers was designed according to the secondary structure of 
a gene transcript, and was used to synthesize the hammerhead ribozymes for the gene 
silence study (Table: 3.3). 
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Molecule Primer PCR product 
Annealing 
temperatures 
WAVE-1 
Forward 
5˝-CCTCCTCCACCACCTCTTC 
 
526bp 55°C 
Reverse 5˝-GCACACTCCTGGCATCAC 
WAVE-2 
Forward 5’-CAAGCCATCCACCACCAG 
595BP 55°C 
Reverse 5’-ACAGCAATGCGACGAGAC 
WAVE3 
Forward 5˝- TACTCTTGCCGCTATCATACG 
532bp 58°C 
Reverse 5˝- TGCCATCATATTCCACTCCTG 
 
β-Actin 
Forward 5’-ATGATATCGCCGCGCTCG 
580bp 55
o
C 
Reverse 5’-CGCTCGGTGAGGATCTTCA 
 
Table: 3.1: Primers for RT-PCR used for detection of WAVEs. 
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Table: 3.2: Primers for RT-PCR used for detection of MMPs. 
 
Molecule Primer 
PCR 
product 
(bps) 
Annealing 
temperatures 
MMP-1 
Forward 5˝- GGATGCTCATTTTGATGAAG 
110 55°C 
Reverse 5˝- TAGAATGGGAGAGTCCAAGA 
MMP-2 
Forward 5˝- TGCAGCTCTCATATTTGTTG 
472 55°C 
Reverse 5˝- TTTGATGACGATGAGCTATG 
MMP-7 
Forward 5˝- GCTATGCGACTCACCGTGCTGTG 
530 55°C 
Reverse 5˝- AGCGTGTTTCCTGGCCCATCAAATG 
MMP-9 
Forward 5˝- AACTACGACCGGGACAAG 
357 55°C 
Reverse 5˝- ATTCACGTCGTCCTTATGC  
MMP-11 
Forward 5˝- GTGCCCTCTGAGATCGAC 
88 55°C 
Reverse 5˝- CAGGGTCAAACTTCCAGTAG 
 
GAPDH 
Forward 5’- GGCTGCTTTTAACTCTGGTA 
475bp 55
o
C 
Reverse 5’- GACTGTGGTCATGAGTCCTT 
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Ribozyme 
 
Name of primer 
 
Sequence of primers 
 
T7F 
 
5´-TAATACGACTCACTATAGGG 
 
RBBMR 
 
5’-TTCGTCCTCACGGACTCATCAG 
 
RBTPF 
 
5’-CTGATGAGTCCGTGAGGACGAA 
WAVE-3 
ribozyme-1 
 
WAVE-3RIB1F 
 
5˝-CTGCAGTTGTAAATATCAGCAACAGCTGATGAGTCCGTGAGGA 
 
WAVE-3RIB1R 
 
5˝-ACTAGTTTCAAAGAACAGCATTCCTAATTTCGTCCTCACGGACT 
WAVE-3 
ribozyme-2 
 
WAVE-3RIB2F 
 
5’-CTGCAGCTTCCTCTGTGGTGACTGATGAGTCCGTGAGGA 
 
WAVE-3RIB2R 
 
5’-ACTAGTAGCTGTGAAAGTGTTTTCGTCCTCACGGACT 
 
Table: 3.3: Primers used to synthesize hammerhead ribozymes for the gene 
silencing study. 
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3.1.3: Antibodies 
 
3.1.3.1: Primary antibodies 
Full details about the primary antibodies used in this study are in Table 3.4. 
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Antitibody name Host species 
Predicted  product  
size (kDa) 
Antibody/d i lu t ion 
used 
Supplier and 
catalogue 
number  
 
Anti-WA VE- 3 
 
Goat 
 
55kDa 
 
1:500 
 
Santa Cruz 
Biotechnology Inc 
(sc- 10395 ) 
 
Anti-rabbit 
(Whole 
molecule) IgG 
peroxidise 
conjugate 
 
Goat Dependent on primary 1 : 1 000 Sigma (A-9169) 
Anti-β-actin (C- l l )  
Goat 42 kDa 
 
1:500 
Santa Cruz 
Biotechnology Inc. 
(sc-1615) 
 Anti-paxillin Mouse 68 kDa 1:500 
BD Transduction 
Laboratories 
(610051) 
Anti-phophorylated 
paxillin 
Rabbit 68 kDa 1:250 Sigma (P-6368) 
Anti-FAK Mouse 125 kDa 1:500 
BD Transduction 
Laboratories 
(610088) 
Anti-Radexin Goat 82 kDa 1:250 
Santa Cruz 
Biotechnology 
Inc.SC-6408 
Anti-Moesin Mouse 77 kDa 1:250 
Santa Cruz 
Biotechnology 
Inc.SC-13122 
Anti-Ezrin Goat 87 kDa 1:250 
Santa Cruz 
Biotechnology 
Inc.SC-6409 
Anti-GAPDH Mouse 37 kDa 1:500 
Santa Cruz 
Biotechnology 
Inc.SC-47724 
Anti-MMP-2 Mouse 63 kDa 1:250 
Santa Cruz 
Biotechnology 
Inc.SC-53630 
 
Table: 3.4: Antibodies used for detection of different proteins in western blotting, 
immunoflourescence and immunocytochemistery experiments. 
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3.1.3.2: Secondary antibodies 
Peroxidase (horseradish peroxidase, HRP) conjugated anti-goat IgG, anti-rabbit IgG 
and anti-mouse IgG antibodies were obtained from Sigma (Poole, Dorset, UK). TRITC 
conjugated secondary antibody to rabbit IgG was obtained from Sigma (Poole, Dorset, 
UK).  FITC conjugated secondary antibodies to mouse and goat IgG were obtained from 
Santa-Cruz Biotechnology (Santa-Cruz, California, USA). 
 
3.1.4: General reagents and solutions 
 
3.1.4.1: Reagents and chemicals 
Protein-A/G agarose beads used during immunoprecipitation were obtained from Santa-
Cruz Biotechnology (Santa-Cruz, California, USA). The Super SensitiveTM Wash Buffer 
(BioGenex, USA) was used in the immunofluorescent staining (IF). SDS-6H (Sigma-
Aldrich, Inc., Poole, Dorset, England, UK), a protein molecular weight marker mixture 
was used to determine the protein size. The SupersignalTM West Dura system (Pierce 
Biotechnology, Inc., Rockford, IL, USA), a highly sensitive chemiluminescence substrate 
was used to detect the horseradish peroxidase (HRP) in western blot. All other 
chemicals or reagents were purchased from Sigma, unless otherwise stated. 
 
3.1.4.2: General solutions 
The following solutions are generally used throughout the study. 
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Tris-boric acid-EDTA (TBE) 
For a 5×TBE buffer, 540g Tris-Cl, 275g Boric acid and 46.5g EDTA was dissolved in 9.5 
litres of distilled water, pH adjusted to about 8.3 using NaOH, and a final volume of 10 
litres was made with distilled water.  
 
Tris buffered saline (TBS) 
A 10× stock solution was made by dissolving 24.228 Tris and 80.06g NaCl in 1 litre 
distilled H2O and adjusting the pH to 7.4 with concentrated HC1. This solution contained 
200mM Tris and 1.37M NaCl. 
 
Balanced salt solution (BSS) 
A 5 litre stock solution of 1 x BSS consists of 137mM NaCl, 2.6mM KCl, 1.7mM 
Na2HPO4 and 8.0mM KH2PO4 and was made by dissolving 40g NaCl, lg KCl, 5.72g 
Na2HPO4 and 1 g KH2PO4 in dH2O and adjusting the pH to 7.4 with 1M NaOH. 
 
0.05M EDTA in BSS 
A 5 litre stock solution at 1x concentration contained 1g KCl, 5.72 Na2HPO4, 1g 
KH2PO4, 40g NaCl and 1.4g EDTA, and dissolved in 5 litres distilled H2O and adjusted 
the pH to 7.4 before autoclaving. 
 
Loading buffer (for DNA electrophoresis) 
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A stock solution was made by dissolving 25mg bromophenol blue and 4g sucrose in 
distilled water to a final volume of 10ml. Solution was stored at 4°C to avoid mould 
growing in the sucrose until use. 
 
Ethidium bromide solution 
A stock solution of ethidium bromide (10mg/ml) was made by dissolving 200mg 
ethidium bromide in 20ml distilled water, and protected from light by covering the tube in 
aluminium foil. 
 
Transfer buffer (for Western blot) 
Glycine in quantity of 72g and15.15g of Tris dissolved in distilled water along with 1 litre 
methanol, final volume of 5 litres was made with distilled water.  
 
0.5% amino black staining solution 
2.5g amino black, 50ml acetic acid, 125ml ethanol were added into 325ml distilled water 
to make a final volume of 500ml. 
 
Amino black destaining solution 
100ml acetic acid and 250ml ethanol were added into 650ml of distilled water for a 1 
litre amino black destaining solution. 
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Running buffer (for SDS-PAGE) 
A 10× stock solution was made by dissolving 303g Tris, 1.44kg glycine and 100g SDS 
in 10 litres distilled water.  
 
3.2: Cell culture and storage 
 
3.2.1: Preparation of growth medium and maintenance of cells 
 The culture medium used in the study was Dulbecco's Modified Eagle's Medium 
(DMEM / Ham's F-12 with L-Glutamine; PAA, E15-813) (pH 7.3) containing; 2mM 
L-glutamine, 15mM HEPES and 4.5mM NaHCO3. 
 DMEM was then supplemented with 10% heat inactivated foetal calf serum (PAA 
Laboratories, Austria); 50 ml FCS in 500 ml DMEM/HAM F12. 
 Antibiotics were added to the medium at a final concentration of 100 units/ml 
(60μg/ml) for benzylpenicillin (Britannia, Pharmaceuticals Ltd, UK) and 100 μg/ml 
for streptomycin (Streptomycin Sulfate salt, Sigma-Aldrich Co.). Benzylpenicillin 
(Britannia, Pharmaceutical Ltd, UK) powder 600mg (1x106units) in each bottle 
was dissolved in 5ml sterilized water, and kept at 4 oC in a fridge until ready for 
use. The concentration of streptomycin stock solution was 250mg/ml. 200μl of 
streptomycin was dispensed into each 500 ml of culture medium, to give a final 
concentration of 100μg/ml. 
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 The cell lines were cultured in monolayer either 25cm2 or 80cm2 culture flasks 
(Cell Star, Germany) at cell densities of 1x105cells/ml. 
 Culture flasks were loosely capped and placed in an incubator at 37
o
C with a 
98% humidification (water tray in the incubator) and 5% CO2. 
 The flasks were then left until sub-confluent (2-3 days) for experimental work or 
fully confluent (7 days) for subculture. 
 
3.2.2: Trypsinisation and counting of cells 
 
 All handlings of cells were performed under sterile conditions using class II hoods 
and autoclaved instruments to keep sterile conditions. 
 Following removal of culture medium, the flasks were rinsed once with 5ml of 
sterile HBSS (Hanks Balanced Salt Solution) (137mM NaCl; 8mM Na2HPO4; 
3mM KCl; 1.5mM KH2PO4) buffer to remove all possible traces of serum, which 
would inhibit the enzymatic action of trypsin. 
 1-2ml of trypsin EDTA, which has trypsin 0.01% (w/v) and EDTA 0.05% (w/v) in 
BSS buffer, was added to the flasks, which were incubated for 5 minutes at 37
o
C 
to allow cell detachment. 
 Once the cells had detached from the surface of the flask, the effect of trypsin 
was neutralised by the addition of 5ml of DMEM and placed in a universal 
container. 
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 The cells were centrifuged at 1,500 rpm for 5 minutes. 
 The excess medium was aspirated and the pellet re-suspended in 5mls of 
DMEM. 
 The cells were then either re-cultured in flasks or counted for immediate 
experimental work or stored by freezing in liquid nitrogen (see below). 
 Cell counts were performed using an improved Neubauer haemocytometer 
counting chamber with an inverted microscope (Reichert, Austria) at 10×10 
magnification. 
 
3.2.3: Storage of cell lines in liquid nitrogen 
 
 The cell lines were stored in liquid nitrogen by resuspending at a cell density of 
1x106 cells/ml in DMEM, containing 10% (v/v) dimethylsulphoxide (DMSO; 
Fisons, UK).  
 1 ml aliquots of cell suspension were transferred into cryopreserve tubes; 
 Transferred to -80
o
C for 24 hours before storage in liquid nitrogen (-196
o
C) until 
required. 
 
3.2.4: Resuscitation of cells 
 After removal from liquid nitrogen, the cells were allowed to thaw rapidly to 37
o
C 
in 1-2 minutes; 
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 The cell suspension was transferred to a universal container, with 2ml of pre-
warmed DMEM. The cells were then incubated at 37
o
C for 10 minutes. 
 The cells were then centrifuged at 1600 g for 5 minutes and the excess medium 
removed.  
 The cell pellet was re-suspended in DMEM and washed twice to remove any 
possible trace of DMSO. 
 After the final wash, the cell pellet was re-suspended in 5ml of DMEM and the 
cell suspension transferred to a 25cm2 tissue culture flasks. The cells were 
incubated at 37°C, 98% humidification and 5% CO2. 
 
3.3: Methods for detecting mRNA 
 
3.3.1: Total RNA isolation 
Ribonucleic acid (RNA) is present within the nucleus, cytoplasm and mitochondria of all 
living eukaryotic cells.  The total cytoplasmic RNA is representative of three main sub 
types which are classified as; ribosomal (rRNA), transfer (tRNA) and messenger 
(mRNA) RNA. Although mRNA accounts for only 1-2% of total cellular RNA, it is of 
particular importance as it carries the genetic information for protein formation. The 
presence of specific mRNA sequences indicates which protein is being produced by a 
cell at any given time. 
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RNA is susceptible to degradation by RNases and therefore, special care must be taken 
to minimize this during its isolation.  All methods involving RNA isolation rely on the use 
of strong denaturants to inhibit the action of endogenous RNases for preserving intact 
RNA during the isolation.  Guanidine, thiocyanate and chloride used for the RNA 
isolation are amongst the most effective protein denaturants and inhibitors of 
ribonucleases.  The guanidine thiocyanate method described by Chomczynski and 
Sacchi in 1987 (Chomczynski and Sacchi, 1987), has evolved as a rapid procedure 
which combines acid guanidium thiocyanate, phenol and chloroform in a single step 
RNA extraction.  Using this method, the extraction of RNA is set under acidic conditions, 
so that the DNA is selectively partitioned into the organic phase whilst the RNA remains 
in the aqueous phase.  The quality and concentration of the RNA isolated can then be 
detected using a spectrophotometer at a wavelength of A260nm/A280nm. 
 
3.3.1.1: Homogenisation 
 
 After aspiration of culture medium, cells in the mono-layer were lysed directly in the 
culture flask by adding the RNA reagent (1ml/3.5cm petri dish, or 1ml/5-10 x 106 cells). 
The resultant cell lysate was transferred immediately to eppendorf or polypropylene 
tubes. Washing the cells before addition of the RNA reagent was avoided as this might 
increase the possibility of mRNA degradation. 
3.3.1.2: RNA extraction 
  Following homogenisation,  
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 The homogenate was stored for 5 minutes at 4°C to permit the complete 
dissociation of nucleoprotein complexes.  
 0.2ml of chloroform per 1ml of RNA reagent was added, shaken vigorously for 15 
seconds and placed on ice at 4°C for 5 minutes. 
 The homogenate was centrifuged at 12,000g (4°C) for 15 minutes. 
 Centrifugation resulted in separation of homogenate in two phases: the lower phase, 
organic phase and the upper aqueous phase. DNA and proteins are present in the 
organic phase and in the interface while RNA is present in the aqueous phase. The 
volume of the aqueous phase thought to be about 40–50% of the total volume of the 
homogenate plus chloroform. 
 
3.3.1.3: RNA precipitation 
 
 The aqueous phase was carefully transferred to a fresh tube while taking care 
not to disturb the interface. 
 An equal volume of isopropanol was added and samples were stored for 10 
minutes at 4°C. 
 The samples were centrifuged at 12,000g (4°C) for 10 minutes. 
 RNA precipitation formed a white pellet at the bottom of the tube after the 
centrifugation. 
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3.3.1.4: RNA wash 
 The RNA pellet washed twice with 75% ethanol (prepared using DEPC treated 
distilled water) by vortexing and subsequent centrifugation for 5 minutes at 
7,500g (4°C). 
 At the end of the procedure, the pellet was dried briefly at 50°C for 5–10 minutes 
in a hybridiser drying oven. 
 Care was observed not to let the RNA pellet dry completely, as it can greatly 
decrease its solubility. The RNA pellet was dissolved in 50–100µl of DEPC 
treated water by vortexing for 1 minute. 
 
3.3.1.5: Qualification and quantification of RNA 
The concentration and purity of RNA was determined by measuring its absorbance at 
wavelength A260nm/A280nm (WPA UV 1101, Biotech Photometer).  The ratio of 
A260nm/A280nm can give an estimate of the purity of the RNA. Pure RNA solutions 
have an optical density ratio of 2.0. Optical density values less than 1.5 indicates 
ethanol or protein contamination. The RNA samples were either stored at -80oC until 
used later or used for reverse transcription (RT). 
3.3.2: Reverse transcription (RT) 
RT-PCR is a simple, versatile and sensitive technique, which has greatly enhanced the 
study of genes and how they are controlled. It provides an alternative and more 
sensitive approach for the analysis of mRNA, compared with other procedures such as; 
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Southern blots for DNA analysis and Northern blots for RNA analysis. This technique 
has the advantage over more traditional methods because it requires a smaller amount 
of RNA, and yet is more sensitive and rapid. In this study, complimentary DNA (cDNA) 
was synthesized by using the DuraScriptTM RT-PCR KIT (Sigma-Aldrich, Inc.). 
According to the manufacturer's instructions, a 20-μL-reaction mixture was added in a 
polypropylene tube (Eppendorf):  
0.25μg of total RNA template (volume depends on concentration) 
PCR H2O (volume=8μL – volume of the RNA template) 
1μL of deoxynucleotide mix (500 μM of each dNTP)  
1μL of anchored oligo (dT) 
The samples were heated at 70°C for 10 minutes to denature RNA secondary structure 
which allowed for more efficient reverse transcription, and were then placed on ice. The 
following components were added to the samples:  
6 μL PCR H2O 
2μL 10×buffer for DuraScript RT 
1μL RNase inhibitor 
1 μL DuraScript reverse transcriptase 
The resultant total volume in each eppendorf tube was 20 μL. The samples were 
incubated at 50oC for 50 minutes. The cDNA samples were then diluted to 1:4 by 
adding 60 μL of PCR H2O. The samples were stored at -20
oC until required. 
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3.3.3: Polymerase chain reaction (PCR) 
The polymerase chain reaction is a very powerful technique for enzymatically amplifying 
a nucleic acid target sequence. It was devised by Karey Mullis in 1983, for which he 
was awarded the Nobel prise in 1994. A particular gene was amplified by using a 
REDTaqTM ReadyMix PCR reaction mix (Sigma-Aldrich, Inc.). A 12-μl-reaction mixture 
was prepared in a thin walled PCR tube: 
1μL of cDNA template 
1μL of forward primer (at a working concentration of 1 μM) 
1μL of reverse primer (at a working concentration of 1 μM) 
6μL of 2×REDTaqTM ReadyMix  
3μL of PCR H2O 
Cycling conditions for the 12-μL-reaction mixture were 94˚C for 5min, followed by 30-36 
cycles of 94˚C for 30s, 55˚C for 30s, and 72˚C for 40s. This was followed by a final 
extension of 10 min at 72˚C. PCR products were visualized on a 0.8% or 2% agarose 
gel through staining with ethidium bromide after electrophoresis. 
 
3.3.4: Agarose gel DNA electrophoresis 
Agarose gel electrophoresis is the easiest and commonest way of separating and 
analyzing DNA. The purpose of the gel might be to look at the expression of DNA, to 
quantify it or to isolate a particular band. The DNA is visualised in the gel by addition of 
ethidium bromide. This binds strongly to DNA by intercalating between the bases and is 
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fluorescent by means of absorbing invisible UV light and transmits the energy as visible 
orange light.  
A 0.8% gel was used for of large DNA fragments (1–10kb), while a 2% gel  showed 
good resolution for small fragments (<1kb). In the present study, 20mls of agarose gel 
solution at the appropriate concentration was poured into an universal container 
(Sterilin, UK) and cooled to about 55˚C before casting the gel in the mould.  A well 
forming comb was then inserted into the gel mould and the gel was allowed to set at 
room temperature for about 30-40 minutes. 
Once the gel had set, TBE buffer was carefully poured into the electrophoresis tank until 
it reached a level of about 5mm from the surface of the gel.  The PCR products were 
loaded into the wells (6μL per well) by placing the gel loading tip through the buffer and 
locating it just above the bottom of the well.  The sample was slowly and delicately 
delivered into the well. This procedure was continued until all the samples had been 
loaded into the gel.  A 1Kb DNA ladder (Cat No. 15615-016, Invitrogen Inc., USA)  was 
prepared according to the manufacturer’s instructions, and delivered into the well (5μl 
per well) in the same manner as for the PCR products. 
A power pack (Gibco BRL, Life Technologies Inc.) was connected to the electrophoresis 
apparatus and the gel was run at a constant voltage of 100 Volts.  Electrophoresis was 
continued for 30-50 minutes or until the samples had migrated about two-thirds of the 
way down the agarose gel (depending on the size of the PCR products).  The PCR 
products were stained using ethidium bromide (10mg/ml) for 5 minutes with continuous 
agitation to ensure even staining of the agarose gel.  This was followed by destaining in 
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distilled water for about 1 hour, to reduce the background staining.  PCR products were 
then visualised on the agarose gel using an UV Transilluminator (UVP, Inc, Cambridge, 
England, UK). Gel images were printed using a Mitsubishi thermoprinter (Mitsubishi UK, 
London) and saved as a TIFF image file using a default image saving facility.  
 
3.3.5: Quantitative real time PCR (Q-RT-PCR) 
Real time quantitative PCR is a sensitive technique to determine quantitatively prevalent 
levels of messenger RNA of the gene of interest. Q-RT-PCR is capable of detecting 
very small quantities of cDNA within a sample and carries minimal chances of error if 
standards are followed. In our laboratory we used real-time quantitative PCR, based on 
the Amplifluor™ technology, modified as previously reported (Jiang et al. 2005). The 
cDNA used in this technique was generated by this same technique as described 
before. This cDNA was used to make up a master reaction mixture containing the 
following amounts of each component per reaction 
Forward Z primer – 0.3 µL (1 pmol/µL) 
Reverse primer - 0.3 µL (10 pmol/µL) 
Q-PCR master mix (Hot-start Q-master mix ABgene, Surrey, UK) - 5 µL 
Probe Ampiflour (FAM-tagged probe) - 0.3 µL (10 pmol/µL) 
PCR H2O – 2.1 µL 
cDNA - 2 µL 
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Pairs of PCR primers were designed using the Beacon Designer™ software (version 2, 
Palo Alto, CA, USA), but added to one of the primers was an additional sequence, 
known as the Z sequence (5'actgaacctgaccgtaca'3) which was complementary to the 
universal Z probe (Intergen Inc., Oxford, UK). In each reaction one of the primer pair 
contained a Z sequence at 1/10 concentration of the other primer and probe. The 
Ampiflour system was used to detect and quantify transcript copying number. The 
ampiflour probe consists of a region specific to their Z sequence together with a hairpin 
structure labelled with a fluorescent tag (FAM). While in the hairpin structure this 
fluorescent tag is effectively quenched and produces no signal. However the specificity 
of the 3' region of the ampiflour probe to the Z sequence causes the incorporation of this 
uniprimer. Subsequent DNA polymerisation, following the incorporation, results in the 
destruction of the hairpin structure and effective signalling of the fluorescent tag within 
the structure. The degree of fluorescence within each sample is compared to a range of 
standards of known transcript copying number, allowing the calculation of transcript 
copying number within each sample. Detection of β-actin copy number within each 
sample was subsequently used to allow further standardisation and normalisation of the 
samples. 
Sample cDNA was amplified and quantified over a large number of shorter cycles using 
i-cycler IQ thermal cycler and detection software (BioRad laboratories, 
Hammelhempstead, UK) and experimental conditions as outlined below. 
Step 1: Initial denaturing period - 94ºC for 5 minutes 
Step 2: Denaturing step - 94ºC for 10 seconds 
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Step: 3: Annealing step - 55ºC for 15 seconds 
Step 4:  extensions step - 72ºC for 20 seconds 
Step 2 to 4 was repeated over 60 cycles.  
The camera used for detection of fluorescence in the system was set to detect 
fluorescent signal during the annealing stage. The experimental procedure was 
repeated twice and data are representative of expressional trends of different 
messenger RNAs. In this established method, approximately 20 cycles were required 
for the generation of Z-tagged products. Quality standards were maintained using 
specific Q-PCR primers verified using a positive control known to express molecule of 
interest and a negative control. PCR water replaced DNA in the negative control and it 
also helped to rule out contamination of the reaction. 
 
3.4: Methods for detecting protein: 
 
Two different methods were employed in present study to assess the expression of a 
certain gene at the protein level. These included western blot and immunofluorescent 
staining. 
 
3.4.1: SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blot 
3.4.1.1: Preparation of cell lysates 
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 Cells were removed from the base of the culture flask using a disposable cell 
scraper. Cells were transferred using a pipette in to a clean universal container. 
 Samples were centrifuged at 2,000 rpm for 5 minutes. 
 The supernatant discarded and cell pellet resuspended in 200-300 μL of lysis 
buffer (20 μL per 500,000 cells) and the resultant lysates transfered into 1.5ml 
eppendorf tubes. 
 Samples were incubated at 4˚C for 40 minutes with continuous rotation in order 
to extract protein from the cell lysate. 
 Samples were centrifuged at 13,000 rpm for 15 minutes in order to remove 
cellular debris. The supernatant was transfered to a new tube and the pellets 
were discarded. The protein samples were quantified and utilised for SDS-PAGE, 
or were stored at -20˚C until used. 
 
3.4.1.2: Determination of protein concentration of cell lysates 
This method was based on a protocol supplied by BIO-RAD, from whom the protein 
assay kit was purchased. 
 Preparation of working reagent. 20 μL of reagent S was added to each ml of 
reagent A which was required for the run.  
 Bovine serum albumin stock with known concentration (Sigma; 100mg/ml) was 
diluted serially and prepared in the same cell lysis buffer to give a working 
concentration range between 0.50-0.79 mg/ml. A standard curve was prepared 
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each time the assay was performed. For best results, the standard was always 
prepared in the same buffer as the sample. 
 5 μL of standards and samples were added into a 96-well plate. 
 25 μL of reagent A (see note from step 1) and 200 μL of reagent B were added 
into each well. 
 After 15 minutes, absorbance was read at 590 nm. The absorbance is usually 
stable for about 1 hour.  
 A standard protein curve for the bovine serum albumin was constructed and the 
unknown protein concentrations of the cell lysate samples were determined. 
 Protein concentrations were adjusted to a working range of 1-2 mg/ml by diluting 
in cell lysis buffer. 
 Crude cell lysates were prepared for SDS-PAGE by diluting a portion of the 
quantified lysate sample with a 2x sample buffer (containing 2x 
mercaptoethanol). 
 Crude cell lysate samples were denatured by boiling at 100˚C for 5 minutes. 
Cooled at room temperature for 5 minutes and centrifuged to collect droplets. 
 The samples were subsequently loaded on a gel, or stored at -20˚C until 
required. 
 
3.4.1.3: Preparation of immunoprecipitates 
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Immunoprecipitation is an invaluable technique used to analyse intracellular 
phosphorylation events occurring following extracellular stimulation. The process of 
immunoprecipitation involved cell lysis, followed by the addition of a specific antibody 
directed against the phosphorylated protein present within the cell lysate sample. The 
resultant antigen-antibody complexes were then collected by the addition of 
staphylococcal protein A, protein G or their mixture, which was covalently attached to 
agarose beads. These immune complexes were precipitated by centrifugation, 
separated by SDS-PAGE and analysed by immunoprobing. A brief description of the 
immunoprecipitation method used in this study is outlined in the following paragraph. 
 Specific quantities of PY20/PY90 antibody were added to the cell lysate. The 
concentration or dilution of the antibody followed the corresponding instruction of 
the antibody used. 
 Samples were incubated at 4˚C for 1 hour with constant agitation on a rotating 
wheel. 
 50μL of conjugated A/G protein agarose beads (Santa Cruz Biotechnology, 
supplied by Insight Biotechnologies Inc, Surrey, England, UK) were added into 
each sample, and then the samples rotated on the rotating wheel for 1 hour to 
allow the antibody-antigen complex to get attached to the beads. 
 Samples were centrifuged at 7000 - 8000 rpm for 5 minutes, to remove unbound 
protein or excess antibodies from the supernatant fraction. 
 Protein pellets were washed twice using 200-300μL of lysis buffer. 
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 The pellets were resuspend in 40-60μL of 2x sample buffer, and denatured by 
boiling at 100˚C for 5 minutes. 
 The samples were stored at -20˚C until required for use. 
 
3.4.1.4: Gel preparation 
 Four glass plates (2 large rectangular and 2 small rectangular plates) were dried, 
cleaned and assembled in pairs of gel cassettes on a casting stand. Alignment 
was checked by a card to verify glass plates and spacers were aligned properly. 
Glass plates were held in place securely by tightening the thumb screws. 
 The space between the glass plates was filled with some alcohol to test the seal 
for leaks.  
 Polyacrylamide resolving gel was prepared after adding the specified amount of 
TEMED and 10% APS, with gentle stir to mix. 
 Using another plastic pipette, immediately the resolving gel was applied carefully 
by running the solution down from one side between the glass plates until it 
reached a level about 1 cm below the top of the smaller plate. 
 Using a new pipette, the top of the resolving gel was covered with 0.1% solution 
of SDS until a layer of about 2mm formed on top of the gel solution. This ensured 
the gel would set with a smooth surface. 
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 Gels were left to polymerize at room temperature for about 30 minutes. When the 
gel had set a sharp refractive change at the overlay/gel interface could be 
observed on polymerization. Furthermore, the unused resolving gel in the 
universal container was also used to confirm the setting of gel. 
 SDS solution was removed and the gel surface rinsed with deionized or distilled 
water.  
 The stacking gel was prepared as per instructions specified by manufacturer 
remembering not to add the TEMED and APS until ready to use. 
 The stacking gel solution was added immediately to the gel cassette (on top of 
the resolving gel) in the same manner as the resolving gel, until its upper surface 
was flush with the smaller glass plate. 
 A well forming Teflon comb was inserted carefully, (taking care not to trap 
bubbles between the glass plates) into the layer of stacking gel, until it reached 
within 1mm from the top of the spacers. 
 The stacking gel was allowed to polymerize for 30minutes at room temperature.  
 Once the stacking gel had set, the Teflon comb was removed without tearing the 
edges of the polyacrylamide wells. The wells were rinsed with distilled water and 
gel cassettes were placed in a gel electrophoresis rig with the small glass plate 
facing the silicone gasket. 
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 The gel rig was placed into the electrophoresis chamber and central reservoir, 
formed by the gel plates was filled with running buffer so that the top of the wells 
was completely covered.  
 Subsequently the chamber was filled with sufficient 1x running buffer to immerse 
the thumb screws. 
 
3.4.1.5: Loading the samples 
 Equal volumes (10μL) of crude cell lysates or precipitated proteins (containing 
sample buffer) were inserted into the wells. This was accomplished using a 50μL 
syringe (Hamilton) with a flat-tipped needle, and carefully locating the tip of the 
needle just above the bottom of the wells and then slowly delivering the protein 
into the well. 
 Control wells were loaded with 10μL of pre-stained molecular weight standard. 
Documentation regarding the sequence of the protein samples was completed.  
The lid of the tank over the apparatus was replaced and leads were connected. 
 
3.4.1.6: Running the gel 
 High voltage lead wires were connected according to manufacturer instructions. 
The gel was allowed to run on constant current 40mA at 125V (20mA per gel) 
until the ladder had reached within 1 cm of gel bottom. The usual running time 
was about 40-60 minutes. 
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3.4.1.7: Preparation of membrane 
 A nitrocellulose membrane (Hybond C, Ammersham, Cardiff) was cut to the 
dimensions of the gel (7.5×7.5cm) and immersed in 1× transfer buffer for about 
10-20 minutes to ensure proper binding of the protein to the membrane. 
Similarly, four sheets of filter paper of the same dimensions (7.5×7.5cm) were cut 
and soaked in 1× transfer buffer for 10-20 minutes.  
 Upon completion of the electrophoresis, the gel was separated from the glass 
plates by disassembling the apparatus and it was transferred in to a container 
with transfer buffer. 
 
3.4.1.8: Electroblotting 
 The pre-soaked nitrocellulose membrane was placed on the two sheets of 
soaked filter papers previously placed on electrode. The gel was transferred on 
top of the nitrocellulose membrane taking care not to trap air bubbles between 
the gel and membrane and maintaining the orientation of loaded samples. 
 Two more sheets of wet filter paper were placed on top of the gel creating a 
sandwich of paper-nitrocellulose-gel-paper (Figure 3.1). 
 Any air bubbles were removed by rolling a glass rod across the surface to ensure 
good contact between the gel and nitrocellulose membrane. 
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 The surface of this sandwich was carefully smoothed out, using a transfer pipette 
as a rolling pin to remove the formation of air bubbles which may interfere with 
protein transfer. 
 Finally the cover, containing the cathode plate of the blotter was positioned on 
top of the transfer “sandwich” and high voltage leads connected to the power 
supply. A constant current at 5 Volts, 500 mA and 8 Watts for 30-40 minutes, 
was applied. 
 After transfer was complete, the cathode plate of blotter was removed after 
turning off the power supply. Complete transfer was assured before removal of 
membrane from sandwich. 
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Figure 3.1 Diagram of assembling the semi dry blotting unit. 
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3.4.1.9: Specific protein detection – Immunoprobing procedure 
Specific solutions for membrane blocking and washing were prepared, including 
Solution A 
10% milk powder (5g) 
0.1% Tween 20 (50ul) 
Dissolved above in 50ml TBS 
 
Solution B 
3% milk powder (3g) 
0.1% Tween 20 (100ul) 
Dissolved above in 100ml TBS 
 
Solution C 
0.2% Tween 20 (60ul) in 30ml TBS 
 
 The blotted membrane was incubated in this blocking solution (solution A) with 
agitation for 40-60 minutes at room temperature, in order to block non-specific 
protein binding of the antibody on membrane. 
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 Followed by incubation of the membrane with 10ml of solution B for 15 mins. 
 Diluted primary antibody (1:200 diluted in the solution B) was added and the 
membrane was left on a roller for one hour at room temperature. 
 Membranes were washed for 30 minutes with agitation, changing the wash 
medium every 10 minutes with 10ml of solution B. 
 Then the membranes were treated with 5 ml of diluted Horse Reddish 
Peroxidase (HRP) conjugated secondary antibody (typically 1:1,000 in solution 
B) with agitation for one hour at room temperature. 
  The membrane was washed again with 10ml of solution B twice, each for 15 
mins. 
 Finally membranes were washed twice using 10ml per wash of the solution C, 
and than washed twice for 15 minutes each in TBS to remove residual detergent 
and transferred to weighing boats containing TBS solution using forceps until 
ready for chemiluminescent detection. 
 
3.4.1.10: Chemiluminescent detection of protein 
 The SupersignalTM West Dura system (Pierce Biotechnology, Inc., Rockford, IL, 
USA), which has a highly sensitive chemiluminescence substrate, was used to 
detect the horseradish peroxidase (HRP) in western blot. The two substrate 
components were mixed at a 1:1 ratio with a final volume of 0.125ml/cm2 (for a 
mini gel – 4ml of each reagent). 
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 Excess TBS buffer was removed from the membrane by draining the membrane 
over a piece of folded tissue paper and briefly touching the edge of the 
membrane. 
 The membrane with protein side down was immersed in a clean tray containing 
the chemiluminescence working solution and agitated for 5 minutes.  
 The membrane was wrapped in the saran wrap and placed in a plastic tray with 
the right-side facing up. The chemiluminescence signal was captured and 
visualised by using a UVITech imager (UVITech, Inc., Cambridge, England, UK). 
The protein bands were then quantified by using UVIband software (UVITEC, 
Cambridge, UK). 
 
3.4.1.11: Amido black staining protocol 
 After protein band visualization the membrane was immersed in Amido black 
stain for approximately 15-30 seconds. 
 The membrane was destained in a solution containing 10% acetic acid /10% 
isopropanol until bands were clearly observed. 
 The Amido black stain provided a permanent record of the membrane which can 
then be compared to corresponding images from the chemiluminescence assay, 
to aid in the orientation of the membrane. 
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3.5: Zymography: 
Numerous methods have been developed to measure the expression and activity levels 
of proteolytic enzymes in different tissues and biological fluids (Cheng et al. 2008). 
Zymography is a technique now routinely used for the detection of MMPs in complex 
biological samples (Snoek-van Beurden  et al. 2005). It was first pioneered by Granelli-
Piperno and Reich (1978) and subsequently described by Heussen and Dowdle (1980) 
as a method for detecting plasminogen activators in gelatin substrate slab gels.  
Zymographic analysis involves the electrophoretic separation of proteins under denaturing 
but non-reducing conditions through an SDS-polyacrylamide gel containing a co-polymerised 
protease substrate such as gelatin. Upon electrophoresis, resolved proteins are renatured 
in non-ionic detergent which removes the SDS, and susbsequently incubated in a buffer 
system which supplies the chloride and zinc ions, the enzymes require to be active. As 
previously known, zymogen forms of MMPs are activated through this process of gentle 
denaturation and renaturation; and they can therefore be detected in zymograms along 
with the active forms based on their different molecular weights (Kleiner et al. 1994). 
Following Coomassie Blue staining, MMPs are visualised as clear zones in gelatin 
containing gel, which represent proteolytic activity resulting in degradation of the gelatin 
substrate. Zymography has been described as an extremely sensitive technique. Leber 
and Balkwill (1997) reported the detection of less than 10 pg of MMP-2 on gelatine 
zymograms which can be compared favourably with techniques like Enzyme-Linked 
immunosorbent Assays (ELISA) (Kleiner and Stetler-Stevenson, 1994). Moreover, 
zymography has been used extensively in the qualitative evaluation of proteases 
88 
 
present in tumours and cell culture media (Kleiner and Stetler-Stevenson, 1994). In this 
study, gelatin zymography was employed which is routinely used for the detection of the 
gelatinases MMP-2 and MMP-9.  
 
3.5.1: Conditioned medium collection: 
As described before cells were seeded into 60mm3 culture dishes at a density of 5xl05 
cells/dish and allowed to form a monolayer. Medium was removed and cells were rinsed 
with PBS. For zymographic analysis of MMP expression, cells were cultured overnight 
in the lowest possible culture medium volume (1ml per dish) to increase the MMP 
concentration in the collected medium. Cells were cultured in serum free medium to 
eliminate contamination with exogenous constitutively expressed MMPs contained in the 
FCS of routine culture medium. The serum-free medium was removed, centrifuged at low 
speed to remove cellular debris and the supernatant was collected. It was stored at -4ºC 
until used. 
 
3.5.2: Substrate gel electrophoresis: 
Gelatinase zymography was performed in 10% SDS polyacrylamide Gel. The gels were 
prepared as described before with addition of gelatin and final concentration of gelatin 
0.1% was achieved (Table: 3.5). Prior to loading, culture medium samples were 
combined with an appropriate amount of non-reducing sample loading buffer (Ix; see 
buffer appendix), vortexed, pulsed and incubated for 30 minutes at RT to allow coating 
89 
 
of the proteins with SDS.  Samples were not boiled before electrophoresis. Following 
incubation, samples were applied to the gel as described in western blotting alongside 
the protein molecular weight marker. A standard volume of 40 µl was loaded for each 
sample. Gels were electrophoresed at 70V for 4 hours at 4°C to prevent spontaneous 
enzyme activation. 
 
3.5.3: Staining and destaining 
Following electrophoresis, gels were washed in the detergent Triton X-100 (2.5% in H2O) 
three times for a total of 1 hour to allow renaturation of the MMP proteins contained in 
the gel matrix before overnight incubation in activation buffer (see buffer appendix) at 
37°C to allow digestion of the gelatine substrate by the enzymes. Upon overnight 
incubation, gels were briefly rinsed in distilled water. A stain stock solution (0.2%) was 
prepared by   dissolving one Phast Blue® tablet (GE Healthcare, UK) in 80ml of distilled 
water,   adding 120ml of methanol, and stirring until all dye was dissolved, according to 
manufacturer’s recommendations. The solution was then filtered through Whatman filter 
paper to remove undissolved stain particles. A stain working solution was prepared by 
adding a certain volume of stain stock solution to an equal amount of glacial acetic acid 
(0.2% in water). Gels were incubated in stain working solution (200ml per gel) on a rotor-
shaker for 6 hours and then washed in destain solution (see buffer appendix) until clear 
bands against a dark blue background appeared. Gels were subsequently scanned on digital 
scanner and digital images were saved for subsequent analysis. 
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Table 3.5:  Resolving gel for zymography. 
 
 
 
 
 
8% (w/v) gel (10 ml) 
 
Final concentration in gel 
 
Acrylamide/bis-acrylamide 30% 
solution (ratio 29:1) 
 
2.7 ml 
 
8 % (w/v) 
 
H20 
 
3.6 ml 
 
- 
 1% gelatin stock solution 
 
1ml 
 
0.1% 
 Tris(1.5M,pH8.8) 
 
2.5 ml 
 
375mM 
 SDS (10% solution in H20) 
 
100 µl 
 
0.1% (w/v) 
 
APS (10% solution in H20) 
 
100 µl 
 
0.1% (w/v) 
 TEMED 
 
40µl 
 
0.4% (v/v) 
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3.6: Immunofluorescent staining (IFC) 
 
This fluorescent staining method was previously reported (Jiang et  al. 1999; Parr et al. 
2001; Martin et al. 2003) and currently used. 
 20,000 cells in 200μl aliquots per well were seeded into a 16-well chamber slide 
(Nalge NUNC International, LAB-TEK®), and then incubated at 37ºC with 5% 
CO2 overnight. 
 After incubation and treatment with HGF (40 ng/ml), medium was aspirated and 
cells fixed with ice-cold ethanol at -20ºC for 20 minutes. 
 Cells were rehydrated in BSS buffer for 20 minutes at RT. 
 Cells were permeabilised with 0.1% Triton×100 for 5 minutes. 
 Blocking was performed for 20 minutes using blocking buffer (2 drops of horse 
serum in 5ml wash buffer). 
 Samples were washed twice with wash buffer after blocking.  
 Samples were probed with primary antibody for 1 hour (1:100 made up in wash 
buffer with horse serum for blocking). 
 Samples were washed twice with wash buffer. 
 Samples were incubated with specific secondary antibody for 1 hour in the dark 
according to the primary antibody used which labelled with FITC or TRITC (1:100 
made up in wash buffer with horse serum for blocking). 
 Samples were washed twice with wash buffer. 
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 Slides were mounted with a fluorescence mounting medium, Flour-Save, 
CalBiochem, Nottingham, England). 
 Cells were viewed under a fluorescent microscope (Olympus) and photos were 
taken. Analysis was carried out using Cell Analyser software (Olympus). 
3.7: Immunocytochemistry (ICC): 
 
Specific solutions for blocking and washing were prepared, including, 
 ABC Complex: 
8 drops Reagent A to 20 ml of wash buffer; 
5 drops Reagent B to the same mixing bottle and mixed immediately 
(ABC Reagent allowed to stand for about 30 minutes before use) 
 DAB Chronogen: 
 Agents added in order and shaken each time in 5 ml distilled water 
2 drops buffer 
4 drops DAB 
2 drops hydrogen peroxide 
Wash Buffer 
 20xWash Buffer, Super SensitiveTM Wash Buffer (Bio Genex, USA) 
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 PC-3 cells (PC-3WT, PC-3pEF and PC-3WAVE-3KD) were seeded in chamber slides 
(Nunc, Denmark), at a density of 20,000 cells/well. 
 Cell culture medium was removed by aspiration and washed twice with TBS 
buffer to remove culture medium proteins. Buffered formalin (4%) was added and 
incubated at RT for 10 minutes.  
 The fixative was aspirated and cells were washed twice with TBS buffer. 
Permeabilization buffer mixture (0.1% Triton in TBS buffer) was added and 
incubated for 10 min.  
 Cells were washed twice with washing buffer following aspiration of 
permeabilization buffer. 
 Non specific protein block was performed with diluted horse serum for 20 
minutes (1 drop to 5 ml washing buffer).  
 Chambers were washed again in washing-buffer for 4 times.  
 Cells were incubated with diluted primary antibody (anti-MMP diluted 1:100 in 
blocking buffer) at 37˚C, for 1 hour.  
 Cells were washed again in washing buffer for 4 times to remove any unbound 
primary antibodies.  
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 Secondary antibodies were added (anti-mouse, rabbit or goat depending upon 
the origin of primary antibodies, with a dilution of 1:250 in blocking buffer) and 
incubated for 30 minutes at room temperature.  
 Cells were washed again in washing buffer for 4 times to remove any unbound 
antibodies.  
 ABC complex was added and incubated for 30 minutes at RT.  
 DAB chromogen was added for 5 minutes in the dark after washing again four 
times (covered by a tray).  
 Excess chromogen was removed by washing with water for 2 minutes.  
 Cells were counterstained with Mayer's Haematoxylin for 1 minute. Finally they 
were washed in water for 5 minutes to remove excess of Haematoxylin. 
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3.8: Knockdown of gene transcripts using ribozyme 
transgenes  
 
Ribozyme stands for ribonucleic acid enzyme and represent RNA molecule capable of 
catalyzing a chemical reaction. Kruger et al. (1982) were the first ones to use this term, 
followed by pioneering work from Cech and Altman (Cech, T.1990; Altman, S. 1995). 
Ribozymes are found ubiquitously in nature and many of them catalyze hydrolysis of 
their own phosphodiester bonds are responsible for hydrolysis of bonds in other RNA 
molecules. The hammerhead ribozyme got its name due to the peculiar appearance of 
its molecular shape. It was first discovered as a self cleaving domain in the RNA 
genome of many plant viroids and virusoids. With the advancement in understanding 
regarding their role in cells, it was demonstrated that the hammerhead motif could be 
incorporated in to short synthetic oligonucleotides and transformed in to a true catalyst 
which was capable of cleaving many varieties of RNA.   
All hammerhead motifs share a typical secondary structure consisting of three helical 
stems (I, II and III) that enclose a junction characterized by several invariant nucleotides 
(i.e., the ‘catalytic core’). In most trans-acting hammerhead ribozymes, helix II is formed 
intramolecularly by the catalyst, whereas helices I and III are formed by hybridization of 
the ribozyme with complementary sequences on the substrate. The best triplets in terms 
of cleavage rates were found to be AUC, GUC and UUC. 
We synthesised ribozymes with a Touchdown PCR procedure, and cloned ribozymes in 
a suitable vector which was followed by transformation and transfection using an 
electroporator.  After 3-4 weeks selection with a specific antibiotic, a stable cell line with 
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a transgene was verified by using RT-PCR and Western-blot. This method has been 
extensively used and reported previously in our laboratory (Jiang et al. 2001, 2003 and 
2005). 
3.8.1: Production of ribozyme transgenes: 
Messenger RNA for WAVE proteins was targeted by specifically developed transgenes 
targeting WAVE mRNA. The secondary structure of mRNA was predicted using Zuker’s 
RNA Mfold software (Zuker 2003). It can predict the stem and loop structure of mRNA 
with quiet reliable accuracy, under optimal condition. From this predicted structure a 
suitable GUC codon was selected. In this programme usually the codons which are 
located in the loop segment of secondary structure, are targeted. It allows easy access 
of the ribozyme to the codon. Once designed the transgenes were ordered from 
Invitrogen (Invitrogen Corporation, California) as sense/antisense strands (Table: 3.3) 
and combined in to transgene using touchdown PCR, under conditions as follows: 
Step 1: Initial denaturing period: 94˚C for 5 minutes 
Step 2: Denaturing: 94˚C for 20 seconds 
Step 3: Annealing: 72˚ C for 15 seconds for 1st cycle 
   60˚ C for 15 seconds for 2nd cycle 
   58˚ C for 15 seconds for 3rd cycle 
   54˚ C for 15 seconds for 4th cycle 
Step 4: Extension:  72˚ C for 50 seconds 
Step 3: Final extension period: 72˚ C for 8 minutes 
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Step 2-4 were repeated for 32 cycles. Once combined, the transgenes were run 
electrophoretically on 2% agarose gel to confirm their presence and accurate size 
before they were inserted in to empty pEF6 plasmids. 
 
3.8.2: Topo TA cloning 
The TOPO TA Expression system provides a highly efficient, 5 minute, one step cloning 
strategy ("TOPO Cloning") for the direct insertion of Taq polymerase amplified PCR 
products into a plasmid vector for high-level expression in mammalian cells. No ligase, 
post-PCR procedure, or PCR primers containing specific sequences are required. Once 
cloned, analysed, and transfected into a mammalian host cell line, the PCR product can 
be constitutively expressed. Cloning of ribozyme transgenes was carried out according 
to manufacturer’s recommendations and using the kit provided. 
Spontaneous ligation between vector and appropriate insert occurs when they are 
combined in specific concentration and conditions. Cloning reaction was set up by 
adding 4 μl of PCR product, 1 μl of salt solution and 1 μl of TOPO® vector in the PCR 
tubes. The solution was gently mixed and incubated at room temperature for 30 minutes 
and stored in ice until ready to proceed with one shot chemical transformation. 
Following ligation, the cloning reaction was transformed immediately into E. coli, to 
prevent any compromise for the transformation efficiency. 
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Figure 3.2: Schematic presentation of cloning reaction  
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3.8.3: Transferring plasmid into E.coli 
The cloning reaction was transferred into the chemically competent E. Coli cells 
(OneShottm TOP10 E.Coli, Invitrogen Inc.) through following process: a 100 μl aliquot of 
the chemically competent bacteria (stored at -70°C) was thawed by immersion in to an 
ice-bath for 5 minutes. Following this, the cloning reaction was added and gently mixed 
using a pipette; this suspension was then placed on ice for 30 minutes. Cells were heat-
shocked, in a water bath, at exactly 42°C for 30 seconds, then immediately placed back 
on ice for 2 minutes. Following which, 250μl of SOC medium was added. These cells 
were incubated for 60 minutes at 37°C with continuous shaking at approximately 225 
rpm. The resultant transformation mix was plated out (at two different volumes) onto 
pre-warmed selective LB-agar plates containing ampicillin (50 μg/ml). LB medium was 
prepared by dissolving l0 g tryptone, 5 g yeast extract, and l0 g NaCl in 950 ml 
deionised water. The pH was adjusted to 7.0 with NaOH, and final volume made up to 1 
liter. The solution was autoclaved and Ampicillin was added. This medium was then 
stored at room temperature. To create LB plates, 15g of agar was added to the one liter 
of LB medium before autoclaving. Following cooling, it was added to plates and allowed 
to set. Once prepared these plates were stored in an inverted position, at 4°C. 
 
3.8.4: Selection and analysis of colonies 
Following overnight incubation, the plates revealed a large number of bacterial colonies 
containing the plasmid vector. The plasmid vector encodes a gene to enable resistance 
to Ampicillin and when transformed into the E. coli, it confers this resistance to these 
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cells. Thus, selection occured in the presence of Ampicillin, as cells without the plasmid 
vector will not survive. The next step was to establish a population of bacteria 
containing plasmid with correct orientation of inserted transgene, in order to get correct 
and effective ribozyme transgene. Analysis of the individual colonies was performed to 
determine which of the colonies grown on the plate contained the vector plus insert in 
the correct arrangement, prior to amplification. 
At least 10 colonies were screened with PCR, to amplify the target sequence of insert 
DNA at the correct position within the plasmid vector. Samples were obtained by 
touching individual colonies with a pipette tip then transfering those cells into the PCR 
reaction cocktail ready for specific amplification of the desired sequence. This was 
achieved through the use of the forward primer for the plasmid and the reverse primer 
specific for the inserted PCR products. This ensured that amplified products, at the 
expected size, are that of the plasmid and insert in the correct orientation. Once 
confirmed from the results of PCR, these colonies were then ready for amplification. 
 
3.8.5: Amplification and purification of plasmid DNA 
Following identification of positive colonies with the appropriate vector and insert 
positioning, a single positive colony was transferred, aseptically, to inoculate 2ml of LB 
medium, containing Ampicillin at a final concentration of 100μg/ml, and incubated until 
the culture grew to mid-log phase at 37°C in a rotary shaker. At which stage, the 
resultant culture was then added into 100 ml LB medium (plus ampicillin), and 
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incubated overnight at 37°C under rotation. The resulting amplification of recombinant 
plasmids within E.coli, was extracted using a plasmid DNA purification kit (Filter Maxi 
System, QIAGEN, West Sussex, UK), as described below. 
This method using QIAGEN Maxi filter cartridges has the capacity to recover plasmid 
DNA from the 100 ml of bacterial cells. To harvest the culture, cells were centrifuged in 
a refrigerated centrifuge (at 4 oC) at 6000g for 15 minutes. Medium was removed so 
that only bacterial cells could be collected as a pellet. This pellet was then resuspended 
in 10 ml of resuspension buffer, containing RNase inhibitors (available in the pack). To 
lyse the cells, 10 ml of cell lysis buffer was added and the solution mixed gently to 
avoid shearing of genomic DNA. Following 5-minute incubation at room temperature, 
10 ml of neutralization buffer was added and mixed, and then transferred to the 
QIAGEN filter cartridge. After 10 minutes at room temperature, the cell lysate was 
filtered into the barrel of the QIAGEN tip, which was then allowed to enter the resin by 
gravity flow. The plasmid DNA binds to the anion-exchange resin. 
To remove all contaminants from the plasmid preparation, the resin was washed 
throughly with wash buffer. RNA, proteins, dyes, and low molecular weight impurities 
were removed by this medium-salt wash. The DNA was eluted from the resin through 
the addition of a high salt elution buffer, and was collected in a 50 ml universal tube. 
Plasmid DNA was then concentrated and desalted by isopropanol (10.5ml) precipitation, 
followed by a series of centrifugation and washing steps. The pellet was then dried and 
resuspended in a suitable volume of water. The yield of DNA was determined through 
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quantification, following which, a small amount of plasmid DNA was run on agarose gel 
(0.8%) to check both plasmid purity and size. 
 
3.9: Transfection via electroporation of mammalian cells 
 
Once the plasmid DNA had been isolated, purified and quantified, it was ready to be 
introduced into cultured mammalian cells. The method employed during this study, 
utilized electroporation of cultured cells to allow plasmid DNA to be incorporated into the 
cells. The electroporation technique used the Easy Jet Plus system (Flowgen, 
Staffordshire, UK), which passed a voltage of up to 310 volts across the cells to produce 
small perforations in the cell wall integrity, thus allowing passage of plasmid DNA 
across cell membranes to be integrated into the cells.  
 For a transfection, 3 pg of plasmid DNA was added to resuspended cells and mixed. 
The mixture was left to stand at room temperature for 2-5 minutes. The mixture was 
then transferred into an electroporation cuvette (Euro Gentech, Southampton, UK) 
ready for electroporation. The cuvette was loaded into the electroporator and a pulse of 
electricity (310 volts) was passed through the cuvette. The mixture was then 
immediately (within 10 seconds) transferred into 10 ml of pre-warmed culture medium. 
These cells were then cultured under the usual incubation conditions, as described 
before in methodology (Chapter 3; 3.2). 
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3.10: Establishing a stable expression mammalian cell line 
 
To create a stable cell line that does not expresses the WAVE-3 gene; the culture was 
designed to yield only a population of cells expressing the plasmid-insert.  The above 
electroporated cells were allowed to grow to semi-confluence, prior to exposure to 
selection conditions. Selection of plasmid positive cells relies on the presence of an 
additional drug (Blasticidin) resistance gene in the plasmid. Plasmids used in this study 
have dual resistance genes, i.e. one for prokaryotic selection (as already mentioned 
earlier) and one for mammalian selection. For the latter, modified antibiotics that are 
capable of entering mammalian cells are used, such as blasticidin (for pEF6/V5-His-
TOPO). Thus the respective antibiotic was added to cultured cells at an appropriate 
concentration (5pg/ml for blasticidin) to kill cells lacking appropriate plasmid. This 
antibiotic selection period was continued for a week, at which point the cells remaining 
should all contain the plasmid and the inserted DNA fragment. Cells were routinely 
tested for the presence of the plasmid and insert, using RT-PCR. This was achieved 
through study of expression for different WAVEs mRNA and expression of the protein 
itself. The transfectants cell populations were then employed in a series of in vitro 
studies, to examine for the influence of WAVE-3 gene knock down. 
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Figure 3.3 Secondary structure of the hammerhead ribozyme with bound substrate. 
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3.11:  In vitro functional assays: 
3.11.1:  In vitro cell growth assay  
We used the method previously reported in literature (Jiang et al. 2005). Briefly, an 
equal number of the respective cells were plated into a 96-well plate (2,500cells/well). 
Cells were fixed in 10% formaldehyde on the day of plating; days 1, 3, and 5 after 
plating; and then stained with 0.5% (w/v) crystal violet. Following washing, stained 
crystal was extracted with 10% (v/v) acetic acid and absorbance determined at a 
wavelength of 540nm by using a spectrophotometer (BIO-TEK, ELx800, Wolf 
Laboratories, York, England). 
 
3.11.2:  In vitro migration assay (wounding assay)  
The migration of cells across a wounded surface of a near-confluent cell monolayer was 
examined, which has been described in a previous study (Jiang et al. 1999). Cells at a 
density of 50,000/well were seeded into a chamber slide and allowed to reach near 
confluence. The layer of cells was then scraped with a fine gauge needle to create a 
wound of approximately 200 mm. A treatment was then added with appropriate control. 
The movement of cells to close the wound was recorded using a time lapse video 
recorder and analysed using the motion analysis feature in a software package Optimas 
6.0.  
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3.12.3:  In vitro motility assay using Cytodex-2® beads  
We followed the protocol described by Rosen and Jiang (Rosen et al. 1990; Jiang et al. 
1995). 1×106 cells were incubated with 100μl of beads in 10 ml DMEM overnight. The 
beads were washed to remove dead cells in 5ml DMEM twice, and then resuspended in 
800μl DMEM. 100μl of beads/cells were transferred into each well of a 24-well plate, 
and repeated in triplicate. After incubation for 4 hours, the medium was aspirated and 
cells were fixed with 4% formalin for 5 minutes. They were then stained with 0.5% 
crystal violet for 5 minutes. The cells were washed and allowed to dry before counting. 
Counting was performed randomly in 3 random fields per well. This was adopted to 
make sure that more than 9 counts were performed for each sample when experiment 
was set up in triplicate fashon. 
 
3.12.4:  In vitro invasion assay  
This technique was previously reported and modified in our laboratory (Jiang et al. 
1995). The technique works upon the principle that a culture plate is equipped with an 
insert which has one end sealed with a polycarbonate membrane with a pore size of 
8µm in diameter, sufficiently large enough to allow cells to migrate through it.  The 
surface of this membrane is then coated with an extracellular matrix protein solution, 
Matrigel (rich in basement membrane), to form a thin layer of gel matrix.  Since this 
technique determines the capacity of tumour cells to penetrate through the gel matrix 
and porous membrane, it represents an indication of invasive capacity.  The following 
method briefly outlines the procedure used during this study. 
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Cell culture inserts (Becton-Dickinson) for in vitro invasion, were placed into a 24 well 
plate (Nunclon) using forceps.  To prevent irreversible gelling of Matrigel the following 
procedure was carried out at 4˚C.  A stock solution of Matrigel was prepared at a 
concentration of 0.5mg/ml in pre-cooled sterile water and 100µL aliquots of Matrigel 
(50μg per insert) were added to these pre-chilled cell culture inserts.  Once the inserts 
had a thin even coating of Matrigel, they were incubated at 45˚C in a drying oven, to dry 
out the Matrigel.  Prior to use, the Matrigel layers were rehydrated by incubating at room 
temperature for 1 hour using 300μL of sterile water, and then aspirating the water from 
each insert. 
Cell suspensions were added to each insert and treated.  After a culture time of upto 72 
hours at 37oC, the Matrigel layer together with the non-invasive cells were removed 
from the inside of the insert using a cotton swab.  This step was performed as the 
Matrigel is stained in addition to the cells, thus making it difficult to resolve between 
invading cells and background.  The cells which had invaded into the Matrigel and 
migrated through the porous membrane were fixed in 4% formaldehyde, for 10 minutes 
at room temperature.  The cells were washed twice using distilled water and stained 
with 0.5% crystal violet for 10 minutes at room temperature.  Excess stain was removed 
by washing the cells twice in distilled water.  The cells were allowed to air dry and the 
numbers of invading cells were counted using a light microscope, prior to being 
photographed. 
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3.12.5: In vitro cell-matrix adhesion assay  
100μL serum free medium that contained 5μg Matrigel (BD Matrigel™ Matrix, 
Matrigel™ Basement Membrane Matrix, Cat No. 354234) was added in each well of 96-
well plate (NUNC™, TC Microwell 96F, Cat No. 167008), and then the Matrigel was 
dried at 55°C for about one hour in oven. Matrigel was rehydrated in 100μL sterile water 
per well at room temperature for 40 minutes, and then the medium was aspirated. 
40,000-50,000 cells per well were seeded since the plates with Matrigel were ready. 
The cells were incubated with or without treatment of hepatocyte growth factor (HGF) at 
37°C with 5% CO2 for 40 minutes. After the incubation or treatment with hepatocyte 
growth factor (HGF), the medium was discarded. The non adherent cells were washed 
off 3-4 times using BSS buffer.  The cells were then fixed with 100μl per well of 4% 
formaldehyde for a minimum of 5 minutes. The formaldehyde was discarded and the 
cells washed with BSS buffer. 100μl of crystal violet solution (0.5% crystal violet in 
distilled water) was added into each well for up to 5 minutes, washed with BSS buffer, 
and then left to dry at RT. The number of adherent cells were counted under a 
microscope, from random fields in a triplicate fashion and compared to the number of 
adherent cells that remained on the Matrigel after HGF/SF treatment. 
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3.13: Statistical analysis 
 
Data from independent runs of experiments were recorded on Microsoft Excel software 
and latter imported in to statistical software SPSS 12.0.1 for further analysis. One way 
ANOVA (analysis of variance) was mainly used to compare the means for any statistical 
significance. In this method analysis of variance is used to test the hypothesis that 
several means are equal. This technique is an extension of the two-sample t-test. It is 
important to understand that the one way ANOVA test can only determine that at least 
two groups are different in the particular experiment. However it is easy to determine 
which groups are different by performing the post-hoc test. There are multiple tests 
available for post-hoc test. Levene’s homogeneiety of variance test is used first to 
determine the variance in the samples. If equal variance is assumed, Bonferroni, Sidak 
and Dunnett test can be performed for multiple comparisons. If equal variance is not 
assumed than Tamhane’s-T2, Dunnett’s T3 and Dunnett’s-C can be performed. 
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Chapter 4 
WAVE-3 in prostate cancer cell lines: Expression 
and knock down. 
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4.1: Introduction: 
 
WAVE-3 was identified in 1999 as part of the Wiskott-Aldrich Syndrome Protein family 
(WASP) (Suetsugu et al. 1999). This diverse family of proteins plays a critical role in 
actin polymerisation, organisation of the cytoskeleton and cellular motility. The 
expression profiles of WAVE genes have demonstrated overlapping expression of all 
three WAVE transcripts in many embryonic and adult tissues. These proteins have been 
frequently found to be co-localised indicating their involvement in similar processes. 
WAVE-3 was originally found to be truncated and inactivated in a patient with 
ganglioneuroblastoma. It was hypothesized that loss of this molecule resulted in 
accumulation of neural crest cells due to their abnormal migration but at the same time 
retaining their growth potential (Sossey-Alaoui et al. 2002). 
Expression of WAVE-3 has been well documented in breast cancer cell lines (Sossey-
Alaoui et al. 2005; Fernando et al. 2007). Its expression appears to be up regulated in 
motile cancer cells. Genetic silencing of WAVE-3 using different techniques has 
demonstrated a reduced motility and invasiveness of prostate cancer cell lines. The loss 
of WAVE-3 results in increased formation of stress fibers and focal adhesion complexes 
which may indicate its importance in maintaining the balance of cellular motility 
(Sossey-Alaoui et al. 2005). 
HGF is a well-documented cytokine found in patients with aggressive and metastatic 
prostate cancer. It induces growth, cellular motility and interaction of malignant cells 
with its environment resulting in increasing invasive and metastatic potential of prostate 
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cancer. HGF promotes these effects through multiple mechanisms. However the role of 
HGF in WAVE-3 dynamics has not been studied before. 
The aim of the current study was to document the expression of WAVE-3 in different 
cell lines. In the second part of this study we also analyzed the effect of HGF on 
expression of WAVE-3 in PC-3 cell line, following variable concentration and timed 
exposure of HGF. Thirdly, we wanted to generate and confirm a prostate cancer cell 
line, deficient in WAVE-3 through the process of cellular cloning and use of 
hammerhead ribozymes.  
 
4.2: Materials and methods: 
 
4.2.1: Expression of WAVE-3 in prostate cancer cell lines. 
Complimentary DNA samples were selected from a stock of ready prepared kit in the 
department, derived from different cell lines. These cell lines included PC-3, DU-145, 
CAHPVN, LNCaP, PZHPV-7, PNT1A, PNT2C2, HECV and MRCJ. Real time PCR (RT-
PCR) was used to document the expression of WAVE-3 using predefined forward and 
reverse primers, as previously described in the methods section. GAPDH expression 
was also analysed to document the quality of complimentary DNA samples. It also 
helped to normalize the DNA samples from different cell lines. 
The final products from PCR were separated using agarose gel electrophoresis. The gel 
was stained with ethium bromide (10mg/ml) for five minutes, followed by a wash in BSS 
buffer to remove any background staining. The gel was placed on ultraviolet 
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transilliminator (WPA UV 1101; Biotech Photometer, Cambridge UK). The obtained 
images were saved as pictures for subsequent analysis and records. 
Following documentation of good expression for WAVE-3 in PC-3 cell line, the effects of 
HGF at different concentrations as well as exposure over a variable time period were 
studied. Cells were exposed to concentration ranging from 1ng/ml to 100ng/ml over a 
time period of one hour. Similarly cells were exposed to a 40ng/ml concentration of HGF 
ranging from five minutes to 24 hours. Complimentary DNA was prepared as described 
before in the methods chapter (3.3.1 & 3.3.2). 
4.2.2: Knock down of WAVE-3 expression: 
4.2.2.1: Construction of ribozyme transgenes targeting at WAVE-3.  
A hammerhead ribozyme was designed based on the secondary structure of the 
WAVE-3 mRNA. The secondary structure of WAVE-3 was generated using Zuker’s 
RNA mFold programme (Zuker, 2003). The sequence in the mFold programme was the 
entire coding region of human WAVE-3.  According to both the cleavage site of target 
gene and the sequence of hammerhead ribozyme, the primers were designed (refer to 
Table: 3.3). These oligo primers had the following characteristics: restriction sites (Spe1 
(TGATCA) on the 5’ end of the reverse primer and Pst1 (CTGCAG) on the 5’ end of the 
forward primer) were included for cloning purposes; the primers permit template free 
amplification during PCR; Hammerhead ribozyme and antisense were pre-arranged in 
order that correctly oriented ribozymes were amplified. 
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The ribozymes were synthesized by using touchdown PCR (Figure 4.3 A). The 
ribozymes thus generated carried an A- overhang at the 3’ end of the product. The 
ribozyme was subsequently TA cloned into a mammalian expression pEF6/V5-His-
TOPO plasmid vector (Invitrogen Ltd., Paisley, UK), using a protocol as already 
described in chapter:3 (3.8). Following ligation, the vector was then transformed into E. 
Coli, using the heat shock method. After one-hour incubation in SOC medium which 
allows the bacteria with transgenes to generate resistance to the antibiotic, the bacteria 
were plated and incubated overnight at 37˚C. The colonies were then analysed using 
direction specific PCR, which verified both presence and direction of the ribozymes in 
the clone (Figure 4.3 B). Each colony was tested using two separate PCR reactions: 
one using T7F primer coupled with RBBMR primer and the other using T7F with RBTPF 
primer (sequences of primers in Table: 3.3). Colonies with T7F/RBBMR reaction 
positive (and with the correct /sided product) and T7F/RBTPF negative were regarded 
as the colonies with correctly oriented ribozyme insert were grown. These colonies were 
then carefully picked and grown up in a large volume of LB medium (with ampicillin). 
The respective plasmid was finally extracted, and verified using DNA electrophoresis 
(Figure: 4.3-C). 
4.2.2.2: Transfection of PC-3 cells and establishment of the stable 
transfectants.  
Ribozyme transgenes and empty plasmid vectors were transfected into separate groups 
of PC-3 cells using an electroporator (Easjet Plus, EquiBio Ltd, Kent, UK), with a 
voltage at 270V. The cells were immediately transferred to 25 cm3 tissue culture flasks 
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containing 5ml of pre-warmed culture medium. Selection of transfectants began when 
the cells reached 50%-70% confluence. The selection of positive cells was with a 
medium that contained the antibiotic blasticidin (Sigma-Aldrich, Inc., Poole, Dorset, 
England, UK) at 5μg/ml. After identification of colonies that survived the selection, they 
were then expanded into a larger population, and used for verification for the presence 
of the ribozyme and effects of the ribozymes on the expression of the respective target 
gene transcript using RT-PCR. Suitable strains were cultured in maintenance medium 
(blasticidin 0.5μg/ml) and grown to sufficient numbers for experimental studies. The 
selection took up to 2 weeks. 
 
4.2.2.3: RT-PCR for WAVE-3 and β-actin.  
RNA was isolated from the cells, and cDNA was synthesised by reverse transcription 
using 0.25μg RNA in a 20-μl-reaction mixture as described in the methods section 
(Chapter: 3; 3.3.1 & 3.3.2). PCR was undertaken using a REDTaqTM Ready Mix PCR 
reaction mix (Sigma-Aldrich, Inc.). Cycling conditions for the 12-μl-reaction mixture were 
94ºC for 5min, followed by 30-40 cycles of 94ºC for 30 s, 55 ºC for 30 s, and 72 ºC for 
40 s. This was followed by a final extension of 10 min at 72 ºC. The products were 
visualized on a 2% agarose gel and stained with ethidium bromide after electrophoresis. 
The PCR primers used are listed in chapter: 3 (Table: 3.1). 
 
4.2.2.5: Western blot analysis of WAVE-3 and GAPDH. 
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Cells were lysed and after extraction, protein concentrations were measured using the 
DC Protein Assay kit (BIO-RAD, USA). Samples were diluted using the lysis buffer in 
order that same concentration was obtained. These protein samples were then mixed 
with a 2×sample buffer which contained SDS, glycerol and a loading dye. After 
electrophoresis, proteins were blotted onto nitrocellulose sheets, followed by blocking 
before probing with specific primary antibody (anti-WAVE-3 1:100 and  anti-GAPDH 
1:250 dilution), and corresponding peroxidase-conjugated secondary antibodies 
(1:1000). Protein bands were visualized with a SupersignalTM West Dura system 
(Pierce Biotechnology, USA). 
 
4.3: Results: 
 
4.3.1: Expression of WAVE-3 in different cell lines: 
A range of epithelial cell lines were screened for 3 different members of the WAVE 
family. These included prostate cell lines (PC-3, DU-145, CA-HPV-10, LNCaP, PZ-HPV-
7, PNT1A, PNT2-C2), HUVEC (human umbilical vein endothelial cells) and MRC-5 
(human lung cells).  The WAVE-3 was abundantly expressed by prostate cancer cell 
lines including PC-3, DU-145, CA-HPV-10, LNCaP, and PNT1A. However PZ-HPV-7 
and PNT2-C2 did not show any significant expression of WAVE-3. HUVEC and MRC-5 
showed good expression but it appeared to be weaker than prostate cell lines (Fig: 4.1). 
PC-3 (WT) cells were exposed to variable concentrations over fixed time period of 17.5 
hours. Expression of WAVE-3 was noted in middle range concentration (25 ng/ml) as 
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well as high concentration (75 and 100 ng/ml) of HGF (Figure 4.2). On the other hand 
maximum expression of WAVE-3 was noted following one hour treatment with 
concentration of 40 ng/ml (Figure: 4.2). This treatment time and concentration of HGF in 
the medium, was used during subsequent in vitro experiments. 
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Fig 4.1: PCR showing expression of WAVE-3 in different cell lines. 
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Figure 4.2: Expression of WAVE-3 in PC-3 cell line, in response to HGF. PCR showing 
the expression of WAVE-3 RNA in PC-3 (WT) cell line following exposure to HGF over 
variable time (0-24 hours at fixed concentration of 40 ng/ml) and variable concentration 
(0-100 ng/ml) over 17.5 hours) 
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4.3.2: Knock down of WAVE-3: 
4.3.2.1: Generation of pEF plasmid containing WAVE-3 ribozyme 
transgene: 
Suitable sites were selected for generation of two hammerhead ribozymes based upon 
the predicted secondary structure of human WAVE-3 RNA transcript, created through 
mRNA folding programme. Touchdown PCR was used to synthesize anti-WAVE-3 
ribozyme transgene. These ribozymes were inserted in to empty pEF plasmids and 
transferred in to E.Coli. These bacteria were allowed to grow in the Ampicillin selection 
which ensured the growth of pEF plasmid containing bacteria only. Isolated random 
colonies were selected and checked for correct orientation of ribozyme transgene 
insertion to deliver correct and active viable product. Correct orientation was indicated 
by the presence of a band approximately 140 bp in the T7F Vs RbBMR reaction 
whereas band of 140bp bp in the T7F Vs RbToP was taken as incorrect orientation. 
Following selection, the colonies were amplified by overnight incubation. The plasmid 
was extracted (as described previously in chapter: 3; 3.8.2) and confirmed by gel 
electrophoresis on a 0.8% agarose gel with a band corresponding to approximately 
5890bp (Fig: 4.3). 
4.3.2.2: Expression of WAVE-3 protein in PC-3ΔWAVE-3 transfected cells: 
Expression of WAVE-3 was significantly reduced in successfully transfected cells. This 
phenomenon was exclusively observed on RT-PCR and western blotting (Fig: 4.4). 
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Figure 4.3: Cloning of WAVE-3 Ribozyme-1 & 2 (WAVE-3 Rib-1 and WAVE-3 Rib-2) 
(A): PCR showing the successful generation of the WAVE-3 ribozyme transgenes as indicated by the correct predicted product size. 
(B): PCR screening of E.Coli colonies to select those with correct orientation of the ribozyme transgene in the pEF6 plasmid. Correct orientation is indicated by a band of approximately 140bp in the 
T7F Vs RbBMR reaction, whereas a band of 140bp in the 7TF Vs RbToP is considered incorrect orientation. 
(C): PCR confirming purified pEF6 plasmid containing the ribozyme (6kb) following extraction from E.Coli. 
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4.3.3: Expression of WAVE-3 transcripts in Q-PCR: 
To confirm the knock down of WAVE-3 in the transfected cell, Q-PCR was used to 
determine the levels of mRNA expression, in addition to RT-PCR and western blotting. 
Table 4.1 and graph 4.1 shows that cells transfected with the WAVE-3 ribozyme-2 
(W3R2) transgene (PC-3 ΔWAVE-3 Rib2) exhibited a reduced level of WAVE-3 expression 
at the mRNA level. Data regarding the expression of different WAVEs was normalized 
against the expression of house keeping gene (β-actin). In contrast, cells transfected 
with the WAVE-3 ribozyme-1 transgene (PC-3 ΔWAVE-3Rib1) failed to knock down WAVE-
3 expression as demonstrated by the presence of transcripts. Similarly, both wild type 
(PC-3WT) and pEF6 transfected (PC-3pEF6) cells exhibited transcripts for WAVE-3 
expression. The β-actin transcript was present in all samples screened and was used as 
a quality control. There was no significant change observed in expression of WAVE-1 
and WAVE-2 following WAVE-3 knock down on Q-PCR, among different cell lines 
(Table4.1 & Graph 4.1). 
 
 
 
 
 
 
 
123 
 
 
 
 
 
Figure 4.4: RT-PCR and Western blotting for mRNA and protein levels of WAVE-3 in 
PC-3 cells following knockdown by ribozyme transgenes.The expression of WAVE-3 
was almost completly knocked down on RT-PCR (A) and western blotting (B) in WAVE-
3 (Ribozyme-2) as compred to WAVE-3 (Ribozyme-1). 
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Molecule 
Number of transcript copies of mRNA in cell lines 
PC-3 WT PC-3 pEF PC-3 W3Rib1 PC-3 W3Rib2 
β-Actin 1.35x10
7 1.29x107 1.44 x107 1.01 x107 
WAVE-1 9188.19 6478.76 6546.61 11389.23 
WAVE-2 952.39 919.08 792.58 544.81 
WAVE-3 1414.39 3045.94 865.09 7.53 
 
 
Table 4.1: Number of transcript copies on real time Q-PCR in four different cell lines 
(normalized against the expression of β-actin). 
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Graph 4.1: Real time Q-PCR showing number of transcript copies for WAVE-1, WAVE-
2 & WAVE-3 along with β-actin in different cell lines. 
126 
 
4.4: Discussion: 
The first aim of this part of the study was to document the expression of WAVE-3 in 
different prostate tissue cell lines. The seven prostate cell lines used in this study may 
represent different clinical characteristics of prostate cancer according to their origin. 
PC-3, DU-145, LNCaP and CA-HPV-10 represent prostate carcinomas which were 
derived from either primary tumor or secondary tumor, whereas PZ-HPV-7, PNT-1A and 
PNT2-C2 are immortalised prostate epithelial cell lines. Among the four prostate cancer 
cell lines, PC-3, DU-145 and LNCaP were derived from various metastatic sites and are 
more aggressive than CA-HPV-10, which was isolated from a primary tumor. LNCaP is 
an androgen sensitive cell line, whereas PC-3 and DU-145 represent androgen 
insensitive cell lines. These cell lines have been used in different models for the in vitro 
and in vivo investigation of prostate cancer. Strong expression of WAVE-3 in PC-3, DU-
145, CA-HPV-10 and LNCaP, observed in this study probably indicates its active role in 
prostate cancer dynamics. 
The second aim of this part of study was to generate a clone of prostate cancer cells 
deficient in WAVE-3 for subsequent studies, with particular emphasis on its effect in 
dynamics of prostate cancer metastasis. The cellular cloning involved in our experiment 
comprised silencing the specific gene expression which is usually expressed under 
normal circumstances. Specific gene expression can be modified at transcriptional and 
posttranscriptional levels. Transcriptional genetic silencing involves histone 
modifications through creation of an environment of heterochromatin around the gene, 
resulting in the gene being inaccessible to cellular machinery like RNA polymerase and 
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other transcriptional factors (Perry et al. 2010). Post-transcriptional modification involves 
mRNA of a specific gene being destroyed through introduction of specific agents 
targeted specifically against the gene of interest. A common mechanism is the 
introduction of small interfering RNAs (siRNA) which prevent the translation of specific 
gene mRNA. This concept has been used successfully in therapeutic implications of 
diseases like cancer and has shown promising results. Major targets of this therapy 
include silencing of genes involved in process of angiogenesis, metastasis, apoptosis 
and resistance to chemotherapy (Ramachandran et al. 2012). These RNAs can be 
delivered directly to intracellular environment or production can be induced through the 
delivery of plasmid DNA.  
We successfully utilized the hammerhead ribozymes to knock down the expression of 
WAVE-3 after transcription in vitro. This particular technique used in this study is highly 
effective and had dramatically reduced the levels of the representative molecule at 
protein and messenger RNA level. The hammerhead is able to reduce target gene 
expression through its capability for multiple turnovers and acts in trans or cis forms for 
irreversible cleavage of target RNA. The hammerhead ribozyme can potentially target 
against any substrate mRNA provided it contains a specific combination of nucleotides, 
which allow formation of the correct secondary structure to permit cleavage. Although 
this method is long and time consuming, it provides reliable and stable knock down of a 
specific gene and can be applied in variety of cell lines.  
One study has indicated the possible role of micro RNAs in this process. Sossey-Alaoui 
et al (2007) demonstrated an inverse correlation between WAVE-3 and miR200 
microRNA expression levels in invasive versus non-invasive breast cancer cells 
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(Sossey-Alaoui et al. 2007). The expression of miR200 microRNA is lost during 
epithelial to mesenchymal transition (EMT) and therefore cancer metastasis. This mciro 
RNA directly targets the 3′-UTR of the WAVE-3   mRNA and inhibits its expression. This 
study also stressed that the miR200-mediated inhibition of WAVE-3 expression is 
specific for WAVE-3 because it does not affect the expression levels of the other 
members of the WAVE family. 
These focused genetic tools not only allow construction of experimental models to 
determine the role of specific molecules in cellular function but also have potential role 
in therapeutic applications (Bertrand et al. 1994; Tang et al. 1998). 
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Chapter 5 
Hepatocyte growth factor (HGF) induced 
migration and invasion of prostate cancer cells 
in vitro is dependent on WAVE-3 
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5.1: Introduction: 
 
The invasive and metastatic potential of any cancer is dependent upon expression of 
different cellular characteristics at various steps of the metastatic cascade. Cellular 
motility and cytoskeleton changes are integral parts of this process and depend upon 
actin polymerization. The WASP (Wiskott-Aldrich syndrome protein) and WAVE (WASP 
Verpolin homologous) family are structurally related and responsible for regulation of 
actin polymerization through their interaction with Actin related proteins 2&3 (ARP2/3). 
The WASP gene family includes WASP muted in and responsible for Wiskott-Aldrich 
syndrome and widely distributed N-WASP. The WAVE gene family is comprised of 
WAVE-1, 2 and 3. The WASP and WAVE families of protiens act as downstream 
regulators of small GTPase responsible for signal transduction generated by different 
regulatory factors. Rac (GTPase) controls the formation of lamellipodia through 
regulation of WAVE family. WAVE-1 appears to be crucial for dorsal ruffles, while 
WAVE-2 is necessary for formation of lamellipodia. WAVE-3 has been found to be an 
aetiological factor in the development of low grade neuroblastoma (Sossey-Alaoui et al. 
2002). Prior studies have shown that elimination of WAVE-3 from breast and prostate 
cancer cell lines reduces their invasive potential through reduction in motility and 
reduced expression of enzymes responsible for extra cellular matrix degradation 
(Sossey-Alaoui et al. 2005 and 2007; Fernando et al. 2009). 
Hepatocyte growth factor/scatter factor (HGF/SF) is known to play a crucial role in the 
metastatic process through its effects on proliferation, dissociation, migration and 
invasion (Tajima et al. 1991; Sugawara et al. 1997; Gmyrek et al. 2001). Normally 
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hepatocyte growth factor/scatter factor (HGF/SF) is expressed by supportive 
mesenchymal cells (Kasai et al. 1996), while Met is expressed by epithelial cells (Rong 
et al. 1993). HGF/SF derived from prostate stroma, promotes proliferation, 
differentiation, motility, and invasion of malignant epithelial cells indicating possible 
involvement in the progression of prostate cancer (Gmyrek et al. 2001). The serum 
levels of HGF and PSA are found to be significantly increased in prostate cancer 
patients as compared to a control group (Hashem and Essam, 2005). Higher plasma 
levels of SF/HGF in men with hormone-refractory prostate cancer are associated with a 
decreased patient survival (Humphrey et al. 2006). 
Previous studies have clearly demonstrated the loss of an aggressive phenotype in 
different cell lines following elimination of WAVE-3, including prostate cancer cell lines 
(Sossey-Alaoui et al. 2005; Fernando et al. 2009). WAVE-1 and WAVE-2 have been 
previously addressed as important mediators of PDGF induced cell migration (Suetsugu 
et al. 2003; Yan et al. 2003; Oikawa et al. 2004). This study tried to examine the effects 
of HGF on prostate cancer cells, following WAVE-3 knockdown in order to establish the 
role of WAVE-3 in mediation of HGF induced aggressive changes in prostate cancer, 
known previously. 
 
5.2: Material and methods: 
 
The PC-3 cell line was obtained from ECACC, Sailsbury, UK. Cells were maintained in 
Dulbecco’s modified eagle medium (DMEM)-F12 medium supplemented with 10% fetal 
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calf serum and antibiotics. Anti-WAVE3 antibodies were obtained from Santa Cruz 
Biotechnology, Santa Cruz, CA. Other kits and reagents were obtained from Sigma-
Aldrich, Poole, UK. The recombinant human HGF/SF was from HGF/SF cDNA 
transfected Chinese hamster ovary cell and was a kind gift from Dr. T. Nakamura, 
Osaka, Japan. 
Zuker RNA mFold program was used to construct anti WAVE-3 ribozyme transgene, 
based on the secondary structure of the gene generated. Following synthesis, 
ribozymes were cloned in to pEF6/V5-His TOPO TA Expression kit (Invitrogen, Paisley, 
UK) according to the protocol provided. Plasmid vectors containing anti WAVE-3 
transgenes and empty plasmids were transfected in to PC-3 cells using Easyjet Plus 
electroporator (EquiBio, Kent, United Kingdom). Cells were put in the selection medium 
containing Blasticidin (5ng/ml) for 5 days followed by maintenance medium (0.5 ng/ml). 
Transfection was confirmed by the absence of WAVE-3 transcripts and WAVE-3 protein 
in selected cells. 
 
5.2.1: RNA isolation and PCR: 
RNA was isolated from selected cells using total RNA isolation reagent (ABgene, 
Surrey, UK). Following quantification, this RNA was used to construct complimentary 
DNA using DuraScript reverse transcriptase-polymerase chain reaction (RT-PCR) kit 
(Invitrogen, Paisley, UK). This DNA was used for routine PCR and Q-PCR to confirm 
the knock down of WAVE-3. 
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5.2.2: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot: 
Equal amounts of proteins were separated from cell lysates using the DC Protein Assay 
kit (Bio-Rad Laboratories, Hemel Hempstead, UK). These proteins were separated 
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
blotted on to nitrocellulose membrane. Membrane was treated with milk to block non-
specific proteins prior to probing with anti-WAVE-3 primary antibodies, followed by 
peroxidise conjugated secondary antibodies. Protein bands were visualized and 
analysed using Supersignal West Dura system and documented using a gel 
documentation system (UVITech, Cambridge, United Kingdom). 
5.2.3: Cell growth assay: 
Cell growth was assessed using previously described method (Jiang et al. 2005). In this 
method, 3000 cells were added from each cell line in 96 well plates and growth was 
assessed after 72 and 120 hours, in the presence or absence of HGF (40ng/ml) 
containing medium. Crystal violet was used to stain the cells, which was extracted and 
subsequently used to quantify through absorbance of light (wave length 540 nm) using 
an ELx800 spectrophotometer. Amounts of absorbance represented the number of cell 
and change was calculated by percentage increase as compared to baseline reading.  
At least five independent repeats were done and each repeat was done in 
quadruplicate. 
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5.2.4: Cell matrix adhesion assay: 
Following cell counting, a total of 30,000 cells were added to a 96 well plates, which 
were previously coated with Matrigel (5µg/well). Cells were incubated for 40 minutes 
with or without HGF/SF (40ng/ml). Non-adherent cells were washed with BSS buffer. 
Adherent cells were stained with crystal violet (200µL/well) for 20 minutes. Excess of 
stain was removed by gentle washing with BSS buffer. Cells were counted in each well 
using uniform magnification on an inverted microscope. At least five independent 
repeats were performed and each repeat was done in quadruplicate. 
5.2.5: Invasion assay: 
Transwell inserts with pore size of 8 µm were used for the invasion assay as previously 
described (Jiang et al. 1995). Inserts were precoated with Matrigel (50µg/well, BD 
Biosciences, Oxford UK) which mimics the basement membrane to study the invasive 
potential of cells. A total of 20,000 cells were added to each insert along with medium. 
The experiment was run in duplicate for each cell line with or without HGF/SF (40 
ng/ml). After 72 hours of incubation, the number of cells that had invaded through the 
basement membrane were counted following staining with crystal violet solution as 
described above in adhesion assay. At least five independent repeats were done in 
duplicate. 
5.2.6: Cell motility assay using cytodex-2 beads: 
Cell motility was assessed by dissociation from cytodex-2 micro carrier beads following 
treatment with HGF/SF (40 ng/ml) or not and was adapted from previous published 
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methods (Jiang et al. 2003). Cells at a density of 1 × 105 cells/ml were cultured in 10 ml 
of DMEM medium containing 250 μg/ml of beads for 24 hours at 37°C. The cell/bead 
complex was seeded into a 24 well plate in triplicate, and cultured with (40 ng/ml) or 
without HGF for 4 hours at 37°C. Cells that had migrated from the beads and adhered 
to the bottom of each well were fixed in 4% formalin for 5min and stained in 0.5% crystal 
violet. The stained cells were counted with a light microscope at fixed magnification and 
three fields per well were scored. Duplicated experiment for each cell line was repeated 
at least 5 times. 
 
5.2.7: In vitro cell migration (wounding) assay:  
A wounding assay assesses the migratory properties of cells. In health, cells respond to 
wounding of a monolayer by converging and closing the initial wound. Using a method 
adapted from Jiang et al. (Jiang et al. 1999), this process can be recorded and 
analysed. 500,000 cells of each line were seeded into a single well of a 24 well plate. 
Subsequent serial dilutions reduced the number of cells seeded by a factor of 2, until 6 
wells were seeded. The plate was left for 24-48 hours until an appropriate monolayer 
had formed in one well. The wounding was performed using a 21G needle to scrape 
three parallel lines across the well. The medium was changed immediately after to pre-
warmed HEPES medium, and the cells given 15 minutes to recover. They were then 
transferred to a heated plate (Lecia GmbH, UK) and tracked using a camera attached to 
a Lecia DM IRB microscope (Lecia GmbH, UK). Images were captured at 0, 15, 30, 45, 
60, 75 and 90 minutes time points. Images were retrospectively reviewed using Image J 
software and distances between the opposing wound edges were measured. The 
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arbitrary figure was converted to μm by multiplying by 0.8 as previously calibrated using 
a calibration grid. This method has been previously used exclusively in the host 
laboratory (Parr et al. 2001).  
 
5.3: Results: 
 
5.3.1: Effect of WAVE-3 knock down on cellular growth:  
WAVE-3 knock down did not demonstrate any effect on growth of PC-3 cells at 72 and 
at 120 hours. Assessment of growth response was terminated at 120 hours which was 
in line with the time frame for assessment of invasion assay as well. There was a 
marked growth spurt with addition of HGF (40ng/ml) but the growth response between 
the different cell lines was not statistically significant at 3 days (Table 5.1 & graph 5.1) 
and 5 days interval (Table 5.2 & graph 5.2). 
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Cell type 
Percentage increase after 3 days 
+/-SD 
Significance 
p value <0.05 
PC-3 WT 45.28 +/- 4.81 
 
A B 
PC-3 ePEF 51.29 +/- 10.46 
WT  Vs ePEF 
P=0.19 
PC-3 WT 
without HGF Vs 
PC-3 WT with 
HGF 
P=0.024 
PC-3 W3KD 43.9 +/- 7.33 
WT  Vs W3KD 
P=0.68 
ePEF Vs W3KD 
P=0.18 
PC-3 ePEF 
without HGF Vs 
PC-3 ePEF with 
HGF 
P=0.004 
PC-3 WT with 
HGF 
99.09 +/- 20.01 
 
WT  Vs ePEF 
P=0.89 PC-3 ePEF with 
HGF 
97.3822 +/- 19.78 
PC-3 W3KD with 
HGF 
109.11 +/- 7.03 
WT  Vs W3KD 
P=0.23 
ePEF Vs W3KD 
P=0.16 
PC-3 W3KD 
without HGF Vs 
PC-3 W3KD with 
HGF 
P=0.0096 
 
Table 5.1: Growth assay representing percentage increase after 3 days among three 
trangenic cell lines. Difference in percentage growth did not reach a statistical 
significance among the different cell lines with or without HGF (A). However there was 
significant increase in the cell growth among all cell lines with addition of HGF (B). The 
mean difference was significant at the 0.05 level. 
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Graph 5.1: Percentage increase in cellular growth (+/- SD) after 3 days, among different 
cell lines with and without HGF. There was marked cellular growth following addition of 
HGF, but the difference in percentage growth did not reach statistical differeence (p 
value <0.05) among different cell lines (with and without HGF).  
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Cell type 
Percentage increase after 5 days 
+/-SD 
Significance 
p value <0.05 
PC-3 WT 239.66 +/-24.16 
 
A B 
PC-3 ePEF 238 +/-  32.48 
WT  Vs ePEF 
P=0.91 
PC-3 WT without 
HGF Vs PC-3 WT 
with HGF 
P=0.016 
PC-3 W3KD 238.22 +/- 48.59 
WT  Vs W3KD 
P=0.94 
ePEF Vs W3KD 
P=0.99 
PC-3 ePEF without 
HGF Vs PC-3 ePEF 
with HGF 
P=0.0017 PC-3 WT with HGF 324.57 +/- 33.1 
 
WT  Vs ePEF 
P=0.48 
PC-3 ePEF with 
HGF 
336.38 +/- 21.9 
PC-3 W3KD with 
HGF 
322.18 +/- 48.02 
WT  Vs W3KD 
P=0.91 
ePEF Vs W3KD 
P=0.49 
PC-3 W3KD without 
HGF Vs PC-3 W3KD 
with HGF 
P=0.029 
Table 5.2: Growth assay representing percentage increase after 5 days among three 
trangenic cell lines. Difference in percentage growth did not reach a statistical 
significance among the different cell lines with or without HGF (A). However there was 
significant increase in the cell growth among all cell lines with addition of HGF (B). The 
mean difference was significant at the 0.05 level. 
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Graph 5.2: Percentage increase in cellular growth (+/- SD) after 5 days, among different 
cell lines with and without HGF. There was marked cellular growth following addition of 
HGF, but the difference in percentage growth did not reach statistical differeence (p 
value <0.05) among different cell lines (with and without HGF). 
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5.3.2: Effect of WAVE-3 knock down on cellular motility:  
Elimination of WAVE-3 resulted in a reduction of motile cells on cytodex-2 beads assay. 
The mean number of motile cells (+/-SD) in PC-3WT and PC-3pEF were 10.9 +/-1.35 and 
11.0+/-2.0 as compared to 5.93+/- 0.99 in PC3WAVE-3 KD cell line. With the addition of 
HGF (40 ng/ml), the number of motile cells increased significantly in PC3-WT (23.56 +/- 
2.46) and PC-3pEF (21.46 +/- 1.8) as compared to PC3WAVE-3 KD cell line (7.0 +/- 0.84) 
(Table: 5.4). As described before, there was no significant change in the adhesion 
assay which indicates an independent effect on cellular motility in the presence or 
absence of HGF. Bonferroni multiple comparisons between the PC-3 transgenic cell 
lines for the number of motile cells, showed a statistically significant difference in cell 
motility in PC3WAVE-3 KD  cell line with or without addition of HGF (Table 5.4). 
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Table 5.3: Descriptive statistics for cell motility assay 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3: Number of motile cells in three cell lines without and with 
hepatocyte growth factor (HGF) (40 ng/ml) 
 
 
 
 
Cell line N Mean 
Std. 
deviation 
Std. 
error 
95% Confidence interval 
for mean 
Minimum Maximum 
Lower 
bound 
Upper 
bound 
PC-3
WT
 without HGF 5 10.9333 1.35067 .60404 9.2563 12.6104 9.25 13.00 
PC-3
PEF
 without HGF 5 11.0000 2.06912 .92534 8.4309 13.5691 9.50 14.50 
PC-3
WAVE-3 KD
 without  
HGF 
5 5.9333 .99548 .44519 4.6973 7.1694 4.50 7.00 
PC-3
WT
 with HGF 5 23.5667 2.46620 1.10292 20.5045 26.6289 20.25 26.38 
PC-3
PEF
 with HGF 5 21.4667 1.83579 .82099 19.1872 23.7461 19.25 23.75 
PC-3
WAVE-3 KD
 with HGF 5 7.0000 .84779 .37914 5.9473 8.0527 5.75 8.00 
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Table 5.4: Bonferroni multiple comparisons in between the PC-3 transgenic cell lines for number of motile cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table showing the statistical comparison of the effect of WAVE-3 silencing (PC-3WAVE-3KD) to the wild type (PC-3WT) and control 
(PC-3PEF) using Bonferroni multiple comparisons in between the groups. * The mean difference is significant at the .05 level.
Cell type 
Mean 
difference  
Sig. 
95% Confidence interval 
Lower 
boundary 
Upper 
boundary 
PC-3
WT
 without 
HGF 
PC-3 
PEF
 without 
HGF 
-.06667 1.000 -3.5627 3.4293 
PC-3 
WAVE-3 KD
 
without HGF 
5.00000* .001* 1.5040 8.4960 
PC-3 
WT
 with HGF -12.63333* .0001* -16.1293 -9.1373 
PC-3 
PEF
 with HGF -10.53333* .0001* -14.0293 -7.0373 
PC-3 
WAVE-3 KD
 with 
HGF 
3.93333* .018* .4373 7.4293 
PC-3
PEF
 without 
HGF 
PC-3 
WT
 without 
HGF 
.06667 1.000 -3.4293 3.5627 
 
PC-3 
WAVE-3 KD
 
without HGF 
5.06667* .001* 1.5707 8.5627 
PC-3 
WT
 with HGF -12.56667* .0001* -16.0627 -9.0707 
PC-3 
PEF
 with HGF -10.46667* .0001* -13.9627 -6.9707 
PC-3 
WAVE-3 KD
 with 
HGF 
4.00000* .016* .5040 7.4960 
PC-3
WAVE-3 KD
 
without HGF 
PC-3 
WT
 without 
HGF 
-5.00000* .001* -8.4960 -1.5040 
 
PC-3 
PEF 
without 
HGF 
-5.06667* .001* -8.5627 -1.5707 
PC-3 
WT
 with HGF -17.63333* .0001* -21.1293 -14.1373 
PC-3 
PEF
 with HGF -15.53333* .0001* -19.0293 -12.0373 
PC-3 
WAVE-3 KD
 with 
HGF 
-1.06667 1.000 -4.5627 2.4293 
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5.3.3: Effect of WAVE-3 knock down on cellular invasion through 
matrigel basement membrane: 
WAVE-3 knockdown in PC-3 prostate cancer cells significantly decreased the 
invasion of cells through the matrigel artificial basement membrane. In this technique 
of in vitro invasion assay, cells have to move through the pores of 8 µm size, 
following degradation of basement membrane. The final results are from counts of 
cells that successfully reach the other side of the inserts used (Fig: 5.1). This assay 
also takes in to account the fact that there is no effect of WAVE-3 elimination on the 
cell growth, in same time interval.  It was observed that there was a significant 
decrease in the invasiveness of PC-3WAVE-3 KD cells as compared to PC-3WT and PC-
3pEF cell lines. The mean (+/-SD) number of cells invaded in PC-3WAVE-3 KD was 
22.10+/-5.13 as compared to PC-3WT 53.23+/-2.5 and PC-3pEF 48.64+/-7.33 
respectively (p value <0.05). At the same time there was no statistically significant 
difference between PC-3WT and PC-3pEF (p value 1.0) (Table: 5.6). 
With the addition of HGF 40µg/ml to the medium in inserts and bottom wells (for all 
three cell lines), resulted in stimulation of the invasive potential of the different cell 
lines to variable degrees (Table: 5.6 & 5.7). HGF significantly increased the number 
of invasive cells in PC-3WT (110.65+/-6.82) and PC-3pEF (99.42+/-4.3) cell lines (p 
value <0.05, when compared to the number of cells that invaded without the 
presence of HGF). However this trend of change was not observed in the PC-3WAVE-3 
KD (23.17+/-2.48) cell line. In addition it was also observed that invaded cells in PC-
3WT and PC-3pEF types were significantly higher than PC-3WAVE-3 KD, even after the 
addition of HGF induced stimulation (Table: 5.5 & 5.6). 
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Fig 5.1: Figure illustrating the cells invaded through matrigel basement membrane and 
reached on the bottom of inserts, in different transgenic cell lines on invasion assay 
(magnification 20X). There is markedly reduced number of cells visible in PC-3WAVE-3 KD cell 
line. This effect persisted even following addition of HGF to the medium.
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Table 5.5: Descriptive statistics for cell invasion assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table showing number of invaded cells in three cell lines without and with 
Hepatocyte growth factor (HGF) (40 ng/ml). 
 
 
Cell line 
  
 
Mean 
  
Std. 
deviation 
  
Std. 
error 
  
95% confidence 
interval for mean 
Minimum 
  
Maximum 
  
 Lower 
bound 
Upper 
bound 
PC-3
WT
 without HGF 5 53.2344 2.50795 1.12159 50.1203 56.3484 49.50 56.50 
PC-3
PEF
 without HGF 5 48.6406 7.33042 3.27827 39.5387 57.7425 36.44 55.00 
PC-3
WAVE-3 KD
 without  
HGF 
5 22.1094 5.13687 2.29728 15.7311 28.4876 14.19 28.50 
PC-3
WT
 with HGF 5 110.6594 6.82422 3.05188 102.1860 119.1328 101.00 120.14 
PC-3
PEF
 with HGF 5 99.4219 4.27734 1.91289 94.1109 104.7329 94.63 105.06 
PC-3
WAVE-3 KD
 with 
HGF 
5 23.1797 2.48220 1.11007 20.0976 26.2617 20.09 26.75 
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Table 5.6: Bonferroni multiple comparisons in between the PC-3 transgenic cell lines for number of invaded cells through 
the matrigel basement membrane 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table showing the statistical comparison of the effect of WAVE-3 silencing (PC-3WAVE-3KD) to the wild type (PC-3WT) and control 
(PC-3PEF) using Bonferroni multiple comparisons in between the groups. * The mean difference is significant at the .05 level. 
 
 Cell type 
  
 
Mean 
difference 
 
Sig. 
  
95% confidence Interval 
Lower 
bound 
Upper 
bound 
PC-3
WT
 without HGF PC-3
ePEF
 without HGF 4.59375 1.000 -5.9626 15.1501 
  PC-3 
WAVE-3 KD
 without 
HGF 
31.12500* .0001* 20.5687 41.6813 
  PC-3 
WT
 with HGF -57.42500* .0001* -67.9813 -46.8687 
  PC-3 
PEF
 with HGF -46.18750* .0001* -56.7438 -35.6312 
  PC-3 
WAVE-3 KD
 with HGF 30.05469* .0001* 19.4984 40.6110 
PC-3
PEF
 without HGF PC-3 
WT
 without HGF -4.59375 1.000 -15.1501 5.9626 
  PC-3 
WAVE-3 KD
 without 
HGF 
26.53125* .0001* 15.9749 37.0876 
  PC-3 
WT
 with HGF -62.01875* .0001* -72.5751 -51.4624 
  PC-3 
PEF 
with HGF -50.78125* .0001* -61.3376 -40.2249 
  PC-3 
WAVE-3 KD
 with HGF 25.46094* .0001* 14.9046 36.0173 
PC-3
WAVE-3 KD
 without 
HGF 
PC-3 
WT
 without HGF -31.12500* .0001* -41.6813 -20.5687 
  PC-3
PEF
 without HGF -26.53125* .0001* -37.0876 -15.9749 
  PC-3
WT
 with HGF -88.55000* .0001* -99.1063 -77.9937 
  PC-3
PEF
 with HGF -77.31250* .0001* -87.8688 -66.7562 
  PC-3 
WAVE-3 KD
 with HGF -1.07031 1.000 -11.6266 9.4860 
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5.3.4: Effect of WAVE-3 knock down on cellular matrix adhesion: 
Elimination of WAVE-3 did not significantly affect the cell adhesion to the matrix, as 
observed in our in vitro cellular adhesion assay (Table: 5.8 & 5.9). The mean number 
of adherent cells in PC-3WT and PC-3pEF was 46.45 +/-7.5 and 47.02 +/- 14.6 
respectively, as compared to PC-3WAVE-3 KD 57.4 +/- 11.23. The small difference 
between the cell lines did not reach statistical significance. With the addition of HGF 
(40 µg/ml), the mean number of adherent cells in PC-3WT, PC-3pEF and PC-3WAVE-3 KD 
were 61.2 +/-10.2, 61.68 +/- 18.7 and 63.13 +/- 14.7 respectively. As evident from 
cell number (Table: 5.9), there was an increase in adhesive potential of cells but 
there was no statistical difference between the various cell lines (p value <0.05). 
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Table 5.7: Descriptive statistics for cell adhesion assay 
 
 
 
 
Cell type 
N Mean Std. deviation Std. error 
95% confidence interval for 
mean 
Minimum Maximum 
Lower bound Upper bound 
PC-3
WT
 
without HGF 
 
 5 
46.4531 7.51732 3.36185 37.1191 55.7871 39.33 59.00 
PC-3
PEF
 
without HGF 
5 47.0214 14.69330 6.57104 28.7772 65.2655 29.63 70.33 
PC-3
WAVE-3 KD
 
without  HGF 
5 57.4094 11.23154 5.02290 43.4636 71.3552 43.63 71.08 
PC-3
WT
 with 
HGF 
5 61.2094 10.27046 4.59309 48.4569 73.9618 44.55 71.82 
PC-3
PEF
 with 
HGF 
5 61.6813 18.78015 8.39874 38.3626 84.9999 37.16 89.37 
PC-3
WAVE-3 KD
 
with HGF 
5 63.1344 14.72992 6.58742 44.8448 81.4240 44.72 84.66 
         
 
 
Table showing the number of adherant cells in three cell lines without and with 
hepatocyte growth factor (HGF) (40 ng/ml) 
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Table 5.8: Bonferroni multiple comparisons in between the PC-3 transgenic cell 
lines for number of adherent cells to the matrigel basement membrane 
 
 
 
 
  
 Cell line 
  
 Cell line 
  
Mean 
difference  
 
Sig. 
  
95% confidence interval 
Lower bound Upper bound 
PC-3
WT
 
without HGF 
PC-3
ePEF
 without 
HGF 
-.56823 1.000 -28.1357 26.9993 
  PC-3 
WAVE-3 KD
 
without HGF 
-10.95625 1.000 -38.5237 16.6112 
  PC-3 
WT
 with 
HGF 
-14.75625 1.000 -42.3237 12.8112 
  PC-3 
PEF
 with 
HGF 
-15.22812 1.000 -42.7956 12.3394 
  PC-3 
WAVE-3 KD
 
with HGF 
-16.68125 .904 -44.2487 10.8862 
PC-3
PEF
 
without HGF 
PC-3 
WT
 without 
HGF 
.56823 1.000 -26.9993 28.1357 
  PC-3 
WAVE-3 KD
 
without HGF 
-10.38802 1.000 -37.9555 17.1795 
  PC-3 
WT
 with 
HGF 
-14.18802 1.000 -41.7555 13.3795 
  PC-3 
PEF 
with 
HGF 
-14.65990 1.000 -42.2274 12.9076 
  PC-3 
WAVE-3 KD
 
with HGF 
-16.11302 1.000 -43.6805 11.4545 
PC-3
WAVE-3 
KD
 without 
HGF 
PC-3 
WT
 without 
HGF 10.95625 1.000 -16.6112 38.5237 
  PC-3
PEF
 without 
HGF 
10.38802 1.000 -17.1795 37.9555 
  PC-3
WT
 with 
HGF 
-3.80000 1.000 -31.3675 23.7675 
  PC-3
PEF
 with 
HGF 
-4.27188 1.000 -31.8394 23.2956 
  PC-3 
WAVE-3 KD
 
with HGF 
-5.72500 1.000 -33.2925 21.8425 
 
 
Table showing the statistical comparison of the effect of WAVE-3 silencing (PC-3WAVE-
3KD) to the wild type (PC-3WT) and control (PC-3PEF) using Bonferroni multiple 
comparisons in between the groups.  
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5.3.5: Effect of WAVE-3 knock down on cellular motility (wounding 
assay): 
In this time lapsed motility assay we analyzed the rate of cell movement in order to 
close the wound margins (Figure: 5.2 & 5.3). This method was adapted from a prior 
study and can be recorded as continuous process as well (Parr et al. 2001). The mean 
distance moved by the cells, over 90 minutes, was determined for each cell line. Cell 
motility was first assessed without any treatment, then monitored upon the addition of 
HGF/SF (40 ng/ml). Cells were shown to migrate a far greater distance following the 
addition of HGF. Although again, this HGF/SF induced motility was significantly reduced 
in PC-3WAVE-3 KD cell line as compared to PC-3WT and PC-3pEF (Graph: 5.3 & 5.4). 
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Graph 5.3: Wounding assay of different cell lines without HGF, demonstrating the effect 
of WAVE-3 knock down on cell migration. There was statistically significant reduction in 
the distance covered by PC-3WAVE-3 KD cell line as compared to PC-3WT and PC-3pEF cell 
lines (* p value <0.05). 
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Fig 5.2: Wounding/cell migration assay in three transgenic cell lines without HGF, 
showing the extent of wound closure and cell movement over 90 minutes time period
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Graph 5.4: Wounding assay of different cell lines with HGF, demonstrating the effect of 
HGF treatment on cell migration. PC-3 WT and PC-3pEF cell lines showing increased cell 
migration with reduced effect on PC-3WAVE-3KD cell line. There was statistically significant 
reduction in the distance covered by PC-3WAVE-3 KD cell line as compared to PC-3WT and 
PC-3pEF cell lines (* p value <0.05). 
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Fig 5.3: Wounding/cell migration assay in three transgenic cell lines with HGF, showing 
the extent of wound closure and cell movement over 90 minutes time period
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5.4: Discussion: 
Many actin-binding regulatory proteins have been identified and classified according to 
their effects on actin filaments. These proteins do not function independently but are 
involved in maintenance of perfect harmony to regulate the pivotal role of actin in 
cellular movement. Cell migration through the extracellular matrix (ECM) begins with the 
formation of cell protrusions that contain filamentous actin (F-actin). This process 
involves cell stimulation through multiple pathways involved in cellular polarization 
towards a specific direction. The processes of these cell protrusions heavily depend 
upon polymerization of F-actin. If this process of polymerization can be inhibited, it can 
result in inhibition of cellular movement resulting in potential prevention of invasion and 
metastasis. This crucial step of actin polymerization is controlled by actin related protein 
2/3 (ARP 2/3). WASP family proteins play an important role by triggering the activation 
of the complex in response to mitogenic stimuli via the Rho family of peptides (RhoA, 
Rac, and Cdc42) (Etienne-Manneville et al. 2002). WASP is derived from the clinical 
condition called the “Wiskott-Aldrich syndrome”, which manifests due to malfunction of 
the actin cytoskeleton in the immune system, resulting in a clinical triad of 
immunodeficiency, thrombocytopenia, and eczema, due to inadequate cellular 
movement. WAVE-1, 2 and 3 are members of the WASP family along with N-WASP 
and WASP. The role of WAVE-3 in cellular movement has been documented in knock 
down studies involving breast cancer cells MDA-MB-231 (Sossey-Alaoui et al. 2007) 
and prostate cancer cell lines (Fernando et al. 2010). 
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The role of hepatocyte growth factor/scatter factor (HGF/SF) is well established in 
metastatic process through its effects on proliferation, dissociation, migration and 
invasion. Higher HGF levels have been demonstrated in hormone refractory prostate 
cancer and associated with poor prognosis. Strong expression of WAVE-3 has been 
documented in prostate cancer specimens and invasive cancer cell lines from earlier 
studies in our department (Fernando et al. 2010). In this study we focused on the role of 
WAVE-3 in the mediation of these changes with emphasis on prostate cancer cell lines. 
Our present study provides evidence that WAVE-3 has an important role in HGF 
induced cellular motility and possible metastasis without a significant effect on cellular 
growth. Following genetic silencing of WAVE-3, analysis of functional studies revealed a 
statistically significant reduction in HGF induced cellular motility as compared to control 
cell lines. HGF promotes cell invasion through the matrigel basement membrane in vitro 
which appears markedly reduced following WAVE-3 knock down. In our cellular motility 
experiments, HGF was able to induce non-directional (cytodex beads assay) as well as 
directional movement (wound closure assay) in the parent cell line (PC-3) and the 
control cell line with empty plasmid (PC-3PEF). HGF was not able to induce these effects 
following elimination of WAVE-3. This phenomenon can possibly be attributed to 
reduced lamellipodia formation on the leading edge of cellular movement, as suggested 
from prior studies (Sossey-Alaoui et al. 2007; Fernando et al. 2010). 
Following skeletal muscle injury, muscle satellite cells proliferate and migrate toward the 
site of muscle injury to start the process of regeneration. This migration is mainly 
stimulated through the secretion of HGF from injured and intact muscle fibers. 
Kawamura et al, utilized mouse derived skeletal muscle cells and demonstrated that 
158 
 
HGF promotes directional movement in these cells. Knock-out experiments involving 
WAVE-2 and N-WASP resulted in prevention of lamellipodia formation and cellular 
movement, in response to HGF. Moreover, exogenous expression of wild-type N-WASP 
or WAVE2 promoted lamellipodia formation and migration (Kawamura et al. 2004). 
Similarly Sossey-Alaoui et al, demonstrated that WAVE-3 was in the leading edge of 
cell during cell migration in MDA-MB-231 cells. Platelet derived growth factor treatment 
induced chemotactic migration towards PDGF in three dimensional migration chambers. 
Knock down of WAVE-3 in these cells through small interfering siRNAs resulted in 
reduced migrational potential of these cells. With the addition of PDGF treatment, these 
cells failed to show any significant increase in migration and lamellipodia formation. 
Our findings from this study indicate the important role of WAVE-3 in growth factor 
induced cell migration in prostate cancer cells. The role of WAVE-1 and WAVE-2 in cell 
migration has been documented previously in different cell lines. However it is very 
important to consider that these important members were well expressed in our cell 
lines, which makes the role of WAVE-3 even more important in this setting. 
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Chapter 6 
Role of paxillin in reduced cellular motility 
following WAVE-3 knock down. 
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6.1: Introduction: 
 
A metastatic cancer cell has to undergo a remarkable transition in cell shape during the 
process of metastasis. Dynamic modifications in the actin cytoskeleton mediate these 
changes in shape and cellular movement. Cancer cells interact with the surrounding 
micro environment through formation of small cell projections known as lamellipodia and 
filopodia. Formation of these small cell projections is controlled by small GTPases Rac 
and Cdc42 respectively (Suetsugu et al. 2003). The small projections transiently interact 
with the extracellular matrix and focal adhesion complex sites. Ezrin/Radixin/Moesin 
(ERM) proteins were shown to be required for the formation of focal adhesion 
complexes and stress fibers downstream of Rho GTPases activation (Mackay et al. 
1997).   Ezrin is involved in the dissociation of cell-cell contacts triggered by HGF 
stimulation through its interaction with the Fes kinase and in the formation of membrane 
extensions (Naba et al. 2008). Ezrin promotes cell motility in response to HGF treatment 
as measured by the ability of epithelial cells to close a wound (Crepaldi et al. 1997). 
Following HGF stimulation of epithelial cells, ezrin is rapidly recruited to the lateral 
membrane and to the leading edge of migrating cells where it is supposed to play a role 
in the control of actin polymerization (Crepaldi et al. 1997). Altogether these data show 
that ERM proteins convey signals elicited by membrane receptors to the actin 
cytoskeleton to regulate cell migration. However, it remains unclear how ERM proteins 
control the reorganization of the actin cytoskeleton during cell migration. A likely 
hypothesis is that through their phosphorylation ERM proteins will recruit regulators of 
actin polymerization. These interactions play a key role in linking the external 
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environment with intracellular machinery. The functional status of these proteins may be 
an important factor in tumor progression. In a comparative study, involving protein 
profiles of pancreatic cancers without and with lymph node metastasis indicated an 
increased expression of moesin and radixin in the lymph node metastasis-positive 
group and a change in ezrin phosphorylation, but not expression. 
Integrins are important constituents of focal adhesions and act as intermediate 
molecules between substrates in the microenvironment and actin cytoskeleton. 
Extracellular surface projections of these molecules serve as receptor for different 
growth factors while intracytoplasmic tail ends recruit a variety of cytoplasmic proteins 
which mediate different cellular activities. Paxillin is a key member of integrins, which 
acts as a nexus to control the activity of small GTPases. Primarily paxillin is thought to 
be involved in coordination of cellular movements but with the passage of time its role in 
other activities is also emerging. Although we will be focusing our attention on the role 
of paxillin in the regulation of the actin cytoskeleton through which paxillin exerts its 
effect on pathological processes such as tumor cell invasion (Azuma et al. 2005). 
Paxillin is a well preserved gene in cancer and no mutations have been documented in 
a wide variety of tumors. Kim et al. analyzed somatic paxillin mutations in 45 lung, 45 
gastric, 45 colorectal, 45 breast, 45 liver and 45 prostate cancers by polymerase chain 
reaction and single-strand conformation polymorphism assay.  Paxillin mutation was 
absent in lung cancers and other common solid cancers, suggesting that paxillin 
mutation may not play a principal role in cancer development (Kim et al. 2011). 
However it has been suggested that an increase in paxillin phosphorylation is correlated 
with the metastatic ability of the cell (Rodina et al. 1999). Phosphorylation of the FAK 
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and paxillin proteins is involved in multiple signal transduction pathways during 
metastatic cascade, such as interaction with extracellular matrix. Phosphorylation of 
paxillin and FAK appears to be dependent upon the Src family of protein kinases (v-Src) 
(Richardson et al. 1997). Multiple sites of phosphorylation exist on the paxillin molecule 
which is targeted by different kinases in response to binding of growth factors like HGF 
(Jiang et al. 1996). Multiple cytokines have been identified which play important roles in 
local progression and promotes metastatic potentials. Hepatocyte growth factor is one 
of these cytokines which has been identified as a promoter of aggressive disease and 
metastasis in prostate cancer (Gupta et al. 2008). 
Results from our prior study have demonstrated that WAVE-3 knock down results in 
reduced cellular motility in prostate cancer cells. Interestingly these cells were not able 
to elaborate any significant changes in their motility even after addition of HGF. In this 
part of our study we tried to investigate the role of different important intermediary 
proteins which are responsible for mediating the changes in the cell cytoskeleton, in 
response to HGF stimulation. 
  
6.2: Materials and methods: 
 
6.2.1: Cell lines: 
The human prostate cancer cell line PC-3 was used throughout this study. This was 
originally obtained from the European Collection for Animal Cell Culture (ECACC, 
Porton Down, Salisbury, UK). Cells were routinely cultured with Dulbecco’s modified 
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Eagle medium (DMEM) supplemented with 10% foetal calf serum, penicillin and 
streptomycin (Gibco BRC, Paisley, Scotland). The PC-3 cell line with WAVE-3 knock 
down and control cell line with empty plasmid were generated and maintained in the 
maintenance medium as described before in chapter:3 (3.2). This cloning technique has 
been tested and extensively used previously (Jiang et al. 2001 and 2005). Expression of 
WAVE-3 knock down was confirmed both on RNA and protein levels. 
6.2.2: SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blot: 
Western blotting was used to evaluate the expression of different cytoskeletal proteins 
in cell lysate from prostate cancer cell lines.  All three cell lines including PC-3 WT, PC-3 
pEF and PC-3WAVE-3KD were cultured to confluent layers in duplicate. All cells used in this 
study were subjected to a period of two hours serum starvation prior to any treatment. 
One set of cell lines was treated with HGF 40ng/ml for 60 minutes in serum free 
medium while the other set was treated with serum free medium alone. Cells were 
washed with phosphate buffered saline and scrapped. Cells were pelleted, washed and 
then lysed in HCMF buffer. This buffer contained 1% Triton, 0.2% SDS and 100 mg/ml 
PMSF, and lysed the cells for 45 min at 4°C. This was followed by centrifugation at 
13,000g for 10 min and the resulting protein lysates were collected. Following protein 
quantification, the samples were adjusted to equal concentrations with sample buffer 
and then boiled at 100°C for 5 min. Equal amounts of protein from each cell line (20 
μg/lane) were resolved on an 8% polyacrylamide gel by electrophoresis. These 
separated protein samples were then electroblotted onto a nitrocellulose membrane, 
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before blocking in 10% skimmed milk for 60 min. The membranes were probed with 
selection of antibodies (paxillin, FAK, ezrin, radixin and moesin), followed by a 
peroxidase conjugated secondary antibody (1:800) (Sigma-Aldrich Co. Ltd., Poole, 
Dorset, UK). Protein bands were visualised using an enhanced chemiluminescence 
(ECL) system (Kirkegaard and Perry Laboratories, Maryland), while the protein band 
size was determined using a pre-stained molecular weight marker. 
 
6.2.3: Immunoprecipitation: 
Sub-confluent PC-3 cells (PC-3WT, PC-3pEF and PC-3WAVE-3KD) were cultured in 
duplicate. One set were treated with serum-free DMEM medium for 1 h and other set 
was treated with HGF (40 ng/ml) for 60 minutes. Following this, the cells were washed 
with phosphate buffered saline, then scraped off and lysed as above (SDS free lysis 
buffer). Tyrosine phosphorylation was detected following immunoprecipitation with the 
PY20 antibody (1:500) (Santa Cruz Biotechnology, Calne, Wiltshire, UK). This antibody 
is specific for tyrosine in its phosphorylated form, was incubated at 4°C for 1 h, followed 
by the addition of 5 ml of protein A/G agarose (Santa Cruz Biotechnology, Calne, 
Wiltshire, UK). After overnight binding at 4°C the antigen antibody complexes were 
pelleted by centrifugation, washed three times in lysis buffer and then solubilized with 
sample buffer. The immunoprecipitates were separated by SDS–PAGE (10% gel), 
electroblotted onto a nitrocellulose membrane, and probed with specific antibodies (see 
Western blotting of total protein for details, chapter:3, 3.4.1). Proteins that reacted with 
the antibody were detected using the ECL system as above. Densitometry was 
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performed using Image J software, following the instruction available on line 
(imagej.nih.gov/ij/). Values were normalized against the loading control or housekeeping 
gene expression i.e. GAPDH. The data obtained from these methods was analyzed 
statistically using Student’s t test (Excel software). 
 
6.2.4: Immunofluorescent staining (IFC) 
PC-3 cells (PC-3WT, PC-3pEF and PC-3WAVE-3KD) were seeded in chamber slides (Nunc, 
Denmark), at a density of 20,000 cells/well, and incubated for 60 minutes with and 
without HGF (40 ng/ml). Following the incubation period the cells were washed with 
BSS, fixed with 4% formalin for 20 min and then permeabilised with Triton X-100 (0.1%) 
for 15 min. The cells were washed again with BSS and then blocked with 10% horse 
serum  for 40 min. Cells were then treated with a primary antibodies (paxillin, 
phophorylated paxillin, FAK, ezrin, radixin and moesin) for 60 min, washed in 3% horse 
serum in BSS, and then the secondary antibody (anti-mouse or anti-goat IgG 
TRITC/FITC conjugate, 1:400 dilution), was added for a further 40 min. Following 3 
washes with 3% horse serum and BSS the slides were mounted with Fluosave and 
allowed to dry (Fluosave, Calbiochem, Nottingham, UK), prior to examination under a 
fluorescent microscope and acquisition of pictures. 
 
6.3: Results: 
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6.3.1: Expression and phosphorylation status of different cytoskeletal 
proteins: 
 
Following documentation of the well defined role for WAVE-3 in cellular movement, we 
tried to investigate the underlying mechanism involving different proteins required in the 
spatial orientation of cellular movement. The role of paxillin acting as a nexus for co-
ordination of different proteins has been studied before and tyrosine phosphorylation 
has been observed as an important step in HGF induced cellular changes in prostate 
cancer cells (Parr et al. 2001). We analyzed the expression of paxillin and its tyrosine 
phosphorylation following elimination of WAVE-3 and response to addition of HGF. 
Expression and tyrosine phosphorylation of ezrin, radixin, moesin, FAK and paxillin 
were detected by immunoprecipitation and subsequent western blotting with protein 
specific antibodies. In our experiment, all cell lines revealed good expression of paxillin 
along with the control sample. There were no changes in the expression of paxillin in 
three cell lines (Fig: 6.1 and Graph: 6.1). However levels of phosphorylated paxillin after 
WAVE-3 knock down were reduced. When cells were treated with HGF (40ng/ml for 60 
minutes), there was a significant increase in the levels of phosphorylated paxillin (Fig: 
6.2 and Graph 6.2) in PC-3WT and PC-3pEF cell lines but PC-3WAVE-3KD failed to show 
such a response.  
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Fig 6.1: Western blotting showing expression of ezrin, moesin, radixin, FAK, paxillin and GAPDH in three cell lines without any 
treatment and following treatment with HGF. Expression of these proteins did not show any gross difference in expression.  
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Fig 6.2: Western blotting showing expression of phosphorylated paxillin and GAPDH in three cell lines without and following treatment with 
HGF. This figure illustrates the reduced band density for p-paxillin in PC-3WAVE-3KD cell line as compared to PC-3WT and PC-3ePEF cell lines. 
Reduced level of phosphorylated paxillin was demonstrated following treatment of cells with HGF in PC-3WAVE-3KD cell line. In contrast PC-3WT 
and PC-3ePEF cell lines showed increased expression of phosphorylated paxillin following treatment with HGF. 
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Graph 6.1: Quantification of phosphorylated paxillin bands from western blotting (pixels) 
in three transgenic cell lines with and without HGF treatment. Experiment was repeated 
twice in duplicate fashion. 
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Graph 6.2: Quantification of paxillin bands from western blotting (pixels) in three 
transgenic cell lines with and without HGF treatment. Experiment was repeated twice in 
duplicate fashion. 
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6.3.2: Immunofluorescent detection of paxillin and ERM protiens: 
All PC-3 cell lines (PC-3WT, PC-3pEF and PC-3WAVE-3KD) demonstrated good levels of 
staining for paxillin that was localised to the focal adhesion plaques. However, the level 
of staining in the PC-3WAVE-3KD cell line was remarkably lower than PC-3WT, PC-3pEF cell 
lines. Upon addition of HGF the number of focal adhesions was increased and degree 
of paxillin staining concentrated in the focal adhesions was greatly enhanced in PC-3WT, 
PC-3pEF cell lines, with more prominent peripheral location. Furthermore, these cells 
also displayed membrane ruffling and extensive spreading. The PC-3WAVE-3KD cell line 
failed to exhibit these enhanced changes (Fig: 6.3). No obvious difference was seen in 
the immunofluorescent staining of FAK, ezrin, radixin and moesin, whilst a more 
enhanced staining was seen in the WAVE3 knockdown cells on exposure to HGF (Fig: 
6.4, 6.5, 6.6 & 6.7). 
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Figure 6.3: Immunoflourescent cytology for p-paxillin in different PC-3 cell lines (FITC). 
Arrows pointing to the prominent areas of immunoflourescent antibody, indicating the 
presence of p-paxillin mainly in the periphery of cells.  
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Figure 6.4: Immunoflourescent cytology for FAK in different PC-3 cell lines (FITC). 
Arrows pointing to the prominent areas of iImmunoflourescent antibody, indicating the 
presence of FAK.  
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Figure 6.5: Immunoflourescent cytology for ezrin in different PC-3 cell lines (TRITC). 
Arrows pointing to the prominent areas of immunoflourescent antibody, indicating the 
presence of ezrin.  
 
 
175 
 
 
 
 
 
Figure 6.6: Immunoflourescent cytology for radixin in different PC-3 cell lines (FITC). 
Arrows pointing to the prominent areas of immunoflourescent antibody, indicating the 
presence of radixin.  
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Figure 6.7: Immunoflourescent cytology for moesin in different PC-3 cell lines (FITC). 
Arrows pointing to the prominent areas of immunoflourescent antibody, indicating the 
presence of moesin.  
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6.4: Discussion: 
 
Tumour stage at the time of diagnosis has a major impact on the subsequent treatment 
and future prognosis of prostate cancer patients. From a therapeutic point of view, 
prevention of metastasis would have an important role in improving survival of the 
patient. The metastatic process is a complex of multiple successive procedures and 
involves a multitude of molecules being expressed at appropriate time intervals. 
Adhesion of tumor cells to the matrix and coherant interactions are critical for the 
metastatic process. This interaction relies heavily on the formation of complexes known 
as focal adhesion complexes. These complexes not only provide cells with anchorage 
to the ECM, but also transmit signals from the environment to the actin cytoskeleton. 
During formation of these focal adhesions, integrin clustering occurs along with 
stimulation of different kinases associated with these molecules. Paxillin is a 
cytoskeletal docking protein which localizes to these complexes (Jiang et al. 1996) and 
its active phosphorylated state has been associated with increased metastatic ability of 
cells (Rodina et al. 1999). 
Extensive research has been performed to investigate the key steps in this procedure 
and the different factors controlling cell migration. The role of the actin cytoskeleton in 
this process has been well documented and newer research is being carried out to 
investigate the molecules involved in the regulation of actin dynamics. The actin 
cytoskeleton is dynamically remodeled during cell migration and this reorganization 
178 
 
produces the force necessary for cell migration. Actin-related protein (ARP) 2/3 
complex-dependent actin polymerization and its regulation are of particular interest in 
cancer cell metastasis. WASP family proteins play an important role by triggering the 
activation the actin-related protein (Arp) 2/3 complex in response to external stimuli like 
HGF, via the Rho family of peptides (RhoA, Rac, and Cdc42) (Hall et al. 1998). WAVE-
1, 2, and 3 are members of the WASP family along with N-WASP and WASP. Various 
studies have shown the functions of WAVE-3 through genetic silencing in different 
cancer cell lines like breast and prostate. In our prior laboratory work we have 
documented that WAVE-3 knock down results in reduced cellular motility and invasion. 
Another important aspect of these results was the absence of increased motility and 
invasion following addition of HGF to the cellular environment. It is important to note that 
HGF has emerged as an important factor in prostate cancer dynamics and is known to 
be clinically associated with more aggressive phenotypes of prostate cancer and is well 
documented to induce aggressive changes in prostate cancer cell lines. A previous 
study has reported the localization of paxillin to the actin stress fibre associated ends in 
the focal adhesions (Norman et al. 1998). 
HGF is known to enhance tumor matrix adhesion and interactions (Jiang et al. 1996). 
This study examined the effects of hepatocyte growth factor (HGF) on adhesion of 
HT115 (human colon cancer) and MDA-MB-231 (human breast cancer) tumor cells to 
the extracellular matrix. It was exclusively associated with 
the tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin located to the 
focal adhesion area. HGF was also associated with increased tyrosine phosphorylation 
of FAK and paxillin and increased formation of focal adhesion complexes as well. Our 
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results revealed that HGF enhanced the phosphorylation and peripheral localization of 
paxillin, in the control cells. However this response was very limited in the cell line with 
loss of WAVE-3. This situation resulted in reduced cell migration and reduced 
metastatic potential in these cells. These observed effects can be potentially considered 
in the future for therapeutic values. 
Parr et al demonstrated that HGF was able to induce paxillin phosphorylation in PC-3 
prostate cancer cells with increased cellular motility. These effects were blocked by 
NK40 along with reduced paxillin in the focal adhesion complexes (Parr et al. 2001). 
Reduced appearance of phosphorylated paxillin following WAVE-3 knock down may 
reflect reduced cellular interaction with the extracellular matrix contributing to the 
changes in phenotype of these cells. HGF was also not able to induce paxillin 
associated changes in this cell line. In summary this study has demonstrated an 
important role of paxillin in cell movement and its activity is considerably reduced 
following WAVE-3 knock down which potentially reflect its important role in WAVE-3 
mediated cell adhesion and movement.  
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Chapter 7 
 Role of MMPs in the impaired prostate cancer 
invasion by WAVE-3 knockdown. 
 
 
 
 
 
 
 
 
181 
 
 
 
7.1: Introduction: 
 
Prostate cancer is the most common male cancer and second highest cause of cancer 
related mortality in the Western population. It represents a complex of heterogeneous 
disease which may run an indolent course and therefore does not need any clinical 
intervention. On the other end of spectrum it may be invasive and metastatic to lymph 
nodes and bones. The differences in clinical behavior of prostate cancer in these clinical 
scenarios are still poorly understood. Such an understanding will facilitate advances in 
diagnostic and therapeutic treatment options. A key step in cancer progression and 
establishment of metastasis is the degradation of the extracellular matrix. This is 
achieved through expression of a range of proteases including matrix 
metalloproteinases (MMPs). 
During the metastatic process, prostate cancer cells have to pass through the collagen 
containing barriers such as the basement membrane and interstitial stroma. This 
process is facilitated by expression of specific proteins which cleave constituents of 
extracellular matrix and help the physical passage of metastatic cells through these 
barriers (Jiang et al. 1994; DeClerck, 2000). During this process, proteolysis also 
influences tumour growth through the release of different growth factors and 
chemoattractant molecules. MMPs, plasminogen activators, proteases of collagen 
system and proteins such as Cathepsin B are some representations of these proteolytic 
proteins (Hiraoka et al. 1998). 
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The MMP family comprises more than 16 structurally related proteins which are further 
subdivided into groups based on extracellular matrix proteins substrates (MacDougall et 
al. 1995). There are three major subgroups of MMPs: collagenases degrade fibrillar 
collagen, stromelysins prefer proteoglycans and glycoproteins as substrates, and 
gelatinases are particularly potent in degradation of nonfibrillar and denatured collagens 
(gelatin). They share a catalytic domain with the HEXGH motif responsible for ligating 
zinc, which is essential for catalytic function. MMPs are also characterized by a 
distinctive PRCGVPD sequence in the domain, responsible for maintaining latency in 
the zymogen form (Birkedal-Hansen et al. 1993). MMP activity is regulated at multiple 
levels including mRNA and protein expression. In general once produced these proteins 
are rapidly secreted from the cells and require activation through the enzyme cascades 
for different members of the MMP family. Once activated, these proteins can be 
inhibited by general protease inhibitor like α2-macroglobulin or specific inhibitors known 
as tissue inhibitors of MMPs (TIMPs). These inhibitors do not distinguish effectively 
between individual family members (Birkedal-Hansen et al. 1993; Egeblad and Werb, 
2002). 
Changes in expression of MMPs in the prostate are related to normal physiological 
functions and pathological problems such as prostate cancer. MMP-2 is expressed 
during organ development of the prostate in rats and similar changes are observed 
during castration induced repression of the prostate (Wilson et al. 1991 & 1992). In 
human prostate MMP-2 is up regulated in BPH as compared to normal epithelial cells 
(Luo et al. 2002). High grade PIN usually shows this activity limited to the basal layer of 
cells (Montironi et al. 1996). It is interesting to observe that MMP-2 immunoreactivity is 
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observed in high-grade solid and cribriform prostate cancers exhibiting heterogeneous 
intensity and location (Bodey et al. 2001). Increased expression of MMP-2, the ratio of 
MMP-2:TIMMP-2 and particularly the active form of MMP-2 correlate with increasing 
Gleason score (Still et al. 2000; Bodey et al. 2001). Increased MMP-2 polymorhism is 
shown to be associated with more aggressive and higher Gleason score prostate 
cancer (dos Reis et al. 2010).  
There are a few discrepancies regarding the expression of MMP-9 in prostate cancer. 
Its expression has been detected in macrophages present in areas of prostatic 
inflammation and at the invasive edge of high Gleason score prostate cancers (Knox et 
al. 1996). The expression of MMP-9 in high-grade prostate cancers may indicate the 
process of epithelial to mesenchymal transformation which occurs during cancer 
progression (Behnsawy et al. 2013). The amount and proportion of active and pro-
enzyme form of MMP-9, varies among different prostate cancers and does not appear 
to correlate with increasing Gleason grade (Knox et al. 1996). There are a few studies 
indicating the presence of immunoreactivity for MMP-3 and MMP-11 in prostate cancer 
but it appears to be concentrated around the blood vessels in the stroma rather than 
prostate cancer epithelial cells (Bodey et al. 2001).  
Prior studies have documented that the PC-3 prostate cancer cell line strongly 
expresses MMP-2 & MMP-9 (Roomi et al. 2011). Considering the important role of 
MMPs in prostate cancer invasion and metastasis, we tried to establish the role of these 
proteins in reduced invasion of PC-3 prostate cancer cells, following WAVE-3 knock 
down. 
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7.2: Materials and methods: 
 
7.2.1: Cell lines: 
In this study we used already established PC-3 prostate cancer cell lines which have 
been previously used in our projects. Human prostate cancer cell lines PC-3WT, PC-
3ePEF, and PC-3WAVE-3KD were grown in DMEM medium supplemented with 10% FCS, 
penicillin (100 units/ml) and streptomycin (100μg/ml) in tissue culture flasks. The cells 
were plated at a density 5x105 cells/ml and grown to confluency in a humidified 
atmosphere at 5% CO2 at 37˚C. Serum-supplemented medium was removed and the 
cell monolayer was washed once with PBS and with the DMEM serum-free medium. 
Cells were incubated with 1ml of serum free media at 37˚C in a tissue culture incubator 
equilibrated with 95% air and 5% CO2 for 24 hours. The conditioned media were 
collected separately, pooled, and centrifuged for 10min at 3000rpm to remove cells and 
cell debris. Media samples were stored at -4ºC until used. 
 
7.2.2: RNA isolation and PCR: 
RNA was isolated from selected cells using total RNA isolation reagent (ABgene, 
Surrey, UK). Following quantification, this RNA was used to construct complimentary 
DNA using the Dura Script reverse transcriptase-polymerase chain reaction (RT-PCR) 
kit (Invitrogen, Paisley, UK). The DNA was used for PCR to detect expression of RNA 
for different MMPs in the cell lines described above. 
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7.2.3: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot: 
Equal amounts of proteins were quantified from the cell lysate using the DC Protein 
Assay kit (Bio-Rad Laboratories, Hemel Hempstead, UK). These proteins were 
separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and blotted on to nitrocellulose membrane. The membrane was treated with milk 
to block non-specific proteins prior to probing with anti-MMP primary antibodies, 
followed by peroxidise conjugated secondary antibodies. Protein bands were visualized 
and analysed using the Supersignal West Dura system and documented using a gel 
documentation system (UVITech, Cambridge, United Kingdom). 
 
7.2.4: Zymography: 
Gelatinase zymography was performed in 8% SDS polyacrylamide gel (Invitrogen 
Corp.) in the presence of 0.1% gelatin under non-reducing conditions. Culture media 
(40μL) were mixed with sample buffer and loaded for SDS-PAGE with Tris glycine SDS 
buffer. Samples were not boiled before electrophoresis. Following electrophoresis the 
gels were washed twice in 2.5% Triton X-100 for 30min at room temperature to remove 
SDS. The gels were then incubated at 37˚C overnight in substrate buffer containing 
50mM Tris-HCl and 10mM CaCl2 at pH8.0 and stained with 0.5% Coomassie Blue in 
50% methanol and 10% glacial acetic acid for 30min and destained gradually until clear 
bands appeared. Upon renaturation of the enzyme, the gelatinases digest the gelatin in 
the gel and give clear bands against an intensely stained background. Pre-stained 
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protein standards were run concurrently and approximate molecular weights were 
determined by plotting the relative motilities of known proteins. Gels were subsequently 
scanned on a digital scanner and digital images were saved for subsequent analysis. 
 
 
 
7.2.5: Immunocytochemistry (ICC): 
 
PC-3 cells (PC-3WT, PC-3pEF and PC-3WAVE-3KD) were seeded in chamber slides (Nunc, 
Denmark), at a density of 20,000 cells/well. Cell culture medium was removed by 
aspiration and washed twice with TBS buffer to remove culture medium proteins. 
Buffered formalin (4%) was added and incubated at RT for 10 minutes. Fixative was 
aspirated and cells washed twice with TBS buffer. Permeabilization buffer mixture (0.1% 
Triton in TBS buffer) was added and incubated for 10 min. The cells were washed twice 
with washing buffer following aspiration of permeabilization buffer. 
 Non specific protein block was performed with diluted horse serum for 20 minutes (1 
drop to 5 ml washing buffer). Chambers were washed again in washing-buffer 4 times. 
Cells were incubated with diluted primary antibody (anti-MMP diluted 1:100 in blocking 
buffer) at 37˚C, for 1 hour. The cells were washed again in washing buffer 4 times to 
remove any unbound primary antibodies. Secondary antibodies were added (anti-
mouse, rabbit or goat depending upon the origin of primary antibodies, with a dilution of 
1:250 in blocking buffer) and incubated for 30 minutes at room temperature. The cells 
were washed again in washing buffer 4 times to remove any unbound antibodies. ABC 
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complex was added and incubated for 30 minutes at RT. DAB chromogen was added 
for 5 minutes in a dark area after washing again four times (covered by a tray). Excess 
chromogen was removed by washing with water for 2 minutes. Cells were 
counterstained with Mayer's Haematoxylin for 1 minute. Finally they were washed in 
water for 5 minutes to remove excess Haematoxylin. 
7.3: Results: 
 
7.3.1: Expression of MMPs in PC-3 cell lines: 
We analyzed three prostate cancer cell lines which have been previously used in our 
experiments. These included PC-3WT, PC-3ePF, PC-3WAVE-3 KD. We screened these cell 
lines for expression of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-11. There was no 
significant difference in expression of the different MMPs in three different cell lines 
except MMP-2. Messenger RNA levels of MMP-1, MMP-2, MMP-7, MMP-9 and MMP-
11 in the three different cell lines are illustrated in figure (Figure: 7.1). MMP-2 was 
expressed at a relatively low level in PC-3 WAVE-3 KD cell line as compared to PC-3 WT 
and control PC-3 ePF cell lines. Considering the role of gelatinases in prostate cancer 
invasion, we also analysed the expression of MMP-2 by western blotting in these cell 
lines which did not show any significant difference among different cell lines (Figure: 
7.2). Concordant with this, ICC staining revealed no significant difference in the staining 
intensity of MMP-2 in different cell lines (Fig: 7.3). It was interesting to observe that 
western blotting of conditioned medium from PC-3 WAVE-3 KD revealed reduced 
expression of MMP-2 (Fig: 7.2).   
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Figure 7.1: RT-PCR picture showing the expression of different MMPs in three different 
cell lines. 
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Fig 7.2: Western blotting showing the expression of MMP-2 in cell lysate and 
conditioned cell medium extracted from three different cell lines. There is good 
expression of MMP-2 in cell lysate (PC-3 WAVE-3KD) but minimal expression is 
demonstated in cell medium (PC-3 WAVE-3KD). 
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Fig 7.3: Immunocytochemistry for expression of MMP-2 in three different transgenic cell 
lines. 
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7.3.2: Reduced MMP-2 activity on gelatin zymography: 
Gelatin zymography is a simple but powerful method to detect proteolytic enzymes 
capable of degrading gelatin from various biological sources. It is particularly useful for 
the assessment of two key members of the matrix metalloproteinase family, MMP-2 
(gelatinase A) and MMP-9 (gelatinase B), due to their potent gelatin-degrading activity. 
This polyacrylamide gel electrophoresis-based method can provide a reliable 
assessment of the type of gelatinase, relative amount, and activation status (latent, 
compared with active enzyme forms) in cultured cells, tissues, and biological fluids. We 
used this method to detect the presence of gelatinases activity in the conditioned cell 
culture medium. It was very interesting to note that MMP-2 activity was significantly 
reduced in the medium extracted from PC-3 WAVE-3 KD cell line as compared to PC-3 WT 
and control PC-3 ePEF cell lines (Figure:7.4). No significant MMP-9 activity was observed 
in all three cell lines. 
It was very interesting to note that zymographic analysis of conditioned medium 
duplicated the results of earlier study involving western blotting. MMP-2 expression was 
demonstrated exclusively in the cell lysate among all three cell lines. However western 
blotting did not show any significant expression of MMP-2 in medium extracted from 
cells deficient in WAVE-3. This may potentially indicate towards the failure of 
mechanism to deliver the MMP-2, in to the medium. 
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Figure 7.4: Zymograpy for expression of MMP-2 and MMP-9 in conditioned medium 
from three different cell lines. There was reduced MMP-2 (72kDa) activity in PC-3WAVE-
3KD cell line as compared to control cell lines. No expression of MMP-9 was observed on 
zymography. 
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7.4: Discussion:  
Tumour metastasis is a multistep process including new vessel formation, changes in 
cell attachment and adhesion, invasion, migrational properties and cell proliferation. 
These events are regulated by multiple complex pathways with involvement and cross 
talk of different cellular components. Specific agents aimed to prevent metastasis are 
not available yet but will be a critical achievement in cancer treatment. 
Evidence from our prior research suggested that genetic silencing of WAVE-3 in 
prostate cancer cells results in reduced migratory and invasive potential without any 
significant effect on the cellular growth and adhesion. This effect persisted even with the 
addition of the stimulatory molecule, hepatocyte growth factor (HGF). Subsequent 
studies at the molecular level indicated the important role of paxillin for possible 
mediation of these changes. In the present study we investigated the possible role of 
different MMPs in reducing the invasive potential of prostate cancer cells at different 
levels, including transcriptional, translational and functional levels. Overall our results in 
this study suggested decreased activity of MMP-2 in the extracellular medium on 
zymography, which may reflect reduced activity or reduced availability. There was no 
significant change in the expression of this important gelatinase in all cell lines. 
Numerous studies have shown that inhibition of MMPs activity or expression can be a 
potential target for prevention of metastasis (Coussens et al. 1996; Chakraborti et al. 
2003). MMP-2 and MMP-9 belong to the gelatinase group of MMPs and their role has 
been extensively studied in prostate cancer (Zhang et al. 2004). Expression of most 
MMPs is normally low in tissues, and only induced when remodelling of the extracellular 
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matrix is required. MMP expression is primarily regulated at the transcriptional level, 
although stabilization of MMP transcripts in response to growth factors, as well as the 
influence of cytokines, also plays a role in the regulation of MMP activity (Sasaki et al. 
2000; Reunanen et al. 2002). 
The possible involvement of WAVE proteins in the regulation of MMPs was initially 
reported by Suetsugu et al., who showed that down regulation of WAVE-1, but not 
WAVE-2, affected MMP-2 activity (Suetsugu et al. 2003). In this study, they 
pharmacologically inhibited MMPs with GM6001, which blocks the activities of a wide 
range of MMPs including MMP-2. Migration of WAVE-1 deficient cells dependent on 
MMPs through the ECM was inhibited by GM6001. In contrast, migration of wild-type 
and WAVE-2 deficient cells was reduced only to 70%–80% by GM6001. The levels of 
secreted MMP-2 were also decreased on zymographic studies of conditioned medium 
in the WAVE-1 deficient cell line, although the amount of MMP-2 contained in cells did 
not change significantly. On immunohistochemistry, MMP-2 was co-localized with 
WAVE-1 at dorsal ruffles formed after treatment with PDGF, supporting the relationship 
between WAVE-1 and MMP-2 (Suetsugu et al. 2003).  
Conversely, Sossey-Alaoui et al., while investigating the functional consequences of the 
loss of WAVE-3 using RNA interference (RNAi), identified a MAPK signaling axis, where 
WAVE-3 was essential for regulation of the expression of different MMPs, in human 
neuroblastoma cell  lines (Sossey-Alaoui et al. 2005). They showed that knockdown of 
WAVE-3 expression affects the activity of the p38 MAPK pathway, but not that of AKT 
or ERK1/2 pathways. WAVE-3 mediated down regulation of p38 activity was found to be 
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independent of both WAVE-1 and WAVE-2 expression, as WAVE-3 knockdown did not 
alter the transcription levels of either WAVE-1 or WAVE-2. Loss of WAVE-3 resulted in 
a significant decrease in expression levels of MMP-1, MMP-3, and MMP-9. However no 
significant effect on expression of MMP-2 was noted. The inhibition of these MMPs as a 
result of WAVE-3 loss led to a dramatic inhibition of cell migration and invasion using 
both the in vitro wound closure and matrigel assays in human neuroblastoma 
cells (Sossey-Alaoui et al. 2005). In our study, expression of MMP-1 and MMP-9 was 
not significantly affected. Expression of MMP-2 was reduced as compared to MMP-9 
and zymography showed significantly reduced activity in WAVE-3 deficient cells.  It is 
also important to note that the Sossey-Alaoui et al. study lacks any data on zymography 
which may have added additional information on this matter.  
Paxillin is an important molecule in integrin-mediated adhesion signals and is localized 
in dorsal ruffles, at the leading edge of cellular movement (Pixley et al. 2001). Cortactin, 
dynamin and ARP2/3 complex are localized in the dorsal ruffles and podosomes which 
may represent the invading edge of the cell as well (Kruege et al. 2003). It is not clear 
how the WAVE family is involved in MMP secretion and MMP-dependent migration. 
Suetsugu et al. demonstrated that WAVE-1 dependant cell migration is remarkably 
sensitive to the absence of MMP-2 as compared to WAVE-2 dependant cell migration, 
which is partially affected. It is well documented that integrins generate adhesion and 
induce MMP-mediated ECM degradation (Friedl et al. 2003). Integrin-mediated 
adhesion simultaneously activates Rac (Bishop et al. 2000) and a paxillin-associated 
kinase, FAK (Schlaepfer et al. 1999). Both Rac and FAK enhance secretion and 
activation of MMP-2 (Sein et al. 2000; Zhuge et al. 2000; Hauck et al. 2002). The actin 
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cytoskeleton itself is involved in regulation of MMPs. Treatment of fibroblasts with 
cytochalasins increased expression, secretion, and activation of MMP-2 (Harris et al. 
1975; Tomasek et al. 1997). Our prior studies regarding the role of paxillin showed 
markedly reduced levels of phosphorylated paxillin which may indicate crosstalk 
between these molecules and WAVEs and suggest the differential effects on the MMP-
2 and hence on invasion as well. 
He et al. studied the role of WAVE-1 in leukaemia cell line invasion. K562 cells, deficient 
in WAVE-1 were found to lose their invasive potential along with reduced MMP-2 
expression, as compared to control cells. At the same time forced expression of WAVE-
1 using pcDNA increased the expression of MMP-2. The invasion ability of K562 cells 
was enhanced after transfected with pcDNA3 as well. Immunoflourescence studies 
showed co-localization of WAVE-1 and MMP-2, indicating the close relationship and 
involvement of both in the invasive potential of these cells (He et al. 2009).  
MMP-2 is also expressed by prostate cancer stromal cells. Yu et al. determined that 
estradiol treatment of prostate cancer stromal cells enhanced the production of MMP-2 
in these cells. Subsequent use of conditioned medium showed increased invasion in a 
matrigel invasion assay with prostate cancer cells. Conditioned medium treated with an 
anti-MMP2 antibody lost its stimulatory effect on invasion of prostate cancer cells. 
However, mechanistic studies showed that oestradiol up-regulated MMP2 in an indirect 
manner. It was revealed that estradiol induced TGFβ1 expression via oestrogen 
receptor (ERα); TGFβ1 stimulated MMP2 expression in prostate stromal cells and the 
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invasion of prostate cancer cells was stimulated by elevated MMP2 expression induced 
by estradiol in a paracrine manner (Yu et al. 2011). 
Reduction in the activity of MMP-2 has been attributed to reduced invasive potential in 
different cancer cell lines but multiple associated changes and proposed possible 
underlying mechanisms have been described in different studies. For example Li et al 
investigated the underlying mechanism of β-human chorionic gonadotropin (β-hCG) in 
promoting motility and invasion in human glioblastoma U87MG cells. Through western 
blot and gelatine zymography studies, it was concluded that β-hCG increased 
phosphorylation of ERK1/2 and up-regulated MMP-2 expression in a dose and time-
dependent manner, whereas ERK1/2 blocker, PD98059 (25 μM) significantly decreased 
both ERK1/2 and MMP-2 expression and activity, indicating a possible role for ERK1/2 
in controlling the activity of MMP-2 (Li et al. 2012). 
Kwiatkowska et al investigated the molecular mechanisms underlying the inhibitory 
effect of Cyclosporin-A on the migration/invasion of human glioblastoma cells with 
different alterations of the PI3K/AKT signalling pathway. This study demonstrated that 
Cyclosporin-A impairs Akt and FAK signaling which results in the reduction of motility 
and invasion of glioblastoma cells. Cyclosporin-A, as a pharmacological and genetic 
inhibitor of PI3K/AKT signaling, reduced invasion and MMP-2 proteolytic activity likely 
by two mechanisms: by rapid impairment of MT1-MMP shuttling to lamellipodia and 
delayed downregulation of NFκB-dependent MMP expression. These findings showed 
for the first time, the anti-invasive action of Cyclosporin-A and defined a complex 
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involvement of AKT signaling into the regulation of cellular motility and invasion 
(Kwiatkowska et al. 2011). 
Reduced activity of MMP2 following WAVE-3 knockdown may be the sequel of 
imbalance between the level of MMP-2 and its tissue inhibitors. TIMP1 has been shown 
to regulate MMP2 activity and numerous pieces of evidence have indicated a correlation 
between elevated TIMP1 levels and diminished MMP-2 activity and invasiveness 
(Khokha et al. 1992; Ramer et al. 2008).  
Results of our current study clearly suggest the active role of MMP-2 in the reduction of 
cell motility and invasion following WAVE-3 elimination. It provides part of a larger 
puzzle underpinning the process of metastasis which needs to be further investigated 
for the role of pathways such as ERK1/2 and MAPK/p53. 
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Chapter 8 
General discussion 
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Prostate cancer is the 4th most common cause of cancer deaths in the UK, accounting 
for approximately 7% of all cancer related deaths. Survival from prostate cancer is 
strongly related to the stage of the disease at the time of diagnosis. For organ confined 
prostate cancer, five year survival in England in 1999-2002 was more than 90%. In 
contrast, the presence of metastatic disease at the time of presentation produces five 
year relative survival of around 30%. Since the introduction of PSA testing, the 
incidence of local-regional disease has increased, whereas the incidence of metastatic 
disease has decreased (Newcomer et al. 1997).  
In spite of all advanced treatment options available for prostate cancer, management of 
metastatic disease remains a major challenge. Prevention of the development of 
metastatic disease would be a significant breakthrough in the management of any 
cancer like prostate cancer, which is responsible for a high rate of morbidity and 
mortality in the UK. Morbidity and mortality arising from metastatic disease can result 
from direct organ damage by the enlarging lesions, paraneoplastic syndromes, or from 
the complications of treatment. 
The major problem during the treatment of metastasis is the biological heterogeneity of 
the cells in the primary and metastatic sites. This heterogeneity is exhibited in the form 
of specific biological characteristics such as expression of cell receptors, enzymes, 
growth properties and growth factors. Manipulation of these essential pathways and 
different members of participating cellular molecules can potentially inhibit this process 
and thus halt the metastatic cascade. 
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8.1: WAVEs and cell motility in cancer and cancer metastasis 
 
Cellular movement is an integral part of metastasis and has attracted a lot of attention 
from researchers as a potential target to prevent or inhibit the process of metastasis. 
Cellular movement is primarily controlled by polymerisation and depolymerisation of 
actin. In addition to cellular movement, the actin cytoskeleton also plays an important 
role in cell shape changes, cell proliferation and membrane transport of essential 
molecules. Considering these vital functions, the dynamics of actin polymerization and 
organization is of critical importance. Defects in actin polymerization results in human 
diseases like Wiskott-Aldrich syndrome (Sullivan et al. 1994) but at the same time it can 
be manipulated to modify and stop the metastatic cascade. There are multiple genes 
involved in controlling actin polymerization including genes encoding for the 
WASP/WAVE family of proteins. This family comprises 5 members including WASP, N-
WASP, WAVE-1, WAVE-2, and WAVE-3. Both WASP and WAVE subfamilies activate 
the Arp2/3 complex, leading to the stimulation of actin polymerization and assembly of 
actin filaments.  
The WASP/WAVE proteins are downstream effectors of Rho GTPases (Takenawa et al. 
2001). These small GTPases are responsible for controlling vital functions such as 
cellular motility and proliferation. The activity of WASP and WAVE proteins are 
regulated through different mechanisms. Cdc42 is responsible for activation and 
regulation of WASP and N-WASP (Rohatgi et al. 1999) while activity of WAVEs is 
regulated by a multi-protein complex downstream of Rac (Millard et al. 2004).  
 
202 
 
8.2: Genetic silence of WAVE-3 using constructed ribozyme 
 
Cellular cloning in this project involved silencing the specific gene of interest (WAVE-3) 
which is normally expressed in these cell lines. Specific gene expression can be 
modified at transcriptional and post-transcriptional levels. Transcriptional genetic 
silencing involves histone modifications through creation of an environment of 
heterochromatin around the gene, resulting in the gene being inaccessible to cellular 
machinery such as RNA polymerase and other transcriptional factors (Perry et al. 
2010). Post-transcriptional modification involves the mRNA of a specific gene being 
destroyed through introduction of specific agents targeted against the gene of interest. 
A common mechanism is the introduction of small interfering RNAs (siRNA) which 
prevent the translation of a specific gene mRNA. This concept has been used 
successfully in therapeutic treatment of diseases such as cancer and has shown 
promising results. Major targets of this therapy include silencing of genes involved in the 
process of angiogenesis, metastasis, apoptosis and resistance to chemotherapy 
(Ramachandran et al. 2012).  
The hammerhead ribozyme is a small RNA motif consisting of three helices that 
intersect at a conserved core. They were first discovered as self-cleaving domains in 
the RNA genome of different plant viroids and virusoids (Forster et al. 1987). Soon 
thereafter, it was demonstrated that the hammerhead motif could be incorporated into 
short synthetic oligonucleotides and transformed into a true, multiple turnover catalyst, 
suitable for cleaving a variety of RNA targets (Uhlenbeck et al. 1987; Haseloff et al. 
1988). Their role in research and therapeutic options for cancer has been studied 
203 
 
extensively (Takagi et al. 2002). This method of gene silencing has been previously 
used successfully at our host research facility (Jiang et al. 2001; Jiang et al. 2005). The 
secondary structure of WAVE-3 mRNA was predicted using the Zuker’s RNA Mfold 
software (Zuker, 2003). This software is designed to predict the stem and loop structure 
of RNA under optimal conditions, enabling the identification of a suitable GUC codon. 
The resulting ribozyme targets this specific codon. Following synthesis these ribozyme 
transgenes were cloned in to pEF6 plasmids in the cloning reaction and successfully 
used to transform the PC-3 prostate cancer cell line. The specific plasmid (pEF6) used 
in our experiments, also carries a genetic sequence for resistance to blasticidine 
antibiotic. This characteristic enabled us to select the cell populations with expression of 
plasmid while inhibiting the growth of cells lacking the plasmid. Knock down of WAVE-3 
expression was maintained successfully during culture of progressive cell populations. It 
is also important to note that expression of WAVE-1 and WAVE-2 was not changed (Q-
PCR, chapter: 4, page: 119). Similar results have been reported in MDA-MB-231 cells 
using siRNAs (Sossey-Alaoui et al. 2005). 
The WAVE family of proteins play a critical role in actin polymerization, downstream of 
Rac which leads to cell migration (Takenawa et al. 2001). The exact and definitive roles 
of each family member is not known; however gene silencing studies of each member 
has provided a few glimpses of their function in the regulation of actin polymerization. In 
the present study we were able to demonstrate the stable knock down of WAVE-3 
through ribozyme transgene introduction into the PC-3 prostate cancer cell line. 
Inhibition of WAVE-3 in this cell line did not affect cellular proliferation at 72 hours. 
There was no statistically different change in the number of adherent cells to an artificial 
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basement membrane among the three different cell lines (WT, ePEF and WAVE-3KD). 
The most striking and important phenotypic change following WAVE-3 knock down was 
a change in the motility and invasive potential of these cells. Elimination of WAVE-3 
resulted in reduced cell motility which was evident on the Cytodex-2® beads assay and 
wounding assay. At the same time, the number of invading cells through the artificial 
matrigel basement membrane was reduced quite significantly. Considering there was 
no change in the expression of WAVE-1 and WAVE-2, this finding potentially points 
towards the significant role of WAVE-3 in these processes. Similar data has been 
previously reported (Fernando et al. 2007; Teng et al. 2010).  
 
8.3: WAVE-3 and HGF induced motility of prostate cancer 
cells 
 
Hepatocyte growth factor/scatter factor (HGF/SF) has attracted much attention in recent 
years for its potential role in progression of prostate cancer. HGF is known to play an 
important role in the metastatic process through its effects on proliferation, dissociation, 
migration and invasion (Tajima et al. 1991; Sugawara et al. 1997; Gmyrek et al. 2001). 
HGF/SF derived from prostate stroma promotes proliferation, differentiation, motility, 
and invasion of malignant epithelial cells indicating possible involvement in the 
progression of prostate cancer (Gmyrek et al. 2001). Serum levels of HGF and PSA are 
found to be significantly increased in prostate cancer patients compared to a control 
group (Maha Hashem et al. 2005). Higher plasma levels of SF/HGF in men with 
hormone-refractory prostate cancer are associated with decreased patient survival 
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(Humphrey et al. 2006). Considering a possible significant role of HGF in prostate 
cancer progression and metastasis, the role of WAVE-3 in HGF mediated increased 
cellular motility, proliferation, adhesion and invasion was studied. HGF imparts its 
effects through its receptor c-MET. Various factors downstream of c-Met have been well 
characterised, including the extracellular signal-regulated kinases (ERKs). Radtke et al. 
showed that ERK 1 & 2 play an important role in c-MET mediated cell migration through 
its effect on paxillin. Important findings from this study in non small cell lung carcinoma 
cell lines, demonstrated that paxillin phosphorylation could be blocked by inhibition of 
ERK 1 & 2 (Radtke et al. 2013). Similar findings were reported by Liu et al. in their study 
using mIMCD-3 epithelial cells. They studied the effect of HGF on the focal adhesion 
proteins, focal adhesion kinase (FAK) and paxillin and their associated proteins. HGF 
was found to increase the tyrosine phosphorylation of paxillin and to a lesser degree 
FAK. Interestingly paxillin phosphorylation could be inhibited by the ERK inhibitor 
U0126. Their data suggest that HGF can induce serine/threonine phosphorylation of 
paxillin most probably mediated directly by ERK, resulting in the recruitment and 
activation of FAK and subsequent enhancement of cell spreading and adhesion (Liu et 
al. 2002). In the present study WAVE-3 knock-down resulted in reduced 
phosphorylation of paxillin and this change persisted following treatment with HGF. 
Considering the findings from the above two studies, pathways involving ERK1&2 
appear to play an important role in induction of these changes in prostate cancer cell 
lines. The exact machinery of this effect orchestrated by ERK, WAVE and paxillin 
downstream of HGF/MET pathway requires further investigation.  
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The ERM (Ezrin, Radixin, and Moesin) proteins are a group of highly conserved and 
related proteins which provide a regulated linkage between the membrane and the 
underlying actin cytoskeleton. 
Chuan et al. demonstrated that forced expression of c-Myc in the mouse prostate and in 
normal human prostate epithelial cells results in tumour transformation with an invasive 
phenotype. C-Myc induces cell invasion and anchorage-independent growth by 
regulating ezrin protein expression in the presence of androgens (Chuan et al, 2010). 
Valdman et al. and Musial et al. demonstrated significant inverse correlation between 
ezrin expression and the degree of prostate cancer differentiation (Valdman et al. 2005; 
Musiał et al. 2007).  Valderrama et al. investigated the role of ERM in prostate cancer 
cells. This study showed that radixin is required for migration of PC-3 prostate 
cancer cells. Radixin depletion by RNA interference increases the cell spread area and 
cell-cell adhesion mediated by adherens junctions. Radixin depletion also alters actin 
organization, and distribution of active phosphorylated ezrin and moesin (Valderrama et 
al. 2012). Bartholow et al. reported expression profiles of radixin and moesin in prostatic 
adenocarcinoma. There was a statistically significant difference observed between high 
grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer in terms of radixin 
but no difference was observed in expression of moesin (Bartholow et al. 2011). 
Phosphorylation of a threonine residue (T558 in moesin, T567 in ezrin, T564 in radixin) 
within the C-terminal actin-binding domain of ERM proteins is considered a hallmark of 
ERM activation (Nakamura et al. 1995; Gautreau et al. 1995; Brown et al. 2003). It has 
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also been shown that PIP2 is a key factor for the activation of ERM proteins in vivo 
(Matsui et al. 1999).  
In our studies we investigated the expression and phosphorylation status of 
ERM proteins in prostate cancer cells following WAVE-3 knock down, in order to 
investigate their potential role in the reduced cellular motility and invasion. 
Expression of these proteins was detected through immunoblotting of pre-
quantified protein samples while phosphorylation status was detected through 
immunoprecipitation studies. 
Ezrin has been previously documented as an effector of HGF mediated migration and 
morphogenesis in epithelial cells. Crepaldi et al. reported that ezrin is crucial to 
morhogenesis in polarized kidney derived epithelial cells. HGF produced enrichment of 
ezrin recovered in the detergent insoluble fraction of the cytoskeleton protein fraction. 
Overproduction of ezrin through stable transfection in these cells, enhances cell 
migration and tubule formation induced by HGF. It has also been suggested that site 
directed mutagenesis of ezrin codonY145 and Y353 to phenylalanine does not affect 
ezrin localization but reduced motility and morphological changes induced by HGF 
(Crepaldi et al. 1997). In the present study there were no significant changes in the 
expression and phosphorylation of ezrin following WAVE-3 knock down. Addition of 
HGF to three prostate transgenic cell lines showed cell spreading and peripheral 
localization of these proteins on immunoflourescence studies. However, this effect was 
limited in the cell line lacking the presence of WAVE-3. Similar findings were noted in 
case of the radixin and moesin as well. 
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8.4: WAVE-3 and MMPs in the invasiveness of prostate 
cancer cells 
 
Numerous studies have shown that inhibition of MMPs activity or expression can be a 
potential target for prevention of metastasis (Coussens et al. 1996; Chakraborti et al. 
2003). MMP-2 and MMP-9 belong to the gelatinase group of MMPs and their role has 
been extensively studied in prostate cancer (Zhang et al. 2004). MMP-2 polymorphism 
has been associated with locally advanced or metastatic disease (dos Reis et al. 2010).  
Emerging evidence has shown that the tumour microenvironment plays a crucial role 
in prostate cancer development and progression. Gravina et al. performed phenotypic 
characterisation of human prostatic stromal cells in primary cultures derived from 
human tissue samples. They used cultures from stromal cells obtained from BPH 
(15 cases) and prostate cancer patients (30 cases). This study analyzed the expression 
of matrix metalloproteinase MMP-2, MMP-9 and tissue inhibitors of MMPs (TIMPs). 
MMP-2 was secreted by all primary cultures; whereas MMP-9 secretion was observed 
in only a few prostate cancer derived stromal cells (Gravina et al. 2013). Murray et al. 
performed an immunocytochemical study of MMP-2 expression in 
circulating prostate cells (CPCs), disseminated tumour cells (DTCs), and micro 
metastases (mM) in the bone marrow of men with prostate cancer. Tumour cells were 
identified with anti-PSA immunocytochemistry. PSA positive samples were processed 
with anti-MMP-2 antibody along with its expression compared with Gleason score, 
concordance of expression, and metastatic and non-metastatic disease.  Out of 215 
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men that participated in the study, circulating prostate cells were detected in 62.7%, 
disseminated tumour cells in 62.2%, and micro metastases in 71.4% with non-
metastatic cancer. All patients with clinically metastatic prostate cancer had CPCs, 
DTCs, and mM detected. All CPCs and DTCs expressed MMP-2. In micro metastases, 
MMP-2 expression was positively associated with increasing Gleason score (Murray et 
al. 2012). This study highlighted the early expression and importance of MMP-2 in the 
prostate cancer metastatic process. 
Overall our results suggested decreased activity of MMP-2 in the extracellular medium 
on zymography, which may reflect reduced activity or reduced availability of MMP-2 in 
the medium. There was no significant change in the expression of this important 
gelatinase in all cell lines. In general, activity of MMPs is controlled through expression 
at the transcriptional level (Sasaki et al. 2000). However in the present study there was 
no significant difference in the expression of MMP-2 at mRNA and protein levels in 
different cell lines. Immunoblotting studies of MMP-2 in cell lysates and conditioned 
medium from different cell lines showed markedly reduced MMP-2 in the medium, 
following WAVE-3 knock down. At the same time there was significantly reduced activity 
of MMP-2 in the medium on zymography studies.  
The possible involvement of WAVE proteins in the regulation of MMPs was initially 
reported by Suetsugu et al who showed that down regulation of WAVE-1, but not 
WAVE-2, affected MMP-2 activity (Suetsugu et al. 2003). It is not clear how the WAVE 
family is involved in MMP secretion and MMP-dependent migration. Both Rac and FAK 
enhance secretion and activation of MMP-2 (Sein et al. 2000; Zhuge et al. 2001; Hauck 
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et al. 2002). FAK is a paxillin associated kinase which plays important role in regulation 
of the actin cytoskeleton. 
When cells invade the ECM, cell-ECM adhesion through integrins coupled with 
degradation of ECM by proteases, as well as leading edge formation by actin 
polymerization are important. The integrins generate adhesion and induce MMP-
mediated ECM degradation. Integrin-mediated adhesion simultaneously activates Rac 
and paxillin-associated kinases like FAK. Both Rac and FAK enhance secretion and 
activation of MMP-2. Collectively, the findings of the present study indicate that WAVE-3 
regulates the activation of paxillin and consequently affect the function of MMP-2 and 
eventually coordinate the invasiveness of prostate cancer cells, particularly HGF 
enhanced motility and metastasis. 
 
 
 
 
8.5: Prospects of future study: 
This study examined the role of the WAVE-3 in prostate cancer cell motility and also 
demonstrated its role in the HGF mediated changes in prostate cancer cells. In addition 
the underlying pathways, including role of paxillin and MMP-2 to reduce the cellular 
motility and invasive potential were investigated. There is little doubt about the fact that 
WAVE-3 and HGF expression represent aggressive properties of prostate cancer and 
they can be used as important prognostic markers for the risk stratification including 
clinical studies. The exact mechanisms underlying phenotypic changes following 
WAVE-3 knock-down, still remain unclear and require further investigations. Moreover, 
WAVE-3 being tumour promoter gene, further studies using in vivo tumour model are 
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necessary to elucidate the implication of WAVE-3 in prevention and treatment of 
prostate primary tumour and development of corresponding secondary tumour.  
The interaction and influence of intermediate molecules such as paxillin and their 
interaction with WAVEs family needs further investigations. Reduced levels of 
phosphorylated paxillin following WAVE-3 knock down may be attributed to possible 
loss of positive feedback effect from WAVE-3, which facilitates the activation of paxillin 
through its phosphorylation. This possible interaction should be further investigated 
through co-localization studies involving paxillin and WAVE-3 in resting phase and 
during cellular stimulation like addition of HGF, which may be able to explain the close 
relationship of these molecules. Paxillin plays an important role in the dynamics of focal 
adhesion complexes as well and further studies can potentially investigate the changes 
in these vital structures, following WAVE-3 knock down. Indirectly, these changes 
involving focal adhesions may further explain the role of focal adhesions in reducing 
cellular motility and invasion with loss of WAVE-3.    
MMP-2 appears to play an important role in reduction of invasion following loss of 
WAVE-3. Its expression appears to be stable following WAVE-3 knock-down but 
reduced availability in the medium indicates a possible influence on the secretion into 
the medium. Previous studies have suggested co-localization of WAVE-1 and MMP-2 
on the leading edge of motile cells. Similarly, WAVE-3 warrants further investigation 
such as co-localisation with MMP-2 during cell invasion and motility. N-WASP have also 
been implicated in the promotion of membrane associated MMP (MT1-MMP) trafficking 
in to invadopodia of invasive breast cancer cells. Reduced availability in the medium 
following WAVE-3 loss may result from interference with transport mechanisms such as 
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the movement of storage vesicles, which is also affected by cell movement through 
actin polymerization. Considering the important role of MMP-2 in prostate cancer 
invasion, further studies are required to elucidate the underlying mechanism for this 
effect. Further investigations involving the possible role of pathways such as ERK1/2 
and MAPK/p53 may also be helpful to explain this phenomenon in prostate cancer cell 
line. Reduced activity of MMP-2 following WAVE-3 knockdown may be the sequel of 
imbalance between the level of MMP-2 and its tissue inhibitors such as TIMP-1, which 
has been shown to regulate MMP-2 activity. 
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Appendix: 1. Suppliers of materials and reagents as detailed in this thesis.  
 
Material & Reagent  Supplier  
10% foetal calf serum (FCS)  PAA Laboratories, Coelbe, Germany  
A/G protein agarose beads  Santa-Cruz Biotechnology, Santa-Cruz, CA, 
USA  
Acetic acid  Fisher Scientific, Leicestershire, UK  
Acrylamide mix (30%)  Sigma-Aldrich Co, Poole, Dorset, UK  
Agarose  Melford Laboratories Ltd, Suffolk, UK  
Ammonium persulfate (APS)  Sigma-Aldrich Co, Poole, Dorset, UK  
Bio-Rad DC Protein Colourimic Assay  Bio-Rad Laboratories, Hercules, CA, USA  
Boric acid  Duchefa Biochemie, Haarlem, Netherlands  
Bromophenol Blue  Sigma-Aldrich Co, Poole, Dorset, UK  
CaCl2  Sigma-Aldrich Co, Poole, Dorset, UK  
Chloroform  Sigma-Aldrich Co, Poole, Dorset, UK  
Commasine Blue  Sigma-Aldrich Co, Poole, Dorset, UK  
DAB Chromogen  Vector Laboratories Inc, Burlingame, CA, 
USA  
DEPC (Diethylpyrocarbonate)  Sigma-Aldrich Co, Poole, Dorset, UK  
Dimethylsulphoxide (DMSO)  Fisons Scientific Equipment, 
Loughborough, UK  
DMEM/Ham's F12 with L-Glutamine 
medium  
PAA Laboratories, Coelbe, Germany  
EDTA (Ethylenediaminetetraacetic acid)  Duchefa Biochemie, Haarlem, Netherlands  
Ethanol  Fisher Scientific, Leicestershire, UK  
Ethidium bromide  Sigma-Aldrich Co, Poole, Dorset, UK  
FITC conjugated rabbit anti-goat IgG  Santa-Cruz Biotechnology, Santa-Cruz, CA, 
USA  
FITC conjugated sheep anti-mouse IgG  Santa-Cruz Biotechnology, Santa-Cruz, CA, 
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USA  
Fluorescence mounting medium  CalBiochem, Nottingham, UK  
Glycine  Melford Laboratories Ltd, Suffolk, UK  
HCL  Sigma-Aldrich Co, Poole, Dorset, UK  
Horse Serum  Sigma-Aldrich Co, Poole, Dorset, UK  
Isopropanol  Sigma-Aldrich Co, Poole, Dorset, UK  
KCl  Fisons Scientific Equipment, 
Loughborough, UK  
KH2PO4  BDH Chemicals Ltd, Poole, England, UK  
Mayers Htx  Sigma-Aldrich Co, Poole, Dorset, UK  
Methanol  Fisher Scientific, Leicestershire, UK  
NaCl  Sigma-Aldrich Co, Poole, Dorset, UK  
Na2HPO4  BDH Chemicals Ltd., Poole, Dorset, UK  
NaN3  Sigma-Aldrich Co, Poole, Dorset, UK  
NaOH  Sigma-Aldrich Co, Poole, Dorset, UK  
Nitrocellulose membrane  Amersham, Cardiff, UK  
Penicillin  Sigma-Aldrich Co, Poole, Dorset, UK  
Peroxidase conjugated goat anti-rabbit 
IgG  
Sigma-Aldrich Co, Poole, Dorset, UK  
Peroxidase conjugated rabbit anti-goat 
IgG  
Sigma-Aldrich Co, Poole, Dorset, UK  
Peroxidase conjugated rabbit anti-mouse 
IgG  
Sigma-Aldrich Co, Poole, Dorset, UK  
Ponceau S Stain  Sigma-Aldrich Co, Poole, Dorset, UK  
Precision qScriptTM RT PCR kit  Primerdesign LTD, Southampton, UK  
REDTaqTM ReadyMix PCR reaction mix  Sigma-Aldrich Co, Poole, Dorset, UK  
RNA extraction buffer  Advanced Biotechnologies Ltd, Epsom, 
Surrey, UK  
SDS (Sodium dodecyl sulphate)  Melford Laboratories Ltd, Suffolk, UK  
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Bovine albumin  Sigma-Aldrich Co, Poole, Dorset, UK  
Streptomycin  Sigma-Aldrich Co, Poole, Dorset, UK  
Sucrose  Fisons Scientific Equipment, 
Loughborough, UK  
Supersignal™ West Dura system  Pierce Biotechnology Inc., Rockford, IL, 
USA  
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich Co, Poole, Dorset, UK  
TRI Reagent  Sigma-Aldrich Co, Poole, Dorset, UK  
Tris-Cl  Melford Laboratories Ltd, Suffolk, UK  
TRITC conjugated goat anti-rabbit IgG  Sigma-Aldrich Co, Poole, Dorset, UK  
Trion  Sigma-Aldrich Co, Poole, Dorset, UK  
Trypsin  Sigma-Aldrich Co, Poole, Dorset, UK  
Tween 20  Melford Laboratories Ltd, Suffolk, UK  
Vectastain Universal ABC kit  Vector Laboratories Inc, Burlingame, CA, 
USA  
ZnCl  Sigma-Aldrich Co, Poole, Dorset, UK  
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Appendix: 2. Suppliers of hardware and software as detailed in this thesis.  
 
 
Hardware/Software  Supplier  
16-well chamber slide (for 
Immunohistochemistry)  
Nalge NUNC International, Rochester, 
NY  
25cm2 and 75cm2 culture flasks  Cell Star, Germany  
Cytodex 2 beads®  Sigma-Aldrich Co, Poole, Dorset, UK  
Electroporation cuvette  Euro Gentech, Southampton, UK  
Fluorescent microscope  Olympus, Lake Success, NY, USA  
iCycler iQt system  Bio Rad, Hercules, CA, USA  
Image J  Public Domain  
Lecia DM IRB microscope  Lecia Microsystems GmbH, Wetzlar, 
Germany  
Microscope heated plate  Lecia Microsystems GmbH, Wetzlar, 
Germany  
Microsoft Excel  Microsoft In., Redmond, WA, USA  
Neubauer haemocytometer counting 
chamber  
Reichert, Austria  
Nitrocellulose membrane  Hybond C, Ammersham, Cardiff  
Protein spectrophotometer  BIO-TEK, Wolf Laboratories, York, UK  
RNA spectrophotometer  BIO-TEK, Wolf Laboratories, York, UK  
UVI-doc system  UVITech, Inc., Cambridge, England, UK  
UVITech imager  UVITech, Inc., Cambridge, England, UK  
 
